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Abstract
Misfolding and aggregation of alpha-synuclein (a-syn) are associated with a 
range of neurological disorders, including Parkinson’s disease (PD). Fibrillar, 
insoluble aggregates of a-syn, known as Lewy bodies (LBs) are deposited in the 
substantia nigra and are a pathological hallmark of PD. a-syn is a natively 
unstructured protein, co-populating extended and more compact conformational 
forms under equilibrium. The fine balance of this equilibrium can be shifted due 
to changes in its environment such as alterations in metal content, ionic 
strength, free dopamine or others, promoting the assembly of a-syn into toxic 
conformations. Small, soluble oligomers preceding LB formation are thought to 
be causative. In vitro, different a-syn oligomers have been produced with 
alternate biochemical properties. Here the primary objective was to uncover the 
link between conformation and toxic gain of function by the use of functional 
assays in combination with ESI-IMS-MS. Epitope mapping procedures indicated 
that different a-syn oligomers have unique epitope features. Dye binding assays 
such as ThT and ANS fluorescence inferred that the various oligomer types 
differ in their amyloidogenicity and hydrophobicity. Furthermore, intracellular 
aggregation assays, MTT cell proliferation and Ca(ll) influx analysis in SH-SY5Y 
neuroblastoma cells showed that cellular effects correlated with structural 
features. ESI-IMS-MS spectra of the different oligomers have been acquired 
and allowed the conformations of the oligomer subsets to be determined. The 
oligomers assembled up to a hexameric form with a closed ring-like 
conformation. These results demonstrated that unique structural features are 
required for toxicity and that a subset of oligomers with characteristic structures /  
may be pivotal in PD.
iii /
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1 Chapter 1 
Introduction
1.1 Amyloid disease states
1.1.1 Misfolding and toxic conformations
The propensity of proteins to fold properly and adopt appropriate tertiary 
structures is essential to their function and localisation. A group of proteins 
called intrinsically disordered proteins (IDPs) e.g. alpha-synuclein (a-syn) and 
p53 do not adopt well defined 3 D structures but are very dynamic and sample 
numerous conformational states to perform varied biological functions (Forman- 
Kay et al. 2013).
The failure of proteins to fold or to fold correctly can cause disease states hence 
misfolding and aggregation are of paramount importance in vivo. The 
consequences of misfolding are protein aggregation, fibril formation, loss of 
function or toxic gain of function. A significant proportion of the protein 
misfolding diseases can be accounted for by the appearance of filamentous, 
insoluble protein aggregates, called amyloid that can be deposited into a variety 
of organs and tissue types either locally or systematically as shown in Table 
1.1. below (Uversky 2008).
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Amyloidogenic
protein
Type of structure Disease
Immunoglobulin light 
chain (kappa or 
lambda)
Folded Primary amyloidosis (AL); Associated with plasma cell dyscrasia and multiple myeloma
Serum amyloid A Folded
Secondary systematic amyloidosis; Associated with 
chronic infections and inflammatory diseases such as 
rheumatoid arthritis, familial Mediterrenean fever, 
osteomyelitis and granulomatous ileitis, inflammatory 
bowel disease
a-syn Natively unfolded
Parkinson’s disease (PD), Diffuse Lewy bodies disease 
(DLB), Lewy body variant of Alzheimer’s disease 
(LBVAD), Dementia with Lewy bodies (DLB), Multiple 
system atrophy (MSA), Hallervoden-Spatz disease
Amyloid 3 and its 
fragments Natively unfolded
Alzheimer disease (AD), Dutch hereditary cerebral 
hemorrhage with amyloidosis (HCHWA) also known as 
cardiovascular amyloidosis, Congophilic angiopathy
Tau protein Natively unfolded Alzheimer’s disease (AD), Pick’s disease, Progressive supranuclear palsly (PSP)
ABri& ADan Natively unfolded Familial British Dementia& Familial Danish Dementia
Prion protein and its 
fragments
N-terminal fragement (23-121) is 
natively unfolded, C-terminal 
domain (121-230) is predominantly 
a-helical
Creutzfeld-Jacob disease (CJD), Gertsmann-Straussler- 
Scheineker Syndrome (GSS), Fatal familial insomnia 
(FFI), Kuru, Bovine spongiform encelopathy (BSE) and 
scrapie
Huntingtin Exon 1 is unfolded Huntington disease
Ataxin-1 Unknown (natively unfolded)
Spinocerebellar ataxia (SCA), Neuronal intracellular 
inclusion disease (NIID)
Androgen receptor 
protein
Ligand binding (LBD) and DNA 
binding domains (DBD) are all a- 
helical, amino terminal domain 
(NTD) is natively unfolded
Spinal and bulbar muscular atrophy (SMBA)
DRPLA protein 
(atropin-1)
Unknown (probably natively 
unfolded) Hereditary dentatorubral-pallidoluysian atrophy (DRPLA)
Nuclear poly(A) 
binding protein Natively unfolded Oculopharyngeal muscular dystrophy
Calcitonin Natively unfolded Medullary carcinoma of the thyroid (MCT)
Gelsolin Amyloidogenic fragment 173-243 is natively unfolded Finnish-Type Familal Amyloidosis
32 microglobulin 3-sheet Hemodialyis related amyloidosis
Table 1.1. Some amyloid diseases and their associated proteins. Protein
misfolding and aggregation are a common theme in amyloidogenic disorders of
structurally distinct amyloid proteins (Adapted from Uversky 2008).
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In the case of neurodegenerative diseases, for example new variant Creutzfeld- 
Jacob disease, the prion protein (PrP) assembles and forms extracellular 
aggregates including amyloid fibrils (Prusiner 2012; Kraus et at. 2013). In 
Alzheimer’s disease (AD) the characteristic senile plaques are composed of the 
amyloid beta-peptide (Ap) and neurofibrillary tangles containing Tau protein 
(Hardy et at. 1991; Allsop 2000; Selkoe 2011), whereas in Parkinson’s disease 
(PD) the principal component of proteinaceous intracellular inclusions, termed 
Lewy bodies (LB), is a-syn (Jellinger 2011). These amyloid plaques are 
diagnostic hallmarks of the disease states and share a common cross-p 
structure. It is known that amyloid fibrils share common structural features 
despite each disease being characterised by the deposition of a unique protein 
or peptide (Westermark et al. 2005). Amyloid is described as “an in vivo 
deposited material, which can be distinguished from non-amyloid deposits by 
characteristic fibrillar electron microscopic appearance, typical X-ray diffraction 
pattern and histological staining reactions, particularly affinity for the dye Congo 
red with resulting birefringence” (Westermark et al. 2007). Amyloid fibrils of 
unrelated proteins and peptides share a common core structure in that they are 
unbranching macromolecular assemblies many pm in length, having a regular 
cross-p structure in which p-sheets are stacked parallel to the fibril axis (Jahn et 
al. 2010).
1.1.2 Synucleinopathies
In 1817, James Parkinson released an essay entitled “An essay of the shaking 
palsy”, summarising his clinical observations of six individuals and providing 
impetus for the diagnosis and terminology of PD. Another milestone was the
isolation of levodopa and its move to become a therapeutic agent for “dopamine
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replacement” -1960’s, alleviating the symptoms of PD (Hornykiewicz 2010). 
Meanwhile, Friedrich Henry Lewy first described the Lewy bodies containing 
abrnormal intracellular protein inclusions in 1912 (Holdorff 2002). Thereafter, 
Spillantini found that these filamentous protein inclusions contain predominantly 
a-syn and that this brain pathology is shared between PD, Dementia with Lewy 
bodies (DLB) and Multiple System Atrophy (MSA), commonly termed as 
synucleopathies (Spillantini etal. 1997; Spillantini 1999).
a-syn is associated with number of diseas i.e. PD, DLB, MSA and Lewy body 
variant of AD. Early differential diagnosis and identification of 
neurodegenerative synucleopathies would be particularly useful involving 
reliable diagnostic biomarkers (Eller et al. 2009). Markers of CSF and plasma 
hold the greatest promise (Foulds et al. 2012) or as another avenue skin 
fibroblasts could perhaps be explored (Hoepken et al. 2008). To date, clinical 
diagnosis is made based on development of special symptoms as listed below 
in Table 1.2. (Eller et al. 2011).
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Idiopathic Parkinson’s disease (IPD)
■ Essential inclusion criteria: bradykinesia plus muscular rigidity, resting tremor and/or postural 
instability
■ Exclusion criteria: sustained remission, supranuclear palsy, upper motor neuron signs
■ Supportive criteria (three required): excellent response to levodopa, progressive disorder, 
unilateral onset
Multiple System Atrophy (MSA)
MSA-parkinsonism
■ Parkinsonism (bradykinesia, rigidity and tremor)
■ Early, severe autonomic disturbance (postural hypotension, sweating abnormalities, severe 
constipation, urinary disturbance, male impotence, Raynaud phenomena), upper motor neuron 
signs, sometimes cerebellar signs
MSA-cerebellar
Idiopathic late onset cerebellar syndrome
Early, severe autonomic disturbance, varying degrees of upper motor neuron signs, parkinsonism 
Dementia with Lewy bodies (DLB)
1. Central feature (essential diagnosis for possible or probable DLB)
Dementia defined as progressive cognitive decline of sufficient magnitude to interfere with normal social or 
occupational function. Prominent or persistent memory impairment may not necessarily occur in the early 
stages but is usually evident with progression. Deficits on test of attention, executive function, and 
visuospatial ability may be especially prominent.
2. Core features (two core features are sufficient for diagnosis of probable DLB, one for possible DLB) 
Fluctuating cognition with pronounced variations in attention and alertness
Recurrent visual hallucinations that are well formed and detailed 
Spontaneous features of Parkinsonism
3. Suggestive features (if one or more of these present in the presence of one or more core features, a 
diagnosis of probably DLB can be made. In the absence of any core features, one or more suggestive 
feature is sufficient for possible DLB. Probable should not be diagnosed on the basis of suggestive 
features alone.)
REM sleep behaviour disorder
Severe neuroleptic sensitivity
Low dopamine transporter uptake in basal ganglia demonstrated by PET imaging
Table 1.2. The typical clinical features of IPD, MSA and DLB. Table adapted 
from Eller and Williams (Eller et al. 2011).
1.2 a-syn is associated with Parkinson’s disease (PD)
1.2.1 PD
PD has a prevalence of approximately 0.5 to 1 % in the age group of 65-69, 
rising to 1 to 3 % over the age of 80 (Marder et al. 1996; de Lau et al. 2006). 
The clinical symptoms of the disease include resting tremor on one or both 
side(s) of the body, stiffness of the limbs (rigidity), generalised slowness of 
movement (bradykinesia) and gait or balance problems (postural dysfunction) 
and non-motor symptoms including cognitive abnormalities and sleep disorders 
(Jankovic 2008). A key finding in PD is the selective and gradual degeneration 
of dopaminergic neurons in the substantia nigra pars compacta (SNPc), yet the 
precise mechanisms of neuronal death are not fully understood. Surviving 
neurons in PD post-mortem brains display abnormal intracellular protein 
aggregates called Lewy bodies (Forno 1996; Shults 2006). The main 
constituent of Lewy bodies and Lewy-neurites found within these cells is the 
protein a-syn (Wakabayashi et al. 2013). Approximately 5-10 % of PD cases 
have a genetic cause with both recessive and dominant modes of inheritance 
as shown in Table 1.3.. The autosomal recessive (AR) genes that cause a loss- 
of-function phenotype include parkin, DJ-1 and PINK1, whereas SNCA and 
LRRK-2 are inherited in autosomal dominant (AD) fashion. Ubiqutin carboxyl 
terminal esterase L-1 (UCLH-1) has recently been identified and its role is not 
well understood.
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Locus Inheritance Gene Protein function Clinical presentation Neuropathology Age at 
(protein) onset
PARK1 AD 
(PARK4)
PARK2 AR
PARK5 AD
PARK6 AR
PARK7 AR
PARK8 AD
SNCA
(a-syn)
UCLH-1
PINK1
DJ-1
LRRK2
(dardarin)
poorly
characterised 
synaptic function
Parkin E3 ubiqutin ligase
Ubiquitin 
hydrolase and 
ligase
Mitochondrial Ser- 
Tyr kinase 
Oxidative stress 
response 
poorly
characterised 
protein kinase
Duplications: IPD; some LBs 
postural tremor, slow 
progression.
Triplications: PD; PD 
with dementia: diffuse 
LB disease; aggressive 
course mutations: A53T,
A30P, E46K: Idiopathic 
PD; H50Q and G51D; 
parkinsonism and 
diffuse LBs 
Parkinsonism; slow 
progression 
PD
Parkinsonism
Parkinsonism
PD
Mid 30- 
60
Variable presence Juvenile 
of LBs to 40
unknown 30-50
unknown
Unknown
30-50
30-50
Diffuse LBs; Lewy 40-60 
Neurites; ±Tau 
inclusions; ± 
amyloid plaques
Table 1.3. Mendelian PD genes. Adapted by permission from Elsevier: Trends 
in Molecular Medicine, (Wood-Kaczmar et al. 2006).
More recent genetic linkage analysis and genome-wide association studies 
identified more than 11 loci and 9 genes responsible for the disease 
(International Parkinson Disease Genomics Consortium etal. 2011).
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The most compelling evidence for the direct role of a-syn in PD has been 
provided by three known missense mutations Ala30Pro(A30P) (Kruger et al. 
1998), Ala53Thr (A53T) (Polymeropoulos et al. 1997) and Glu46Lys (E46K) 
(Zarranz et al. 2004) in the SNCA gene that have been linked with the 
autosomal dominant early-onset PD. a-syn containing these mutations is 
thought to have higher propensity to aggregate in vitro, however evidence 
regarding the ability of A30P a-syn to accelerate the rate of fibrillation is 
inconclusive (Conway et al. 1998; Greenbaum et al. 2005; Fredenburg et al. 
2007). Furthermore, duplications (Chartier-Harlin et al. 2004) and triplications 
(Singleton et al. 2003) of the SNCA gene have also been detected in familial 
forms of PD. However, most forms of PD classed as sporadic and appear to be 
not strictly genetic in nature but arise from a number of factors acting in 
conjunction with each other during the life time of an individual (Irwin et al. 
2013). A recent two-hit animal model incorporating neuroinflammation induced 
by lipopolysaccharide treatment and human A53T mutant a-synuclein 
overexpression demonstrated the synergistic effects of genetic predisposition 
and environmental exposures in the development of PD (Gao et al. 2011). In 
addition to the three well described familial mutations A53T, A30P and E46K 
two probable pathogenic mutations, His50Gln (H50Q) and Gly51Asp (G51D) 
and two possible missense mutations, Ala18Thr (A18T) and Ala29Ser (A29S) 
have recently been identified (Fujioka et al. 2014). The H50Q point mutation 
was identified in a single PD patient using Sanger sequencing of SNCA coding 
exons, who showed responsiveness to levodopa treatment, had cognitive 
impairment, apathy and dementia (Appel-Cresswell et al. 2013). Another case 
of the H50Q missense mutation has been reported by Proukakis et al. 
(Proukakis et al., 2013). The pathogenic G51D mutation was found both in a
French (Lesage et al. 2013) and in a British family (Kiely et al. 2013). The 
clinical manifestation of this mutation is characterised by early onset, rapidly 
progressive PD, displaying pyramidal signs and psychiatric symptoms with the 
absence of cognitive impairment (Fujioka et al. 2014). The A18T and A29S 
mutations were identified in Polish patients with characteristic clinical features of 
PD (Hoffman-Zacharska etal. 2013).
Indications for the role of a-syn in the disease state have been highlighted 
through transgenic adenoviral, lenti-viral based animal models. In these 
systems, overexpression of a-syn recapitulated signs of neurodegeneration and 
Lewy-body like inclusions (Lo Bianco et al. 2002; Masliah et al. 2000; Martin et 
al. 2006). In contrast, dopaminergic cells have been rescued with down- 
regulation of a-syn expression in an 1-methyl-4-phenylpyridinium (MPP) (+) PD 
rat model (Hayashita-Kinoh et al. 2006). Yet, the survival of neurons with 
intracellular Lewy bodies indicates that these aggregates are not explicitly 
causative in all cases but they might be responsive inclusions that sequester 
potentially toxic constituents from other cell compartments (Tompkins et al. 
1997).
Alternatively, it has been proposed that small soluble oligomers, or protofibrils 
populated prior to fibril formation are responsible for neurotoxicity (Quist et al. 
2005; Winner et al. 2011; Giehm et al. 2011). One of the explanations for the 
toxic effect of amyloid oligomers suggests that some oligomeric species are 
capable of forming pores or channel-like structures (Lashuel et al. 2002) that 
can cause defects in the control of membrane permeability, may activate pre­
existing ion channels or the oligomers may enhance the ability of ions to move 
through the phospholipid bilayer without the formation of pores (Kim et al. 2009;
Malchiodi-Albedi et al. 2011). It has been shown that some species of a-syn 
oligomers resemble annular or pore-like structures with outer diameters of 10- 
12 nm and inner diameters of 2 nm (Lashuel et al. 2002). This concept is 
analogous to the toxic oligomeric amyloid (3 (Af3) hypothesis proposed in AD 
where Ca(ll) dysregulation is a central element of neurotoxicity (Quist et al. 
2005; Demuro et al. 2005). The build-up of oligomeric species may cause 
oxidative stress, disruption of axonal transport, synaptic dysfunction, 
mitochondrial dysfunction and an overload in the physiological quality control 
systems (molecular chaperones, ubiquitin-proteasome system (UPS) and 
phagosome-lysosome system) hindering the elimination and clearance of toxic 
agents as shown in Figure 1.1. (Irwin et al. 2013).
Proteasoi
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random coil
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Disruption of axonal transport 
Synaptic dysfunction 
Inhibition of UPS 
Mitochondrial dysfunction
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Figure 1.1. Toxic mode of action o f a-syn and its assemblies involving multiple 
cell components and mechanisms as reviewed by Irwin, Lee and Trojanowski. 
Adapted by permission from Macmillan Publishers Ltd: Nature Reviews 
Neuroscience, (Irwin et al. 2013).
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Strategies to regulate a-syn synthesis by small interfering RNA or microRNA or 
hinder self-assembly of the protein by peptides or small molecule inhibitors are 
in development. Other points for therapeutic intervention are being sought 
including enhancing disassembly or clearance of aggregates, activating 
autophagy and the proteasome system, restoring functions of heat shock 
proteins, using antioxidants, anti-inflammatories and neuroprotective agents 
(Irwin etal. 2013, Lashuel et al. 2013).
1.2.2 The role of metal ions in PD
Increased chronic exposure to heavy metals such as manganese, lead, iron and 
copper acting individually or synergistically has been documented as a potential 
risk factor in PD and has been underpinned by an array of epidemiological 
studies (Gorell et al. 1999; Gorell et al. 2004; Coon et al. 2006). In a recent 
critical review, Santer and Uversky have summarised the progress of research 
made to date about the interactions of a-syn with metals e.g. aluminium, cobalt, 
copper, iron, lead, magnesium, manganese, terbium and zinc in relation to 
binding and aggregation propensities.
Regarding iron, Fe(ll) is thought to cause oxidative damage through promoting 
the formation of reactive oxygen species (ROS) and oxidative stress which is 
detrimental to cell function. Redox active metal ions such as Fe(ll) can react 
with hydrogen peroxide (H20 2) leading to the formation of hydroxyl radicals by 
Fenton chemistry. Furthermore, Fe(ll) can promote aggregation of a-syn which 
is then deposited in LB and plays a part in the development of nigrostriatal 
injury and neurodegeneration (Santner et al. 2010).
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Binolfi et al. have investigated the interactions of a-syn with a range of divalent 
metal ions, namely Fe(ll), Mn(ll), Co(ll), and Ni(ll) in comparison to Cu(ll) and 
their influence on its aggregation at the atomic level. The study showed that 
divalent metal ions bind predominantly to the C-terminal of a-syn. The preferred 
binding site site is the DPDNEA motif (119-124 aa), where Asp121 serves as an 
anchoring residue to which they bind with low selectivity and affinity (Kd ~1 
mM). The interactions are not only dependent on electrostatic forces but are 
determined by the residual structure of the C-terminus as well (Binolfi et al. 
2006). The specificity and high binding affinity of Cu(ll) for a-syn in the 
submicromolar range was highlighted in a further study undertaken by Binolfi et 
al., where binding of this metal ion was demonstrated using nuclear magnetic 
resonance (NMR), electron paramagnetic resonance (EPR), circular dichroism 
(CD) and matrix assisted laser desorption ionisation mass spectrometry (MALDI 
MS) measurements. Both in the case of a-syn and (3-syn, two distinct binding 
sites of Cu(ll) have been identified in the presence of competitive chelators, one 
in the N-terminus encompassing Met1 and another lower affinity binding site 
located at the imidazole ring of the unique His residue (Binolfi et al. 2008). 
Further Cu(ll) specifics of the His50 residue were reported by Valensin et al. 
who estimated a dissociation constants of 1.5 pM at pH 7.5 for a-syn 44-55 
peptide containing either E46K or A53T substitutions, in the pH range of 6.5- 
7.0, revealing information about co-ordination geometry of Cu(ll) and its binding 
constraints (Valensin et al. 2011). In a cellular model, oligomer and aggregate 
formation was reduced upon lower levels of cellular Cu(ll) (~ 10 pM), and a-syn 
was shown to become more closely associated with the plasma membrane 
where these changes appeared to be reversible. Deletions of the C or N- 
terminal residue conferred an inability of the protein to aggregate, and mere C-
teminal truncation reduced susceptibility of cells to Cu(ll) induced cytotoxicity, 
while overexpression of a-syn increased the sensitivity to Cu(ll) (Wang et al. 
2010c).
1.2.3 Posttranslational modifications
Posttranslational modifications of a-syn e.g. phosphorylation, nitration, 
ubiquitination and truncations can contribute to dramatic biophysical and 
biochemical changes and are active areas of research (Shults 2006; Oueslati et 
al. 2010; Beyer et al. 2013). Lewy bodies in the brain contain phosphorylated 
a-syn and it has been detected in blood plasma as well (Foulds et al. 2012). 
Investigations into the molecular mechanisms governing phosphorylation at 
Seri 29 and Ser87 modification sites are underway (Inglis et al. 2009). Recently, 
Ouselati et al. reported the relevance of Polo-like kinase 2 enzyme as a 
regulator of a-syn turnover that is up-regulated in synucleinopathies and co­
localised with phosphorylated Ser129 in diseased brains. It has been shown 
that Polo-like kinase forms a complex with a-syn and phosphorylates it at 
Seri 29, resulting in an enhanced autophagic degradation of a-syn in an ATP 
dependent manner. Overexpression of this enzyme in a rat model of PD led to a 
decreased intraneuronal accumulation of a-syn, less severe dopaminergic 
neurodegeneration and to reversal of motor impairments (Oueslati et al. 2013).
Importantly, the C-terminal domain contains metal binding motifs and 
phosphorylation sites in close proximity. Some insights into the modulatory 
effects of phosphorylation dependent metal binding including Al(lll), Fe(lll) and 
Tb(lll) have emerged (Liu et al. 2007) but are not fully conclusive yet. 
Overproduction of oxygen reactive species and nitration species create nitrating
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agents that convert the Tyr residues of a-syn to three nitrotyrosine. A variety of 
nitration specific antibodies have detected nitrated a-syn in insoluble
intracellular deposits of a-syn. It is speculated that nitration of the Tyr residues 
of a-syn promotes fibrillisation or perhaps nitration occurs after a-syn
assembles into fibrils and play a part at the onset of synucleopathies (Giasson 
et al. 2000).
As another posttranslational modification, C-terminal truncation of a-syn has 
been shown to occur in human brain tissue and neuronal cell culture as 
demonstrated by immunoblotting procedures. The C-terminal has an essential 
chaperone activity and cellular processes remain to be identified that cause 
truncation of full length protein. The C-terminally truncated protein in vitro has a 
propensity to promote the self-assembly of the full length protein. Further 
evidence has shown that C-terminal truncation, i.e. the loss of at least 17 amino 
acids was observable both in neuronal cultures and the brain from A53T 
harbouring human familiar forms of transgenic mice and was not a mere artifact 
of pathological processing as revealed by utilising a Cipergen Surface 
Enhanced Laser Desorption and Ionisation (SELDI MS) approach in
combination with immunoblotting procedures (Li et al. 2005).
1.2.4 Links of a-syn to other disease states
Interestingly, insights obtained from cell culture models and brain extracts 
strengthen the hypothesis that extracellular a-syn is involved in propagating the 
LB like pathology by mechanisms described in prion disease. Despalts et al. 
reported that a-syn was transmitted via endocytosis to neighbouring neurons 
and neuronal cells, forming LB like inclusions when the recepient’s lysosomes
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were inhibited (Desplats et al. 2009). Postmortem examination of two subjects 
with PD who had long-term survival of transplanted foetal mesencephalic 
dopaminergic neurons showed that the transplanted cells had developed 
immunopositive LBs raising a possibility of a host-to-graft disease propagation 
(Li et al. 2008). Since these early reports, an increasing body of evidence for 
the cell-to-cell propagation of a-syn has been now gathered (Angot et al. 2012) 
which suggests common links between misfolded a-syn and other prion 
diseases as argued by Prusiner (Prusiner 2012).
a-syn inclusions apprear in numerous taupathies (Mukaetova-Ladinska et al. 
2006). Equally, a group of PD patients present with strong dementia, clinically 
classified as Parkinson’s disease dementia group (PDD). Symptoms often 
coincide with the spread of a-syn from the brainstem to limbic and neocortical 
regions (Braak et al. 2003). Of note, 50 % of the affected cells also show 
amyloid-p plaques and neurofibrillary tangles consisting of Tau that are critical 
hallmarks of AD. These distinct but converging pathologies and their 
relationships will require a better understanding in order to develop successful 
therapies (Irwin etal. 2013).
Tsigelny etal. have examined the potential interactions of Ap and a-syn both by 
analysing immunoblots of brains from patients with AD/PD and amyloid 
precursor protein/a-syn transgenic mice and by molecular stimulations and 
other in vitro studies. Molecular modelling showed that Ap binds to a-syn 
monomers, homodimers and trimers, forming more stable pentamers and 
hexamers with a ring-like topology. Moreover, membrane docking experiments 
implied that a-syn and Ap co-structures docked to a 1-palmitoyl-2-oleoyl-sn- 
glycero-3-phosphocholine (POPC) membrane have incorporated other a-syn
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molecules resulting in a ring-like organisation. In accordance with these 
findings, cell-free studies highlighted that freshly-solubilised Ap1-42 promoted 
the aggregation of soluble a-syn in a time and dose dependent manner. The 
hybrid a-syn and Ap complexes formed functional cation nanopores in 
HEK293T cells potentially leading to increase in the influx of Ca(ll) (Tsigelny et 
al. 2008).
An early indicator of a-syn induced neuronal demise is synaptic dysfunction. 
Synapse damage was studied by measuring synaptophysin in cultured neurons 
incubated with overexpressed a-syn, or with amyloid-p 1-42 (Ap 1-42) peptides. 
Treatment with recombinant human a-syn decreased both the synaptophysin 
content of cells and synaptic vesicle recycling as indicated by the uptake of the 
fluorescent dye FM 1-43. While the addition of p-syn moderated the effects of a- 
syn, Ap 1-42 enhanced the negative effects of a-syn on synaptic vesicle 
recycling as well as on synapse damage and similarly a-syn accelerated 
synapse damage provoked by Ap 1-42. Additionally, the synaptophysin content 
of cortical neurons did not differ when treated with prion-derived peptide PrP 82- 
146 alone or with the mixture of a-syn/ PrP 82-146. These observations imply 
that interactions between these proteins or other peptides might influence the 
manner of synapse degeneration (Bate et al. 2010).
1.3 a-syn monomer and its misfolded forms
1.3.1 Physiological roles and structure of human a-syn
a-syn is a 140 amino acid cytosolic protein which was first isolated from
synaptic vesicles of Torpedo californica and rat brain (Maroteaux et al. 1988). It
is encoded by chromosome 4 and is abundantly expressed in neurons, mostly
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localised at the presynaptic nerve terminals. The physiological functions of a- 
syn include regulation of vesicle transport (Murphy et al. 2000), synaptic 
plasticity and chaperone activity. It also plays a part in the assembly of SNARE 
protein complex (Burre et al. 2010) that is instrumental in neurotransmitter 
release, vesicle recycling and synaptic integrity (Chandra et al. 2005). Similarly, 
a-syn is associated with mitogen activated protein kinases (MAPKs) (Iwata et al.
2001) and phospholipase D (Ahn et al. 2002). Moreover, it plays an important 
role in the metabolism of dopamine by modulating tyrosine-hydroxylase that is a 
rate-limiting enzyme in dopamine production (Lotharius et al. 2002a; Yavich et 
al. 2004). a-syn is an intrinsically unstructured or natively unfolded protein with 
a negative net charge. The main domains of a-syn are the N-teminal region (aa 
1-37) consisting of imperfect, repetitive tandem motifs that can adopt 
amphipathic helical structures upon membrane binding (Uversky et al. 2009), 
the central hydrophobic domain (amino acids 61-95) referred to as non-amyloid 
P-component (NAC) of Alzheimer disease amyloid (Ueda et al. 1993), with a 
tendency to form p-structures and associated with pathological brain lesions (El- 
Agnaf et al. 1998, Uversky et al. 2000) inducing apoptotic cell death in culture, 
and finally the highly acidic, proline rich, C-terminal residue (amino acids 96- 
140) (Meuvis et al. 2010) with a chaperone-like activity (Burre et al. 2010). The 
domains of human a-syn are shown below (Figure 1.2.) (Bisaglia etal. 2009).
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Figure 1.2. Schematic representation o f a-syn domains. The N-terminal (1-60) 
is denoted by regular capital letters, the NAC region (61-95) by bold capital 
letters, and the C-terminal region (96-140) by italics. The three well known 
familial mutations (A30P, E46K and A53T), two recent probable pathogenic 
substitutions (H50Q and G51D) and the phosphorylation sites (S87, Y125 and 
S129) o f a-syn are marked by arrows, metal interaction sites by italics. 
Reproduced by permission of Springer, Neuromolecular Medicine, (Bisaglia et 
al. 2009).
At neutral pH, far-UV circular dichroism (CD) and Fourier transform infrared 
(FITR) spectra typing have shown a significantly unfolded polypeptide chain 
with low content of ordered secondary structure. The reported radius of gyration 
(Rg) at neutral pH is smaller (40 A) than that estimated for a random coil (52 A), 
indicating that a-syn is more compact than an expected random coil (Uversky et 
al. 2001a). However, Rg of the partially folded conformer (30 A) is greater than 
folded globular protein’s with the same size (15 A), suggesting that it is slightly 
expanded, lacking a tightly packed secondary structure. Nuclear magnetic 
resonance (NMR) analysis reported that the region of 6-37 amino acids has a
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preference for adopting helical conformation. The far-UV CD spectrum of a-syn 
at neutral pH is typical that of an unfolded polypeptide chain, at acidic pH the 
natively unfolded a-syn is transformed into a partially folded conformation with 
substantial amount of ordered p-structure. Changes in temperature can 
equivocally induce structural changes in the polypeptide chain more likely by a 
stronger hydrophobic driving force for folding (Uversky et al. 2001 a).
Conformational behaviour of a-syn has been extensively investigated under a 
variety of conditions depending on not only pH and temperature but on organic 
solvents (Munishkina et al. 2003), various salts (Munishkina et al. 2009), 
pesticides (Uversky et al. 2002), herbicides (Manning-Bog et al. 2002), heparin 
(Cohlberg et al. 2002) polycations (Goers et al. 2003), methionine (Met) 
oxidation (Glaser et al. 2005) and metal ions (Uversky et al. 2001c; Brown 
2007; Bisaglia et al. 2009; Lee et al. 2008b; Lucas et al. 2011) and 
agrochemicals (Silva et al. 2013).
1.3.2 Aggregation of a-syn
As shown by atomic force microscopy (AFM) and electron microscopy, there 
are distinct final products of a-syn aggregation; soluble oligomers, fibrils and 
amorphous, large aggregates, occasionally arising from different competing or 
parallel aggregation pathways driven by their own adequate energetics and 
kinetics. Aggregation of a-syn starts with a distinct, slow lag phase which is 
followed by a nucleation step and a growth phase (elongation) until a 
thermodynamic equilibrium is reached between the aggregate and the 
monomer, marking the steady state (Wood et al. 1999). In the lag phase the 
saturated protein solutions remains stable and formation of pre-nuclear
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oligomers is initiated. Upon the appearance of nuclei, the aggregates elongate 
rapidly during the growth phase and transition into the steady state, where the 
so-called growth equilibrium constant describes the solubility of the protein and 
equates to the critical concentration (Andreu et al. 1986).
The critical concentrations do not deviate greatly for the familial mutants of a- 
syn and the WT protein, implying that accelerated aggregation of the mutants is 
not a matter of increased solubility of the mutant types but perhaps a result of 
different nucleation rates. This nucleation-dependent fibrillogenesis of a-syn is 
similar to that of (3-amyloid (AP) (Takahashi et al. 2008). A common cross (3 
structure is shared between a-syn fibrils and paired helical filaments of Ap fibrils 
(Friedhoff et al. 1998) that are observed in AD (Wood et al. 1999). The 
nucleation dependent polymerisation is dependent on protein concentration and 
time, and amyloid fibril formation can be seeded by the addition of preformed 
fibrils that abolish the lag phase (Harper et al. 1997; Jarrett et al. 1993).
After a nucleation event the self-assembly proceeds by formation of small 
soluble oligomers that may further assemble to larger oligomers then to 
protofibrils (10-50-mers depending on the type of protein) to form large, 
insoluble amyloid fibrils with a characteristic cross-p structrure as illustrated in 
Figure 1.3. (Takahashi et al. 2008). Modifications can stabilise oligomers, for 
example conversion of the four Met residues to methionine sulfoxide (Glaser et 
al. 2005), nitration of the Tyr residues (Yamin et al. 2003), interaction with 
rifampicin (Li et al. 2004), other dopamine analogues (Li et al. 2005) and 
polyphenols. These modifications and the inclusion of co-factors yield hardy 
oligomers, resistant to dissociation and commonly these oligomers do not 
rapidly form fibrils (Fink 2006).
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Figure 1.3. Schematic representation o f the aggregation o f an unstructured 
monomer into amyloid fibrils with /3-sheet structures through small and large 
oligomers and protofibrils. The aggregation kinetics in vitro shows a typical 
sigmoidal curve that is comprised o f a lag phase (nucleation phase), an 
exponential elongation phase (fibril growth phase) and a plateau phase (steady 
state). Adapted with permission from (Takahashi et al. 2008), American 
Chemical Society.
The successfully formed and mature fibrils of a-syn grown in vitro have been 
demonstrated to display a length from 500 nm to 3 pM. Three ranges of heights 
were observed with 3.8±0.6 nm for protofilaments, 6.5±0.6 nm for protofibrils 
and 9.8±1.2 nm for fibrils (Khurana et al. 2003). In this study, a “hierarchical 
assembly model” was described to classify the morphology of different 
subspecies during aggregation whose formation is driven by nucleated 
polymerisation kinetics. It was assumed that nascent protofilaments appear at 
the early phase of fibrillisation and they grow by the recruitment of monomeric, 
partially folded intermediates to the ends of protofilaments. These
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protofilaments (-two or three protofilaments) then associate to yield protofibrils. 
Subsequently, two protofibrils assemble to form more rigid, mature fibrils 
(Khurana et al. 2003). Glycosaminoglycans (GAGs) such as heparin have been 
shown to promote the formation of a-syn fibrils that may influence in vivo 
aggregation of a-syn as Lewy bodies were shown to contain GAGs (Cohlberg et 
al. 2002). Interestingly, p- and y-syn which are also abundant in the brain do 
not form fibrils or form fibrils at a much slower rate, respectively (Uversky et al.
2002).
1.3.3 Amyloidogenic a-syn oligomers are toxic species
a-syn has an increased propensity to form morphologically different oligomers 
and different protocols yield alternate oligomeric forms, where these 
intermediates are often lowly populated and transient.
Importantly, overexpressed recombinant human a-syn can assemble under 
certain conditions into soluble oligomers or fibrils in vitro that are similar in 
morphology and staining to filaments extracted from the diseased brain and are 
toxic to primary neurons and dopaminergic neuronal cell lines (Forloni et al. 
2000; Seo et al. 2002; Danzer et al. 2007; Wright et al. 2009).
First evidence for presence of significantly elevated levels of oligomeric forms of
a-syn was shown in plasma samples obtained from 34 PD patients compared
with 27 controls by a novel ELISA method (El-Agnaf et al. 2006). A more recent
investigation suggested that levels of a-syn oligomers in the CSF and the
oligomers/ total-a-syn ratio can be useful biomarkers for diagnostic early
detection of PD (Tokuda et al. 2010). Moreover, total a-syn, phosphorylated a-
syn and oligomeric forms were measured in 76 post mortem samples taken
22
from patients with PD, DLB progressive supranuclear palsy (PSP) and multiple 
system atrophy (MSA) besides 20 control samples. Out of the four forms, 
phosphorylated oligomeric a-syn differed significantly in MSA when comparing 
to other subgroups, indicating a potentially useful biomarker in differential 
diagnosis (Foulds etal. 2012).
The detailed entities of fibril formation in vitro have been reported in equimolar 
mixtures of A53T/ wild-type (WT), in equimolar mixtures of A30P/ WT and in WT 
a-syn by Conway and colleagues. In this study, three alternate forms of 
prefibrillar, oligomeric species with different morphology (spheres, chains and 
rings) have been detected by using AFM at the early stages of fibril formation 
following their separation from other fibrillar and monomeric species by 
sedimentation analysis and size exclusion chromatography (Conway et al. 
2000).The spheres had a 2-6 nm height, the protofibrils had a height of 4 nm, 
while the rings comprised of two classes, a circular one with a diameter of 35-55 
nm, and an elliptical one with widths between 35-55 nm and lengths of 65-130 
nm. Fibrillation of A30P was found to be comparable to the WT a-syn, whereas 
the monomers were consumed faster in case of A53 during fibril formation. The 
larger a-syn fibrils similarly to other amyloidogenic species displayed a cross p- 
sheet structure when stained by Thioflavin T (ThT) and Congo red in agreement 
with data derived by X-ray diffraction (Serpell et al. 2000).
Lashuel et al. have shed some light on the structure of protofibrils assembled 
from A30P, A53T as well as WT a-syn by employing complementary 
approaches such as analytical gelfiltration, CD, sedimentation velocity analytical 
ultracentrifugation (SVAU) and scanning transmission electron microscopy 
(STEM). Electron microscopy images showed that both autosomal dominant
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mutants populated three to four classes, most commonly annular protofibrils, 
although tubular protofibrils appeared only for A53T. Notably, the wild-type 
protein’s ability to form annular protofibrils was less pronounced than its 
mutants and needed an extended six to eight weeks incubation period (Lashuel 
etal. 2002).
Morphological properties of annular oligomers formed from 10 pM a-syn in the 
presence of 100 pM di- and trivalent metals at 4 °C was examined in an AFM 
study as described by Lowe et al. (Lowe et al. 2004). Cu(ll), Fe(lll) and Ni(ll) 
produced 0.8-4 nm spherical particles, similar to the ones in the absence of 
metals, Mg(ll), Cd(ll) and Zn(ll) that produced 5-8 nm spherical oligomers. 
Addition of Co(ll), Ca(ll) resulted in annular oligomers, with 70-90 nm diameter 
for Ca(ll) and with 22-30 nm diameter for Co(ll). Without metal the protein 
yielded 45-90 nm annular oligomers in diameter after 10 days incubation and 
short, branch like structures with extended filaments occurred after 2-3 months. 
In the absence of the Ca(ll) binding C-terminal domain, a-syn did not form 
annular oligomers following Ca(ll) addition (Lowe etal. 2004).
Rapidly formed sphere like structures were observed to enable the assembly of 
annular protofibrils composed of solely from A53T, A30P and WT a-syn or from 
1:1 mixture of WT/ A53T upon longer incubation (>2 weeks) as detailed by Ding 
et al. (Ding et al. 2002). Spherical structures bound to brain derived membrane 
fractions better than monomeric or fibrillar a-syn and membrane associated 
annular protofibrils displayed dimensions with striking similarities to bacterial 
pore forming toxins. One possibility is that the protofibrils are not participants of 
the direct monomer-to-fibril pathway but they are more stable and first the need 
to “reopen” to be converted to fibrils (Ding et al. 2002).
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The fact that amyloid fibrils of a-syn are sensitive to cold temperatures has been 
harnessed to produce soluble a-syn oligomers in substantial quantity in vitro. 
Oligomers generated by supercooling dissociation were then examined to 
reveal any further structure and toxicity relationship by structural spectroscopic 
methods and electrophysiological measurements. The dynamic radii of these 
oligomers were determined to be ~35 and 125 nm in solution and had p- 
structures that were deemed to be different from the fibrillar form. These 
oligomeric species elicited disturbances in ion channel conductance. The 
oligomers formed slightly cation selective ion channels in a range of 
membranes, monomers and fibrils showed minimal or no channel forming 
activity in synthetic membranes. Green tea cathecin epigallocatechin gallate 
(EGCG) has anti-oxidant effects and it can also directly bind to a-syn and a-syn 
oligomers, redirecting their aggregation into non-toxic forms. In this study, the 
observed pore formation evoked by soluble a-syn oligomers could be inhibited 
by incubation with EGCG for 2 hr at a 1:10 molar ratio. (Kim et al. 2009).
1.4 Biochemical and biological effects of a-syn oligomers and its related 
species in neuronal models
1.4.1 Complex morphological characteristics and cytotoxic effects 
through Ca(ll) influx and seeding associated with in vitro  oligomers
The rationale for Ca(ll) channel formation of a-syn was demonstrated through 
collecting several lines of evidence and it has now widely been accepted that a- 
syn can cause Ca(ll) dysregulation (Voiles et al. 2001; Lowe et al. 2004; 
Lashuel et al. 2002; Quist et al. 2005; Danzer et al. 2007; Zakharov et al. 2007; 
Kim et al. 2009; Winner et al. 2011; Malchiodi-Albedi et al. 2011; Giehm et al.
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2011). AFM images seem to suggest annular structures as the pivot for the 
formation of pore like channels across A(B 1-40, a-syn, ABri, ADan, amylin and 
serum amyloid A (SAA). However the resolving power did not allow resolution of 
individual subunits. The dimensions were estimated to be around 25 nm for 
both Ap 1-40 and a-syn, 35 nm for ADan, 25 nm for amylin and 20 nm for 
serum amyloid as shown in Figure 1.4..
ADan
Figure 1.4. Ion channel-like structures imaged by high resolution AFM with a 
central pore for Af3 1-40, a-syn, ABri, ADan, amylin, serum amyloid A (SAA). 
Adapted by permission from National Academy o f Sciences of the United States 
of America, (Quist et al. 2005).
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Danzer et al. have described in vitro oligomerisation protocols resulting in Type 
A, B and C toxic, soluble, a-syn oligomers. All three aggregation protocols 
described in this study with or without the addition of FeCI3 resulted in a 
heterogeneous population of oligomers. Type A1 and A2 type oligomers evoked 
an increase in the intracellular Ca(ll) levels in support of the previously 
mentioned pore forming theory, whereas extracellularly added type B oligomers 
entered the cells and seeded aggregation of cytosolic a-syn. Both type C1 and 
C2 type oligomers induced punctate aggregate formation in a SH-SY5Y cell line 
overexpressing A53T a-syn (Danzer et al. 2007). A later follow-up study 
provided further evidence that type C oligomers were capable of inducing 
transmembrane a-syn seeding in both primary cortical neurons and in BeM17 or 
SFI-SY5Y cell lines in a time and dose dependent manner when added 
extracellularly. In addition, in vitro type A oligomers could be converted to type 
C oligomers with corresponding biological effects that indicates the two types of 
oligomers have dynamic properties (Danzer et al. 2009). Overall, these two 
studies proposed that different physiological conditions will lead to a 
heterogeneous group of oligomers co-existing under equilibrium and have 
formed a basis of the preparation protocols adapted here and discussed later 
on.
1.4.2 Morphology and toxicity of oligomers prepared in the presence of 
curcumin
Overexpression of a-syn and addition of a-syn oligomers extracellularly have 
been shown to enhance the formation of reactive oxygen species that induced 
apoptosis by increasing the activity of caspase-3. When oligomers were co­
incubated with curcumin a-syn induced cytotoxicity and oxidative stress were
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both attenuated, preventing apoptosis in SH-SY5Y neuroblastoma cells. Co­
incubation of monomeric a-syn with curcumin did not alter toxicity and co­
incubation of fibrils with curcumin exhibited an increased cytotoxic effect. SH- 
SY5Y cell treated with oligomeric a-syn extracellularly displayed increased 
oxidative stress, which was significantly reduced by the addition of curcumin 
(Wang et al. 2010b), supporting the earlier finding that curcumin acts as an 
antioxidant (Ono et al. 2006). It was demonstrated by AFM that curcumin does 
not change the morphology of the monomeric and preformed oligomeric species 
but that does destabilise pre-formed a-syn fibrils, consistent with previous 
findings (Ono et al. 2006; Pandey et al. 2008). Recent biophysical findings 
suggest that the beneficial effect of curcumin is due to its ability to modulate the 
hydrophobic surface exposure of preformed oligomers. 2D-NMR data showed 
that curcumin binds selectively to the preformed oligomers but not to the 
monomeric protein. This study however concluded that curcumin did alter the 
morphology of preformed oligomers by increasing the height of oligomers and 
making them more elongated (Singh et al. 2013). These oligomers were 
prepared by a different preparation protocol from that reported by Ono et al. 
(Ono et al. 2009) limiting direct comparison between the two studies (Singh et 
al. 2013).
1.4.3 Oligomers seeded with Ap are shown to be toxic in ex vivo rat brain 
and mice and neuronal cells
Oligomeric a-syn seeded with a small amount of Ap (1:40) has been applied 
exogenously in various model systems and found to negatively impact vital 
neuronal functions such as synaptic plasticity and cognitive function, a-syn
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oligomers promoted a rise in intracellular Ca(ll) levels, induced calcineurin 
(CaN) activity, dampened the cAMP response element binding protein (CREB) 
transcriptional activity, leading to cell death in SH-SY5Y cells. CaN is a protein 
abundant in the brain and is responsible for synaptic plasticity, learning and 
short- and long-term memory (Mansuy et al. 1998). CaN indirectly regulates the 
transcription factor CREB (Bito et al. 1996). When rat brain slices were treated 
with oligomeric a-syn, higher CaN activity and inhibition of CREB were similarly 
observed. In mice following intracerebroventricular injections, oligomeric a-syn 
elicited an increased CaN activity, inhibited CREB and brought about memory 
impairments (Martin et al. 2012).
1.4.4 Effects of oligomers prepared by metal induced aggregation
As for metal induced cellular aggregation, Wright and colleagues have 
determined the effects of Cu(ll)-induced oligomerisation versus Fe(lll) in SH- 
SY5Y neuroblastoma cells using both WT and missense mutant forms of a-syn 
(Wright et al. 2009). In this cell culture model, the combination of elevated levels 
of extracellular a-syn oligomers and Cu(ll) caused greater toxicity than Fe(lll) as 
suggested by MTT cell viability tests, a-syn oligomers isolated by fractionation 
techniques resembled small spherical aggregates with the diameter of 15-20 
nm, and small fibrils with the length of 50-150 nm and 6-8 nm diameter. 
Moreover, no significant morphological changes appeared in the a-syn fibrils 
formed in the presence or absence of metal with missense mutations (Wright et 
al. 2009).
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1.4.5 Uptake and clearance of a-syn and its intermediates
Lee and colleagues have noted that protein folding stresses and inhibition of the 
protein quality systems increase vesicle translocation and secretion of a-syn as 
a compensatory action to aid the removal of the damaged protein (Lee et al. 
2008a). The clearance of dysfunctional a-syn from the extracellular space might 
become increasingly challenging whilst maintaining the brain parenchyma’s 
integrity. To dissect the translocation machinery, the assembly-dependent 
endocytosis and clearance of extracellular aggregates from oligomeric and 
fibrillar forms and monomeric a-syn were investigated in SH-SY5Y cells, COS-7 
cells and rat primary cortical neurons. It was shown that uptake of fibrillar a-syn 
could be internalised by receptor mediated endocytosis and proceeded through 
the endosomal pathway to facilitate clearance of aggregates by the lysosome. 
The internalisation of non-fibrillar, oligomeric a-syn occurred by endocytosis and 
became degraded by the lysosome. By contrast, the internalisation of 
monomeric a-syn was suggested to proceed by direct translocation across the 
plasma membrane, avoiding any significant proteolysis given its short half-life 
(Lee et al. 2008a).
1.4.6 a-syn fibrils seed intracellular aggregation of endogeneous a-syn 
that undergoes posttranslational modification
Intracellular aggregation of a-syn has been shown to be induced by treatment 
with exogeneously produced fibrillar species in QBI-HEK293 cells and SH- 
SY5Y neuroblastoma cells. These fibrils acted as seeds which then recruited 
intracellular a-syn to produce hyperphosphorylated and ubiquitinated
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aggregates. This resembles Lewy body like pathology observed in PD and other 
synucleinopathies. The inclusions co-localised with ubiquitin and molecular 
chaperones e.g. Hsp 70 and Hsp 90 indicating a reactive response for 
elimination and degradation of misfolded protein and the inclusions also 
disrupted the Golgi apparatus (Luk et al. 2009). It is conceivable that nuclei 
inititating aggregation in glial and neuronal cells may arise by copy number 
variations of a-syn, familial mutations (Devine et al. 2011, Houlden et al. 2012), 
C-terminal truncation of a-syn (Li et al. 2005), due to malfunctions of the protein 
quality control systems (Emmanouilidou et al. 2010b, Mullin et al. 2013) or 
external seeds may enter from surrounding cells (Emmanouilidou et al. 2010a). 
Further evidence for propagation of a-syn involving endocytosis and seeding 
was obtained in subsequent studies performed in cultured cells and also in in 
vivo animal models grafted with neurons (Angot etal. 2012). A working model of 
aggregation and transmembrane seeding has been outlined by Lashuel et al. as 
shown in Figure 1.5. below (Lashuel etal. 2013).
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Figure 1.5. Self-assembly and toxic mode of action o f alternate a-syn species 
including pore formation and transmembrane propagation. Adapted by 
permission from Macmillan Publishers Ltd: Nature Reviews Neuroscience, 
(Lashuel etal. 2013).
After a nucleation step, various types of oligomers with alternate morphologies 
are formed in the cytosol that are capable of converting to amyloid fibrils. Lewy 
bodies consist mainly of insoluble fibrillar a-syn. Meanwhile, membrane bound 
a-syn is chiefly a-helical, under certain conditions the protein undergoes a 
conformational transition that coincides with oligomerisation, yielding (3-sheet 
rich oligomers. These oligomers may be of several types i.e. transmembrane 
amyloid pores or ring-like assemblies. The mitochondrial functions, endoplasmic
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reticulum (ER) and Golgi-trafficking, protein degradation and synaptic 
transmission could be affected due to the formation of these toxic, intermediate 
species. The appearance of ring-like structures results in dysregulation of Ca(ll) 
homeostasis and signalling. Propagation of a-syn can progress via endocytosis, 
direct penetration, trans-synaptic transmission or by a receptor mediated 
mechanism of action leading to the spread of pathology (Lashuel et al. 2013).
1.5 Electrospray ionisation-ion mobility spectrometry-mass 
spectrometry (ESI-IMS-MS) for the study o f non-covalent complexes
1.5.1 The advantages and utility of ESI-IMS-MS
The knowledge of the tertiary and quaternary structure of proteins and protein 
complexes is essential to better understand their functions and interactions in 
biological pathways and disease states. Using ion mobility coupled to mass 
spectrometry holds a great potential in structural biology due to its ability to 
interrogate the structure of heterogeneous complexes in near native conditions 
and to determine the respective overall geometry of individual components 
(Heck 2008). IMS measurements provide detailed structural information through 
calculation of rotationally averaged collisional cross sections (Q) (Ruotolo et al. 
2008; Clemmer, D. E., Indiana University, Cross Section Database) that can be 
directly compared to NMR structures and crystal structure coordinates (Scarff et 
al. 2008). Thus IMS has recently become a powerful analytical tool well suited 
to characterising co-populated stereoisomers, chiral enantiomers and alternate 
protein conformers under varying conditions (Woods et al. 2012; El-Hawiet et al. 
2012a).
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An excellent use of this technique has been illustrated in an IMS analysis of the 
trp RNA binding protein complex (TRAP) that revealed an 11-membered ring 
morphology which could be maintained in the absence of bulk solvent. 
Furthermore, binding of tryptophan increased the stability of the ring structure 
and the structural collapse could be prevented by the binding of a specific 
mRNA molecule that had stabilised the assembly in solution and showed the 
largest Q (7400 A2) (Ruotolo et al. 2005). Several viral coat proteins self- 
assemble into capsids in vitro that are identical to virions in vivo supposedly 
through smaller transient oligomeric intermediates that might be technically 
difficult to monitor. Uetrecht et al. have successfully demonstrated that native 
IMS coupled to computational modelling is capable of elucidating the structural 
features of low abundance oligomers of Hepatitis B virus and norovirus under 
equilibrium (Uetrecht et al. 2011).
1.5.2 Technical considerations of ESI-IMS-MS
Regarding instrumentation, ESI-IMS-MS comprises of a nano-electrospray 
ionisation source, an ion funnel, a modified drift cell and a quadrupole mass 
filter. Ions are generated in the nano-spray source which creates a continuous 
beam of ions that are injected into an ion funnel that serves as an interface to 
the vacuum system. It is capable of converting the continuous ion beam into 
short ion pulses for Q measurements. Ions in the modified drift cell are 
thermalised by collisions with the He or N2 gas. The ions leaving the drift cell 
are analysed in a hybrid time-of-flight mass analyser by their mass-to-charge 
ratio (m/z) and detected to derive their respective arrival time distributions 
(ATD). By an equation described below ion mobility can be related to the Q and
to the arrival time at the detector in the conventional instruments.
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1.6 Drift time IMS-MS
Traditional drift time ion mobility spectrometry measures the time taken for an 
ion to migrate through buffer a gas in the presence of a low electric field. Ion 
mobility under low field conditions can be regarded as "directed diffusion" where 
the velocity of the ion (v) is directly proportional to the electric field (E) as 
follows v=KE. This proportionality constant is termed as the ion mobility 
constant (K) and is related to the Q as follows:
Equation 1. q is the charge on the ion, N is the number density of the buffer 
gas, k is the Boltzmann's constant, T is the absolute temperature, m is the mass 
of the buffer gas, M is the mass of the ion and Q is the collision cross section of 
the ion (Revercomb et al. 1975).
The experimental Q which is buffer gas dependent can be compared to 
theoretical O derived from computational modelling or NMR strucutres and 
crystal structure coordinates (Scarff et al. 2008; Jurneczko et al. 2011). The 
fundamental principles of ion mobility have been laid down by von Helden, 
Bowers, Shvartsburg and Jarrold who evaluated and contrasted the suitability 
and limitations of different models for accurate mobility predictions using either 
the projection approximation, trajectory calculations (von Helden et al. 1993; 
Shvartsburg et al. 2008) and hard spheres scattering methods (Shvartsburg et 
al. 1996). In the travelling wave devices the electric field is not constant and the 
travelling wave of electric potential changes with both time and the length of the
i i
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drift tube, therefore correction parameters have to be adopted to derive the Q 
(Clemmer et al. 1997; Ruotolo et al. 2007; Ruotolo et al. 2008; Smith et al. 
2009) as will be described in more detail in Chapter 4. Two types of operation 
modes have been developed based on the drift time ion mobility spectra: 
reduced pressure ion mobility spectrometry (RPIMS) and ambient pressure ion 
mobility (APIMS) (Kanu et al. 2008).
1.6.1 Travelling wave ion mobility mass spectrometry
A commercial development of ion mobility, Synapt HDMS, was first launched by 
Waters Technologies in 2006. This instrument has three stacked ring regions to 
propel ions through the device, a travelling wave consisting of a series of 
transient DC voltages is superimposed beyond the RF voltage. A second 
generation instrument, Synapt G2 HDMS, was launched in 2009 with a series of 
improved features in terms of sensitivity, mass accuracy, ion resolving power 
and data acquisition rate (Jurneczko et al. 2011).
Further details are discussed in the introduction of Chapter 4.
1.6.2 Field asymmetric waveform ion mobility spectrometry
In field asymmetric waveform ion mobility spectrometry (FAIMS) ions traverse 
between two electrodes in the presence of a tangential gas flow. The voltages 
applied to the electrode and the speed of the gas flow can be altered so that 
ions with a specific mobility transmitted through the device. Thus, one of the 
strengths of this equipment is that it is capable of separating ions from large 
proteomic mixtures specifically by their different mobilities at high and low 
voltage of electric field (Shvartsburg et al. 2010).
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1.7 Ion mobility of monomeric a-syn
1.7.1 ESI-IMS-MS of a-syn depending on pH, different alcohols and 
copper in negative ion mode
Numerous recent ion mobility studies have aimed at defining the conformational 
forms of either WT or mutant a-syn under various conditions. Negative-ion ESI- 
IMS-MS analysis of a-syn at pH 7 resulted in a charge state distribution of -6 to 
-16, centered at -11 where ion mobility data suggested an extended 
morphology. In contrast, a narrow charge distribution was observed at pH 2.5, 
in the range of -6 to -11, centered at -8 indicating a more compact a-syn 
structure. Dimer peaks appeared at -17 to -21 with significant intensity when 
electrosprayed from 5 mM ammonium acetate (AA), pH 7 solution but not from 
pH 2.5 solution. It is estimated that the average O of a-syn at pH 7 is 2530 A2 
corresponding to a relatively open structure, whereas the average Q is 1690 A2 
at pH 2.5, corresponding to a more globular, compact structure (Bernstein et al. 
2009).
Conformational transitions of a-syn induced by a range of alcohols and Cu(ll) 
have been examined by Natalello and co-workers (2001) using a quadrupole 
time-of flight (QTOF) instrument (QSTAR-Elite, Applied Biosystems, Foster 
City, CA) equipped with a nano-ESI sample source in negative-ion mode. At pH
7.4, 12 pM a-syn dissolved in 10 mM AA showed a bimodal charge state 
distribution, predominantly with two main conformational envelopes, one with 
highest signals at -14 and -15 charge states corresponding to less compact 
forms and one with dominant charge states at -7 and -8, being an alternate 
conformer with a greater degree of compactness. According to previous
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observations by far-UV-CD, alcohols can potentially inhibit fibrillisation by the 
formation of (3-structure-enriched oligomers with high concentrations of 
methanol, ethanol, and propanol and lower concentrations of trifluoroethanol 
(TFE), or by the presence of a conformation with high a-helix content at high 
TFE and hexafluoro-2-propanol (HFiP) concentrations (Munishkina et al. 2003). 
This study confirmed that methanol as a co-solvent seemed to stabilise the 
more compact form in relation to the intermediate form, whereas HFiP promoted 
the appearance of a partially folded intermediate conformer with a -9 charge 
state, distinct from the compact and disordered states present at pH 7.4. High 
concentrations of TFE (-15 %) revealed the accumulation of a partially folded 
form with a charge of -12, and with further increments of TFE the protein 
transitioned into a homogeneous intermediate with a charge state centered at - 
11 charge state ions, which is consistent with earlier far-UV CD data 
(Munishkina et al. 2003).
The ability of metals, in particular Cu(ll) to promote oligomerisation (Paik et al.
1999) and fibrillisation of a-synuclein has been established by employing
several spectroscopic methods including CD, Tyr fluorescence (Uversky et al.
2001c) and NMR (Rasia et al. 2005). a-syn has multiple binding sites for Cu(ll)
with different binding constants and stoichiometry that are somewhat argued
(Binolfi et al. 2006; Binolfi et al. 2008; Lee et al. 2008b; Hong et al. 2009;
Valensin et al. 2011). In order to further analyse the interaction of a-syn and
Cu(ll), a titration with a range of 0-80 pM Cu(ll) was performed in the presence
or absence of glycine (Gly). Binding of Cu(ll) resulted in the appearance of
metal adducts and in a mass shift by the factor of 61.5 Da, implying that the
binding of each Cu(ll) ion (63.5 Da) repels two protons from the protein. Only
the 1:1 Cu(ll) to protein complex accumulated significantly in the presence of
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Gly, suggesting the involvement of the more specific, high-affinity binding site 
for Cu(ll). Furthermore, the data presented in this study indicated that the 
protein folding initiated by Cu(ll) decreased the amount of the disordered 
conformer and caused a shift towards a highly compact, partially folded 
conformer (Natalello et al. 2011). The effect of Cu(ll) was very substantial 
regarding both the shift of the dominant charge state from -15 to -8 and the 
stability of the more compact, bound protein (-45 %) as indicated by 
quantitation with Gaussian fitting (Dobo et al. 2001).
1.7.2 ESI-IMS-MS of WT and autosomal, dominant mutant forms of a-syn 
in negative mode
WT a-syn and its A53T mutant exhibited the existence of a compact, partially- 
folded family of structures with charges -6, -7 and -8. For the A30P mutant, this 
compact form was only apparent when the protein possessed a net charge of -6 
(Grabenauer et al. 2008). Spermine is a naturally present polyamine involved in 
neuronal cell proliferation, differentiation, and modulation of ion channel 
receptors (Gilad et al. 1991). It forms a complex with a-syn under physiological 
conditions without significantly affecting the secondary structure and enhances 
the rate of fibrillation of a-syn (Antony et al. 2003). Evidence from NMR data 
suggested that although spermine binds specifically to the C-terminal of the a- 
syn (aa109-110), it induces changes in the N-terminal in the proximity of Gly 
and Tyr residues in the region of aa 22-93 and it leads to adoption of a (3-sheet 
conformation (Fernandez et al. 2004) typical of fibrillar a-syn. Notably, these two 
mutant forms harbour an amino acid substitution in the latter region and were 
therefore chosen to be subjected to investigations. Upon binding to spermine,
all three proteins experienced a structural collapse, causing a charge state
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reduction from -10 to -6 at pH 7.5 that indicated a Q reduction from 2600 A2 to 
1430 A2, respectively. It appears possible that spermine increases the 
aggregation rate of a-syn by a structural collapse as observed with metals 
which subsequently gave rise to formation of aggregates (Grabenauer et al. 
2008).
1.7.3 ESI-MS acquisitions at various pH and alcohol contents reveal four 
conformational families of monomeric a-syn
ESI-MS data has indicated that a-syn populates four different conformations
characterised by varying degree of compactness that co-exist under equilibrium
(Frimpong et al. 2010). Charge state distribution analysis under various
conditions demonstrated distinct, partially folded forms that accumulated in
response to environmental conditions. For example, the most compact form,
was represented under all conditions examined in this work including pH from
2.5 to 10 and its presence was exceptionally abundant at low pH and upon
addition of 10 % to 60 % alcohol. Its solvent-accessible surface area is
approximately 7.3x 10 A2 using estimates developed by the Kalthasov
laboratory (Kaltashov et al. 2005). A further intermediate conformer was also
found to populate all conditions assessed. Another, second intermediate
conformation showed a moderate contribution under most conditions but was
pronounced at high concentrations of ethanol and presumed to have folded p-
strands. The unstructured conformation was not prominent but became
observable as the pH increased, then in the presence of ethanol but not TFE its
population decreased at high pH. Beside the monomeric features, the ESI
spectra was comprised of non-covalent features, a-syn dimers that displayed a
narrow charge state distribution clustering around +11 charge state ion at pH
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2.5, in contrast at higher pH >4, the charge state distribution became broad with 
ions from +13 to +26. This study demonstrated the enrichment of particular 
conformational forms of a-syn in response to alternate concentrations of 
alcohols and pH (Frimpong et al. 2010).
1.8 Ion mobility to study amyloid formation
1.8.1 Collisional cross section and in silico  calculations aid structural 
determination of heterogeneous assemblies
Understanding the morphological and biochemical properties of soluble protein 
or peptide aggregates is critical to developing rational diagnostic and 
therapeutic strategies for amyloid disease. The transition of globular 
conformations into (3-sheet is closely linked to cytotoxicity. However, details of 
the folding pathways that govern the assembly of soluble oligomers indicated in 
the pathogenesis of amyloid diseases including PD, AD or Type 2 diabetes 
have only started to be unravelled within the last decade. IMS-MS allows the 
isolation and study of transient and dynamic oligomers at an early stage in the 
gas phase. This is permitted only to a limited extent by using traditional 
biophysical methods due to the low concentrations of these small, 
heterogeneous species that are often transient in nature and co-exist in solution 
(Figure 1.6.). Key to the usefulness of the system is the ability to determine 
both the mass of a given protein or complex as well as its conformational states 
through calculation of its Cl. The development of ESI-IMS-MS and its 
applications to a range of biomolecular molecules and complexes have recently 
been reviewed by Uetrecht et al. (Uetrecht et al. 2010) and instrumentation 
reviewed by Kanu and Hill (Kanu et al. 2008). Where the structure of the protein
41
or complex is unknown as in the case of the amyloid oligomers, in silico 
algorithms have been developed to predict the O from model protein structures 
allowing the 3 D conformation of known protein complexes to be determined 
(Ruotolo et al. 2005; Ruotolo et al. 2005; Bernstein et al. 2009; Smith et al. 
2010; Politis et al. 2013). In order to obtain this structural information intuitive 
models guided by experimental data or molecular structures obtained from 
molecular dynamics simulations are created and the theoretical Q determined. 
This value is then compared with the experimentally determined Q. 
Fragmentation techniques of selected ions such as Collision Induced 
Dissociation (CID) and Electron Transfer Dissociation (ETD) are also proving to 
be invaluable methods to gain topological information (Beardsley et al. 2009).
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Figure 1.6. A simplified schematic representation o f amyloid formation and the 
role o f early precursor conformations and oligomeric states in assembly. A 
number of possible aggregation pathways of the native monomer are shown, 
leading to the formation of amorphous aggregates (green), non-productive off 
pathway oligomers (blue), amyloid fibrils with alternate morphology assembled 
from differing intermediates (orange and red). Image adapted from Chiti and 
Dobson (Chiti et al. 2006).
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The area shaded in Figure 1.6. (Chiti et al. 2006) with grey colour is readily 
available to ESI-IMS-MS based experimentation. Conformational change within 
the monomer leads to a range of precursor conformations. The conformation of 
these precursors dictates the assembly pathway leading to soluble oligomers 
and larger order insoluble aggregates.
1.8.2 ESI-IMS-MS study of synthetic amyloidogenic peptides
Bleiholder and colleagues have demonstrated that globular peptide oligomers 
convert into peptide fibrils rich in (3-sheet contents as analysed by ESI-IMS and 
AFM (Bleiholder et al. 2011). This study examined the structural transitions of a 
selection of peptides such as NNQQNY from amyloid-forming yeast prion 
protein Sup35, VEALYL from insulin and SSTNVG from IAPP with known X-ray 
structures that in addition to an internal control Leu-enkephalin (YGGFL). 
Macroscopic granular aggregates were seen for NNQQNY and SSTNVG, 
whereas fibril formation was observed for VEALYL, NNQQNY and SSTNVG. 
YGGFL formed only granular structures and no fibrils as judged by AFM 
microscopy. All the amyloid-forming peptides clipped from larger peptides or 
proteins showed pronounced oligomerisation under the IMS-MS conditions. 
IMS-MS experiments performed on the NNQQNY peptide gave a direct 
demonstration of how a globular peptide converts into (3-strand conformation. 
IMS-MS analysis demonstrated that single strand fibril growth proceeded 
isotropically from dimer to pentamer which then transitioned near the 
nonadecamer stage into a more ordered (3-pleated sheet. The Q obtained 
during ESI-IMS experiments helped to discern significant differences in the
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early growth phase of these peptides at the level of one monomer addition at a 
time (Bleiholder et al. 2011).
1.8.3 ESI-IMS-MS analysis of p2 microglobulin
p2 microglobulin is a 99-residue protein that forms the light-chain of the class-l 
major histocompatibility complex (MHC-I). It is constantly shed from cells 
displaying MHC-I and carried by the bloodstream to the kidney to become finally 
degraded (Saper et al. 1991). In case of renal failure, the clearance of p2 
microglobulin is impaired and its level can be up to 50 fold elevated in the 
plasma. The aggregation of p2 microglobulin into amyloid material is closely 
associated with dialysis-related amyloidosis (Gorevic et al. 1986). P2 
microglobulin accumulates in skeletal joints, collagen-rich tissues, attracting 
monocytes and macrophages, subsequently leading to destructive athropathy, 
bone destruction and carpal tunnel syndrome as unwanted complications of 
long-term hemodialysis (Heegaard 2009). In vitro, P2 microglobulin assembles in 
a nucleation-dependent fashion under acidic conditions, at pH 2.5 and low ionic 
strength, giving rise to long straight (LS), fibrils (McParland et al. 2000). 
Analysis of p2 microglobulin oligomers at acidic conditions has been undertaken 
by Smith et al. (Smith et al. 2010). The in-depth characterisation of different 
species by ESI-IMS-MS revealed that monomers to tetramers were populated 
through the lag phase of fibril growth with no apparent higher order conformers 
under the conditions employed as displayed in Figure 1.7.,
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Figure 1.7. Mobility plot and mass spectrum (on the right) o f p2m (pH 2.5) at 1 
min into lag time of fibril assembly. M-monomer, D-dimer, T-trimer, and Q- 
tetramer with associated charge states. The scaling is shown in square root and 
log as marked. The x axis represents drift time (msec) and on the y  axis m/z is 
shown. Adapted by permission from National Academy o f Sciences o f the 
United States o f America, (Smith et al. 2010).
The dimers observed here appeared to be compact species when compared to 
theoretical structures with smaller Qs than predicted for elongated features. 
Experimental Os of trimers and tetramers were larger than would be expected 
for globular proteins of the same mass as the oligomers, suggesting they were 
not spherical but rather stacked, elongated assemblies. The dynamics of each 
oligomeric species in the ensembles were also examined by monitoring the 
subunit exchange of 14N- and 15N labelled oligomers. This showed a decrease 
in oligomer dynamics concomitant with increasing oligomer size. Differences in
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the behaviour displayed by the trimer ions of different charge states indicated 
the presence of two populations: a more highly charged, faster exchanging 
conformer populated at the early stages of aggregation and a less charged, 
more stable conformer that became prevalent later on. These trimeric forms 
preceded tetramer formation and no higher order oligomers were observed 
during the lag phase of assembly. These results have shed light on the size, 
mass, molecular organisation and stability of of p2 microglobulin oligomers. It 
has been also shown that oligomerisation of p2 microglobulin progressed by 
stacked oligomer addition at the early phase of aggregation (Smith et al. 2010).
1.8.4 ESI-IMS-MS analysis of Ap
Alzheimer’s disease (AD) is the most common neurodegenerative disorder in 
which amyloid plaques of Ap and the neurofibrillary tangles of Tau are cardinal 
features. Soluble oligomers of Ap have been associated with synaptic 
dysfunction and neuronal loss (Lesne 2013). Ap40 and Ap42 peptides arise due 
to alternate proteolytic cleavage of the amyloid precursor protein (APP) by 
gamma-secretases (Sinha et al. 1999). The balance of Ap40 to Ap42 has been 
demonstrated to be critical to the progression of AD. Ap42 is predominately 
linked to the disease state and has a higher tendency to aggregate 
(Mondragon-Rodriguez et al. 2010). Identification and characterisation of Ap 
oligomers has been an active area of research in which ESI-IMS-MS has made 
a significant contribution (Bernstein et al. 2009; Gessel et al. 2012; Hyung et al. 
2013). One of the first ion mobility experiments gave insights into the structural 
differences of Ap40 and Ap42 oligomers. Arrival time distributions (ATD) for 
solutions where Ap40 and Ap42 were co-populated suggested that the AP40
form of the peptide may inhibit amyloid formation of the Ap42 form (Jan et al.
46
2008). Analysis of the -5 dimer peak for A(340 showed that this charge state was 
co-populated by both dimeric and tetrameric forms, whereas the same charge 
state for Ap42 populated di-, tetra-, hexa- and dodecameric forms as shown in 
Figure 1.8. (Murray et al. 2009a).
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Figure 1.8. ATDs (in ijs)  of the -5 charge state of various A/3 peptides; 
(predominantly dimeric peak co-populated with higher order oligomers). A: 
A/340 (dimeric and tetrameric populations present), B: A/342 (dimeric, 
tetrameric, hexameric and dodecameric forms are observed) and C: A/340/A/342 
(dimers and tetramers are seen). Adapted with permission from (Murray et al. 
2009a), American Chemical Society.
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The ATDs for the dimeric and tetrameric forms of the two peptide forms differed 
in that the A(342 forms had taken longer to traverse the drift tube, indicating 
more expanded conformations. Notably, a mixture of dimers (-5 charge state) 
and tetramers (-10 charge state) could be observed only at the 1:1 ratio of 
Ap40/Ap42 and not for the 3:1 and 1:3 ratios, indicating that oligomer formation 
proceeded by dimer condensation rather than sequential monomer addition and 
that Ap40 can theoretically prevent aggregation at the tetrameric stage. 
Interestingly, trimers of Ap were not reported in this study (Murray et al. 2009a). 
Bernstein et al. have speculated that tetramers of Ap40 and AP42 determine the 
dynamics of assembly. Moreover, one of the larger, dodecameric (12-mer) 
species of 55.2 kDa that is a stack of two hexamers may be a previously 
identified neurotoxic species (Bernstein et al. 2009). This was observed in 
middle aged Tg2576 transgenic mice, had a corresponding mass and was 
referred to as Ap*56. It was shown to cause memory deficits when administered 
to young rats (Lesne et al. 2006).
1.9 Main objectives 
Overall aim
The hypothesis was that alternate oligomeric forms of a-syn with toxic gain of
function have alternate structures. The main interest was focused on the
formation of small, toxic oligomers that still lack detailed structural determination
regarding their size, shape and compactness. Here, previously described in
vitro a-syn oligomeric preparation protocols have been modified to make
oligomers suitable for ESI-IMS-MS analysis. Structural characterisation was
then undertaken through determination of their respective subunit sizes and
48
assignment of their molecular organisation via Q measurements. In conjunction 
with the native mass spectrometry measurements, the biochemical and 
functional properties of these oligomers were elucidated by using a variety of 
biochemical and cell culture based assays.
The specific goals were:
i. to investigate the biochemical characteristics and biological properties of 
alternate oligomeric forms by using an array of biochemical methods and 
assays in a SH-SY5Y cell culture model.
ii. to develop methods for the production of oligomers suitable for ESI-IMS- 
MS investigation by altering previously published in vitro oligomerisation 
methods of recombinant a-syn either in the presence or absence of metal 
ions.
iii. to ascertain the size, shape and foldedness of the pre-fibrillar oligomeric 
species using native mass spectrometry and to view these findings in the 
context of biophysical and biochemical characteristics to reveal structure 
and function relationships of a-syn oligomers.
iv. to address the immediate effects of binding partners on the 
conformational forms of natively unstructured monomeric protein by ESI- 
IMS-MS with potential implications in its self-assembly.
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2 Chapter 2 
Materials and Methods
2.1 Protein biochemistry and spectroscopy
2.1.1 Transformation of competent BL21 DE(3) cells with pET23a+ 
containing WT a-syn and preparation of glycerol stock
Luria Broth (LB) media was made by dissolving 10 g Bactotryptone (Fisher, 
BPE1421-500), 5 g yeast extract (Oxoid, LP0021) and 10 g NaCI (Fisher, 
S/3120/60) in 1 L ultrapure water and sterilised. BL21 (DE3) competent cells 
(Agilent, 200121) were thawn out on ice. Three reactions were set up: 2 pL of 
the plasmid containing WT a-syn insert was added to 50 pL of the cells, 1 pL of 
the plasmid DNA with a-syn added to 50 pL competent cells and 50 pL 
competent cells only. The reaction mixtures were agitated gently a few times 
over a 30 min incubation period at room temperature. After this step, the 
different samples were exposed to 45 sec heat shock in a 42 °C water bath and 
returned to ice for 5 min. 500 pL sterile LB media was added to each tube and 
incubated for 1 hr at 37 °C 200 rpm shaking to allow the bacteria to express 
antibiotic resistance. After 1 hr growth, the cells were centrifuged at 10, 000 rpm 
for 5 min and the supernatant was removed. The -100 pL pellet was 
resuspended and split into two halves, -20  pL and the remainder -80  pL of 
each reaction mix were spread out on agar plates containing 100 mg/mL 
ampicillin (Fisher, FL-04-0406) for selection. The plates were placed into 37 °C
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incubator overnight and colonies were observed the next day after 
transformation apart from control plates inoculated with competent cells only.
Subsequently, single colonies were picked and inoculated into 50 mL LB media 
containing 50 pL of 100 mg/mL ampicillin solution and grown overnight at 37 °C 
at 200 rpm shaking. 10 mL of overnight culture was then used to seed 100 mL 
LB supplemented with 100 mg/mL ampicillin and the OD6oo was monitored by 
the Jenway 6715 UV/Vis Spectrophotometer and bacterial culture was grown 
until it reached an OD6oo~ 0.40-0.45 value. Cells were then harvested at 4, 000 
rpm and 4 °C for 10 min and the resultant pellet was resuspended in 10 mL 
sterile, prechilled 100 mM M CaCI2 (BDH, 275844L). Tubes were incubated on 
ice for 10 min and centrifuged again as before followed by resuspension of the 
pellet in 2 mL 100 mM CaCI2 and 30 % v/v glycerol (Sigma, G5516) and division 
into 100 pL aliquots, snap freezing at -80 °C for further long term storage.
2.1.2 Qiagen plasmid miniprep kit
Plasmids from overnight cultures were extracted by using the QIAgen Midiprep 
kit (Qiagen, 12143). The procedure was carried out following the manufacturer’s 
recommendations. The plasmid maintaining a-syn was aliquoted out and frozen 
down at -20 °C for further use. The plasmid containing the insert was sent for 
sequencing for confirmation of the open reading frame. The size of the 
extracted plasmid was also assessed by 1 % agarose gel electrophoresis and 
and purity was estimated by calculating the OD26o and OD28o ratio (ideally 
between 0.1-1.0) from values measured on the NanoDrop spectrophotometer.
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2.1.3 Agarose gel electrophoresis
10x TAE buffer was prepared by mixing and dissolving 24.2 g Tris base (Sigma, 
T1503), 5.71 mL glacial acetic acid (Sigma, A6283), 10 mL 0.5 M 
ethylenediaminetetra-acetic acid (EDTA) (Sigma, ED S) in 500 mL total volume 
of distilled water. 1 % agarose gels were prepared by mixing 1 g agarose 
(Fisher, BP1356-1 OOg), 49 mL ultrapure water, 1 mL 1x TAE buffer, 
microwaved to dissolve the solution and after it cooled down ethidium bromide 
(Sigma, E7637) was added to a 5 pg/mL final concentration from a 10 mg/mL 
stock and poured to cast 10-12 mm thick gels. DNA samples were diluted into a 
6x gel loading buffer (Thermo Scientific, R0611). 5 pL of 1 Kb GeneRuler™ 
DNA ladder (Thermo Scientific, SM0314), 100 bp GeneRuler™ marker (Thermo 
Scientific, SM0241) and samples with a DNA content of 100 ng- 1 pg per lane 
were loaded for electrophoresis. The agarose electrophoresis tank was filled 
with 1X TAE buffer containing and ran at 100 V for 1 hr.
2.1.4 a-syn protein overexpression in E. coli and purification by anion 
exchange and size exclusion
BL21 (DE3) Escherichia coli competent cells (Agilent Technologies, 200121) 
were transformed with pET 23 a+ vector containing the human WT a-syn 
sequence. A 50 mL culture was grown overnight and 10 mL of that was 
inoculated into 1 L LB containing 100 mg/mL ampicillin for large scale 
expression. Protein expression was induced at OD6oo 0.6 with 1 M isopropyl (3- 
D-1-thiogalactopyranoside (IPTG) (Fisher, BP1755) for 3 hr. Cells were 
harvested by centrifugation at 10,000 rpm at -20 °C and the pellet was
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resuspended in a lysis buffer containing 10 mM Tris-HCI, pH 8.0, lysozyme (100 
pg/mL) (Sigma, L6876), 1M phenylmethylsulphonyl fluoride (PMSF), DNase (20 
pg/mL) (Sigma, D4263), RNase (20 pg/mL) (Sigma, R6512) and incubated for 
30 min before the addition of 1 mM EDTA. Cells were further lysed by 
sonication. The lysate was centrifuged at 10, 000 xg for 40 min to remove 
debris and the supernatant was acidified to pH 4.5, centrifuged again at 10, 000 
xg for 30 min to remove the aggregated protein that was followed by a final 
neutralisation step at pH 8.0. The crude lysate was injected onto a 50 mL Q- 
Sepharose column (GE Healthcare) for anion exchange at 4 °C. Prior to that the 
column was equilibrated with two column volume of buffer A (25 mM Tris-HCI, 
pH 8.0), then the protein was eluted with a 0-100 % linear gradient of buffer B 
(25 mM Tris-HCI with 1 M NaCI, pH 8.0). a-syn eluted at -  300 mM NaCI 
concentration point of the gradient. SDS-PAGE analysis of Q-Sepharose 
fractions was performed and the fractions enriched for a-syn were pooled. The 
collected fractions were dialysed extensively at 4 °C in ultrapure water and the 
freeze-dried. The lyophilised protein was redissolved and passed over a High 
Load 26/90 SuperdexTM 75 Prep Grade size exclusion column (Amersham 
Biosciences) using 20 mM Tris and 25 mM NaCI, pH 8.0 as running buffer. The 
pooled and purified fractions were dialysed repeatedly, re-lyophilised and stored 
at -80 °C for further experiments. Protein concentration was measured by 
absorbance at 280 nm with extinction coefficient 5960 M‘1cm'1 on a Jenway 
6715 UV/Vis Spectrophotometer. Samples of the protein were analysed by ESI- 
MS to ensure the correct mass.
53
2.1.5 Production of a-syn oligomers
All oligomers were prepared as described by Danzer et al. previously (2007) 
unless otherwise stated (Danzer et al. 2007). To make oligomers suitable for 
ESI-IMS-MS analysis sodium phosphate (SP) buffer has been replaced with 50 
mM AA (Fisher, A/3440/50), pH 7.0.
Type A oligomers were prepared by dissolving lyophilised protein in 50 mM SP 
(500 mL 50 mM SP buffer was prepared by mixing 1.038 g sodium phosphate 
monobasic (Sigma, S1001) and 2.3 sodium phosphate dibasic (Sigma, S2002) 
in deionised water) or AA, containing 20 % ethanol to a final concentration of 7 
pM. In case of type A2 oligomers, 10 pM FeCI3 (Sigma, F7134) were 
additionally added, whereas type A1 oligomers were prepared without addition 
of FeCI3. After 4 hr of shaking, both types of oligomers were re-lyophilised and 
resuspended with one-half of starting volume in 50 mM SP or AA buffer, pH 7.0, 
containing 10 % ethanol (Fisher, M/4450/17). This was followed by shaking for 
24 hr (Thermomixer, Eppendorf, Germany) at 21 °C with open lids to evaporate 
residual ethanol. After 6 day incubation of both oligomers types with closed lids 
at 21 °C, oligomers were used for characterisation by a combination of 
techniques.
Type C oligomers were (spin concentration protocol) also prepared similarly to 
type A oligomers by dissolving lyophilised protein in 50 mM SP or AA, pH 7.0, 
containing 20 % ethanol to a final concentration of 7 pM. In case of type C2 
oligomers, 10 pM FeCI3 was added, whereas type C1 oligomers were prepared 
without addition of FeCI3. After overnight incubation at 21 °C under continuous 
shaking (Thermomixer, Eppendorf, Germany), the oligomers were concentrated
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and separated from monomer using a MWCO 30 kDa filter (VivaSpin500 30,000 
MWCO columns; Sartorius). In an attempt to make Cu(ll) induced oligomers 10 
pM FeCI3 was replaced with 10 pM CuCI2for both type A and C oligomers.
2.1.6 Size exclusion chromatography
For size exclusion chromatography the GE Healthcare 10/300 GL column was 
used (Amersham Biosciences). Instrument was operated by the Unicorn 
software. Separation of different components were achieved by flushing the 
column with either degassed 50 mM AA or SP followed by direct injection of 
samples (30-100 pL) into the injection port and by elution at 0.100 mL/min flow 
rate. 500 pL samples of fraction of interest were collected and solvent 
evaporated under a SpeedVac freeze drier. Typically, oligomeric peaks were 
eluted in 2 or 3x 500 pL fractions per 50-100 pL injection. For an estimation of 
molecular weight compared to globular proteins in a range of -12.5 kDa- 2000 
kDa, a Gel Filtration Molecular Size Standards kit was utilised (Sigma, MWGF- 
200-1KT) and the elution volumes have been plotted.
2.1.7 SDS PAGE
Running buffer was prepared by mixing 25 mM Tris-HCI (Sigma, T5941), 250 
mM glycine (Fisher, BP-381-1), pH 8.3, 0.1 % w/w SDS (Sigma, L3771) in 1 L 
deionised water. Reagents purchased for SDS gel included 
tetramethylethylendiamine (TEMED) (Sigma, 9281), ammonium persulfate 
(APS) (Sigma, A3678) and acrylamide bis acrylamide (Sigma, A2917-1L)
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Solution Added volume for resolving Added volume for stacking
component gel (mL) gel (mL)
30 % acrylamide 3.75 0.415
ultrapure water 1.7 1.7
1.5 M Tris-HCI pH 8.8 1.9 -
1 M Tris-HCI pH 6.8 - 0.315
10 % w/w sodium dodecyl 
sulfate 0.075 0.025
10 % w/w APS 0.075 0.025
TEMED 0.003 0.0025
Table 2.1. Components of 10% SDS gel shown for the resolving and stacking 
gel.
Glass plates were assembled according to the manufacturer’s instructions. The 
resolving gel was cast first and allowed to polymerise followed by pouring the 
stacking gel (Table 2.1.) and by inserting a comb for the formation of wells. 
Samples were diluted 1:5 with 2x NuPage SDS Sample buffer and 
electrophoresed in 1 x Tris-Glycine running buffer at constant voltage of 150 V. 
To aid molecular weight determination, 5 pL SeeBlue Plus 2 molecular weight 
marker (Novex, LC5925) was loaded. Gels were stained in either Instant Blue 
(Expedeon, ISB01L) for 30 min or in Coomassie stain containing 0.25 % w/v 
Coomassie Brilliant Blue R250 (Thermo Scientific, 6104-59-2), 50 % v/v 
methanol (Fisher, M/4056/17), 10 % v/v acetic acid and 40 % v/v ultrapure 
water for 2 hr. Destaining was performed with ultrapure water for Instant Blue 
and with a destaining solution comprised of 50 % v/v methanol, 10 % v/v acetic 
acid and 40 % v/v ultrapure water for Coomassie until background was reduced 
and bands became visible. Gel images were captured on an Epson flatbed 
scanner.
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2.1.8 Native gels
For clear native electrophoresis, 12 % Tris Glycine gels (EC60052BOX) were 
electrophoresed in 10-fold diluted Tris-Glycine Native Running Buffer 10x 
(Novex, LC2672). 5 pL volumes of samples were mixed with 5 pL 2x Native Tris 
Glycine Sample Buffer that had previously been prepared by mixing 100 mM 
Tris-HCI, 10 % v/v glycerol, 0.0025 % w/v Bromophenol Blue, pH 8.6. Unstained 
NativeMark (Invitrogen, LC0725) was loaded for an estimation of molecular 
weight.
Samples were electrophoresed on Novex NuPAGE® Tris-Acetate gels under 
native conditions according to the manufacturer’s instructions. All samples were 
loaded in 1X Tris-Glycine Native Sample buffer composed of 100 mM Tris-HCI, 
10 % glycerol, 0.0025 % Bromophenol blue at pH 8.6 and electrophoresis was 
performed in 10x Tris-Glycine Native Running Buffer (Novex, LC2672) diluted to 
1x at 150 V constant until the front of the blue dye reached the bottom of the 
gel.
Blue Native PAGE was performed using 10 % Bis-Tris gels (Novex, 
NP0302BOX). Samples were prepared in the Native Sample Prep kit 
(Invitrogen, BN2008) containing G250 additive. Unstained NativeMark 
(Invitrogen, LC0725) was loaded for an estimation of molecular weight (0.5 pL 
Unstained NativeMark ladder mixed with 2.5 pL 4x Sample Buffer and 0.5 pL 
G250 additive and 6.5 pL deionised water). For the outside chamber, Native 
Page 20X Running Buffer (Invitrogen, Anode Buffer BN2001) diluted to 1X was 
used, while for the inside chamber the Native Page 20x Cathode Buffer
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(Invitrogen, BN2002) was used diluted and prepared according to the 
manufacturer’s instructions and electrophoresed at 150 V constant.
At non-native conditions, 10 % Bis-Tris Novex gels were also electrophoresed 
using 20x MOPS running buffer (Novex, NP0001) diluted to 1x where samples 
were prepared in NuPage 4x (Novex, NP0007) Sample Buffer.
2.1.9 Silver staining
Silver staining of both native and non-native gels was performed by using the 
ProteoSilver TM2 kit (Sigma, Protosilkit2) following the manufacturer’s 
instructions with minor modifications. Images were taken on an Epson flatbad 
scanner.
2.1.10 Dot blotting procedure
1 pL of each oligomer, a-syn monomer or BSA was pipetted onto nitrocellulose 
membrane and air dried before the addition of 2 % BSA blocking solution in 
PBS for 30 min. After blocking an adequate volume of primary antibody was 
added diluted in PBS-T containing 10 % blocking solution. The PBS-T buffer 
constituted of 8 g NaCI, 0.2 g KCI, 1.44 g Na2HP04 and 0.24 g KH2P 0 4 and 1 
mL Tween 20 (Sigma, P1379) in 1 L, pH 7.2 solution. The range of 
commercially available antibodies used were: syn 211 anti-a-syn mouse 
antibody (epitope aa 121-125, Life Technologies, AHB0261) at dilution 1:500, 
A11 anti-amyloid oligomeric rabbit polyclonal antibody (epitope: n/a; oligomeric; 
Millipore, AB9234) at dilution of 1:1000. The in-house antibodies used in these 
experiments were a kind gift from Prof R. Cappai (University of Melbourne) as 
listed below:
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1. anti-a-syn rabbit polyclonal, 3rd bleed, 1:50,000 dilution
2. 45/08 5G7-1 mouse monoclonal, epitope: EAYEMP, 4.0 mg/mL, 1:30, 
000 dilution
3. 31/09 4H4-14-27-12 mouse monoclonal, epitope: KKDQLGK, 1.8 mg/, 1: 
20, 000 dilution
4. 35/10 7D2 (immunised with AS3X peptide, H-
M[Ox]DVFM[Ox]KGLSKAKC-OH; Met 1 and Met 5-oxidised) mouse 
monoclonal, 1.78 mg/mL, 1:400 dilution
For detection of antibodies raised in mouse, goat anti-mouse IR DyeR 680 LT 
IgG (H+L) fluorescent secondary antibody (Odyssey, 926-68020) was utilised at 
1:20, 000 dilution. For detection of epitopes recognised by the full anti a-syn 
rabbit polyclonal antibody, goat anti-rabbit IR DyeR 800 CW IgG (H+L) 
fluorescent secondary antibody (Odyssey, 926-32211) was used at 1:15, 000 
dilution.
2.1.11 Western blotting
After electrophoresis, SDS gels or 10 % Bis-Tris non-native precast Novex gels 
were transferred onto Immobilon FL PVDF membrane, 0.45 pM pore size 
(Milipore, IPFL20200). SDS PAGE gels were transferred in 1x Tris Glycine 
transfer buffer consisting of 20 mM Tris-HCI, 150 mM glycine and 20 % v/v 
methanol and 0.038 % w/v SDS in 1 L deionised water, whereas precast gels 
were transferred in chilled, 20-fold diluted NuPage Transfer Buffer 20x 
(NP0006-1) containing 20 % v/v methanol at a constant of 150 V for 90 min. 
The membrane then was treated with 0.4 % paraformaldehyde (PFA) (Sigma, 
441244) for 30 min at room temperature except for membranes probed with
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anti-amyloid, A11 antibody (Millipore). The membrane was then blocked with 2 
% BSA or 5 % blocking grade blocker (Biorad, 170-6404) in PBS. Blocking was 
followed by incubation with the appropriate primary antibody in PBS-T with 10 
% v/v of blocking solution for 1 hr at room temperature or overnight at 4 °C. As 
primary antibodies, syn 211 anti-a-syn mouse antibody at dilution 1:500 or A11 
anti-amyloid oligomeric rabbit polyclonal antibody at dilution of 1:1000 or full 
length anti-a-syn rabbit polyclonal antibody at 1:50, 000 (gift of Prof R. Cappai, 
University of Melbourne) were used. After washing at least 3 times for 10 min 
with PBS-T, the membrane was incubated for 1 hr with an appropriate 
secondary antibody for fluorescent detection on the Licor system.
2.1.12 ThT assay and dot blotting to monitor fibril formation
70 pM a-syn (1 mg/mL) was dissolved in 50 mM AA or SP at pH 7.1 and 
shaken at 200 rpm at 37 °C. Fibril growth was monitored by taking daily aliquots 
for 7 days. For seeded fibril formation measurements, 10 % or 20 % v/v of 
oligomers were added to the 70 pM monomeric mixture at day 0 and fibril 
formation was monitored by taking daily aliquots over 7 days to perform 
Thioflavin T (ThT) assay. 1000 pM stock solution of ThT (Sigma, T3516) was 
made fresh in ultrapure water on the day of the assay and diluted to a 100 pM 
end concentration in either 50 mM AA or SP. To 100 pL of ThT reagent 20 pL 
sample of the various groups was added in a black 96 well plate and 
fluorescence intensity was measured between wavelengths of 350-600 nm at 5 
sec intervals at 0.5 mm slith width. The fluorescence values from triplicate 
measurements have been averaged and expressed as a percentage of ThT
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buffer only at 382 nm wavelength. For emission scan of only mature fibrils and 
monomeric protein the samples were dissolved in 20 mM Tris buffer at pH 7.2.
Aliquots were obtained on each day of the experiment to perform dot blotting 
with anti-amyloid fibrils LOC rabbit polyclonal antibody (Millipore). 1 pL of each 
sample was spotted onto nitrocellulose membrane and air dried before blocking 
with 2 % BSA (Fisher, A/1278/46). Following blocking, the rabbit anti-amyloid 
fibris LOC antibody (Millipore, 2197267) was added at 1:1000 dilution and 
incubated on a shaker at room temperature for 1 hr. Subsequently, the 
membrane was rinsed three times for 15 min with PBS-T and then it was 
incubated with the secondary goat anti-rabbit antibody IR DyeR 800 CW IgG 
(H+L) (Odyssey, 926-32211). The fluorescence signal was detected by using 
the Licor system employing the 700 nm, green channel.
2.1.13 1-Anilinonaphtalane-8-sulphonic acid (ANS) fluorescence
ANS (Sigma, A1028) was dissolved to a final concentration of 25 pM in 50 mM 
AA or 50 mM SP and to 100 pL of ANS solution 20 pL of the respective sample 
of oligomers or monomeric a-syn was added in a black 96 well plate. For all 
alternate samples measurements were performed in triplicate. For excitation, 
385 nm wavelength was used and the emission scan was recorded between 
400-600 nm on the Tecan Infinite M200 plate reader. All values of triplicate 
measurements were averaged, expressed as mean±standard deviation (SD) 
and normalised to ANS only.
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2.2 Cell culture techniques
2.2.1 Maintaining and cryopreserving SH-SY5Y neuroblastoma cells
SH-SY5Y human neuroblastoma cells were maintained and grown in complete 
Dulbecco’s modified Eagle medium (CDMEM) consisting of 500 mL DMEM+ 
GlutaMAX™ -II (Gibco, 804781), 50 mL fetal bovine serum (Biosera, heat 
inactivated, qualified , S06908S1900), 5 mL Pen Strep ( Penicillin
Streptomycin, 5000 units/mL penicillin, 500 pg/mL streptomycin, Gibco, 15070) 
up to a maximum of 20 passages. The identity of the cell line was confirmed by 
a 16 loci Cell Line Authentication certificate. Transient transfection and then a 
stable transfection with the familial A53T mutant was kindly established by 
Mafalda Ramos (Erasmus Programme). Overexpression of the A53T mutant 
was confirmed by immunocytochemistry and Western blotting. SH-SY5Y 
neuroblastoma cells overexpressing the the A53T a-syn mutant were 
maintained in CDMEM with 200 pg/mL selective G418 antibiotics (Sigma, 
G8168-10 mL). A freezer stock of both SH-SY5Y neuroblastoma cells and SH- 
SY5Y cells overexpressing A53T was deposited for long term storage in liquid 
nitrogen dewars. The freezing procedure involved obtaining a -300 pL 
homogeneous cell suspension in CDMEM to which culture media comprising of 
30 % v/v dimethyl sulfoxide (DMSO) (Sigma, D8418) and 70 % v/v fetal bovine 
serum was added with a final cell count of approximately 1 million cells per 
cryovial. Cells were gradually cooled down on ice to prevent osmotic rupture 
and stored at -80 °C before filing them in a dewar for replenishment of stock.
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2.3 3-3’-diaminobenzidine (DAB) staining
SH-SY5Y cells were cultured in CDMEM and SH-SY5Y neuroblastoma cells 
overexpressing the familiar mutant A53T were maintained in CDMEM 
supplemented with 200 pL/mL G418 antibiotics. Both cell line types were 
seeded in CDMEM in 8 well Lab-Tek II chamber slides (Nunc, 154534) at
0.5x105 cells/mL and 600 pL cell suspension was added for each chamber and 
grown to -70  % confluence. Thereafter, the media was removed from the 
chambers and the cells were fixed with ice cold methanol for 15 min, followed 
by three 3 min washes in PBS-T and 5 min incubation with 0.5 % Triton-X100 
(Sigma, X-100) in PBS to permeabilise cells. An incubation step with 3 % H20 2 
for 10 min followed the permeabilisation. Then another three 3 min washes 
were carried out in PBS-T before blocking with 2 % horse serum provided in the 
VECTASTAIN® kit (Vector Laboratories, PK-4000) and syn 211 mouse 
monoclonal anti-a-syn primary antibody was added for 1 hr incubation at 1:1000 
dilution at room temperature that was followed another three 3 min washes with 
PBS-T. The secondary biotinylated antibody (1:1000 dilution) was incubated for 
1 hr at room temperature and two 3 min washes followed the secondary 
incubation step before adding the avidin containing ABC Reagent from the 
VECTASTAIN® kit for 30 min prepared according to the manufacturer’s 
instructions. Then the chromogen DAB was added for 20 min according to the 
manufacturer’s instructions and the chambers were protected from light, 
followed by one 5 min wash in deionised water. Then 4 ’6-diamidine-2’- 
phenylindole dihydrochloride (DAPI) (Sigma, D8417) was used for 
counterstaining the nuclei followed by one more wash with PBS-T. Mounting 
was carried out by using two drops of Fluoromount-G water soluble mounting
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agent (SouthernBiotech, 0100-01) for each chamber which were covered by 
glass coverslips for visualisation by fluorescent microscopy on an Olympus 
BX60 microscope. To assess background staining, primary antibody was 
omitted in a designated chamber. Acquisition settings of Capture Pro6 software 
were on an Olympus BX60 microscope using light microscopy at 40x 
magnification.
2.3.1 Cell lysis of SH-SY5Y cells for Western blotting
SH-SY5Y cells were grown to -80-90 % confluency in a T75 flask and rinsed 
with PBS twice. To one T75 flask of neuroblastoma cells 1 mL lysis buffer was 
added, consisting of 0.9 mL RIPA buffer (Sigma, R0278) and 0.1 mL 
mammalian protease inhibitor cocktail (Sigma, P830) for 2 min at 37 °C at 5 % 
C 02. The cells were then scraped off with a cell scraper and collected into an 
Eppendorf tube and incubated on ice for 30 min. Incubation was followed by a 
centrifugation step at 15, 000 xg for 10 min and the supernatant aspirated and 
analysed by bicinchronic acid (BCA) assay and Western blotting.
2.3.2 MTT cell viability assay
SH-SY5Y neuroblastoma cells and SH-SY5Y cells overexpressing A53T a-syn
were seeded in a 96-well plate at a density of 1x105 cells/well and cultured
overnight. Next day the cells were treated with a-syn oligomers at 10 % v/v
(0.01 mg/mL) or 20 % v/v ( 0.02 mg/mL) or 7 pM monomer in the presence of
appropriate solvent and positive controls and incubated for 4 hr, 24 hr and 48 hr
at 37 °C, 5 % C 02. Subsequently, 20 pL of 0.5 mg/mL 3-(4,5-dimethylthiaziazol-
2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) (Sigma, M2128) was added to
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each well and incubated for a further 4 hr. The medium was then removed 
followed by the addition of 150 pL of DMSO to dissolve the purple formazan 
crystals. After 15 min agitation, the colour intensity was read at 570 nm and 650 
nm on the Tecan Infinite M200 plate reader. The data was analysed by the 
GraphPadPrism software to evaluate the statistical difference. One-way Anova 
followed by Bonferroni post-hoc test was used to establish whether significant 
differences existed among various treatment groups. The cell viability of 
untreated cells is considered as 100 %, all treatments are expressed in relation 
to that. Mean cell viability (%) and standard error of measurement (SEM) are 
shown for each group.
2.3.3 Measurement of intracellular Ca(ll) influx
For the initial experiments to evaluate intracellular Ca(ll) influx, the fluorescent
blue dye Mk-1 (Molecular Devices) reconstituted with Krebs Ringer buffer
(Sigma, K4002) supplemented with 1 mM CaCI2 and 20 mM HEPES to 2X
working strength and used to replace the medium of the SH-SY5Y cells seeded
in CDMEM into 96 well black wall, flat clear bottom fluorescent plates at 1x105
cells/well density one day prior to the assay. After 60 min loading time at 37 °C
at 5 % C 02 in dark conditions, the previously prepared 50 pL fixed aliquots of
alternate treatment groups dissolved in modified Krebs Ringer buffer were
directly injected onto the loaded cells cultured in the fluorescent imaging plates
and fluorescent intensities were read at 485 nm and 535 nm. Fluorescence
intensities were monitored immediately after the addition of treatment groups
and every 10 min up to 60 min. All measured values were averaged and
matched solvent controls were subtracted. To determine statistical significance,
one-way Anova was used combined with Bonferroni post-hoc test of selected
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pairs and all values were expressed as mean±SEM of relative fluorescence 
units. The dye has been discontinued and a new generation, higher sensitivity 
fluorescent marker was used as follows: SH-SY5Y cell were cultured and 
seeded the day before the assay at 1x105 cells/well density in CDMEM in 96 
well black/clear, tissue culture treated, flat bottom fluorescent imaging plates 
(BD Biosciences, 353219). Next day the media was removed and the cells were 
rinsed with 100 pL Krebs Ringer buffer for each well and loaded with 50 pL of 
2X FLIPR Fluo6 dye (Molecular Devices, Calcium 6-QF Assay, R8192) 
dissolved in modified Krebs buffer (50 pL/well). The plate was then incubated 
for 120 min at 37 °C at 5 % C 02 in dark conditions.The various oligomers were 
prepared to a 10 % v/v or 20 % v/v end concentration (for oligomers 0.01 
mg/mL or 0.02 mg/mL referring to the monomer’s concentration) and ionomycin 
(Sigma, I0634) positive control to a 5 pM final concentration in modified Krebs 
Ringer buffer and equal volumes (50 pL) of the various oligomers, vehicles and 
controls were pipetted directly onto the cells before measurement. The 
fluorescent intensity was measured at 485 nm and 535 nm. At regular time 
intervals, the intensities were collected and the 60 min after injection readings 
were stopped. After appropriate solvent subtraction values were analysed by 
one-way Anova using Bonferroni multiple comparison test for selected pairs and 
expressed as mean±SEM.
2.3.4 Measurement of intracellular ROS formation by using CMF-DA 
fluorescence
SH-SY5Y cells and SFI-SY5Y cells harbouring the A53T mutant were cultured 
and seeded in a 96 well plate the day before the assay in CDMEM. For SH-
SY5Y cells overexpressing A53T a-syn, 200 pg/mL G418 was included as a
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selective antibiotics. The media was removed next day and cells were rinsed 
with 100 pL/well PBS 1X and loaded with 10 |jM 2,7-dichloromethylfluorescein 
diacetate fluorescent dye (CMF-DA, Molecular Probes, C2925) dissolved in 
DMEM-Glutamax II (50 |jL/well) and incubated at 37 °C at 5 % C 0 2 for 45 min 
in dark conditions. After the incubation the alternate treatments were added to 
the plate at 10 % or 20 % v/v (for oligomers 0.01 mg/mL or 0.02 mg/mL) 
including hydrogen peroxide (Sigma, H3410) as positive control and incubated 
for various lengths of time (4 hr, 8 hr and overnight treatment). The wells were 
then emptied and 100 pL/mL PBS was added to the plate to measure the 
generated intracellular oxidative species at wavelengths of 485 nm of excitation 
and 530 nm of emission. After solvent subtraction the values were analysed by 
one-way Anova followed by Bonferroni post-hoc test for selected pairs and 
expressed as mean±SEM.
2.3.5 Im m unocytochem istry
2.3.6 Assessing in tracellu lar aggregation
SH-SY5Y cells were cultured in CDMEM and the same cell line containing the 
familial mutant A53T was maintained in CDMEM supplemented with 200 pL/mL 
G418 antibiotics. For seeding, both cell line types were seeded in CDMEM in an 
8 well Lab-Tek II chamber slides (Nunc, 154534) at 0.5x105 cells/mL and 600 
pL cell suspension was added to each chamber and grown to -70  % 
confluence. Treatment groups were added in the presence of appropriate 
vehicle controls at 10 % or 20 % v/v (0.01 mg/mL or 0.02 mg/mL concentrations 
referring to the monomer’s concentration) for 8 hr treatment. Thereafter, the 
media was removed from the chambers and the cells were fixed with ice cold
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methanol for 15 min, followed by three 3 min washes in PBS-T and 5 min 
incubation with 0.5 % Triton-X100 (Sigma, X-100) in PBS to permeabilise cells. 
Then another three 3 min washes were carried out in PBS-T before blocking 
with 2 % horse serum (VECTASTAIN®, PK-4002) and the appropriate primary 
antibody (syn 211, monoclonal antibody, or anti-a-syn rabbit polyclonal 
antibody, a gift from Prof R. Cappai, University of Melbourne) was added for 
overnight incubation at 4 °C or for 1 hr incubation at 1:1000 dilution or 1:5000 
dilution respectively at room temperature that was followed another 3 washes 
with PBS-T. The secondary fluorescent antibody, either Alexa Fluor 594 
conjugated goat anti-mouse antibody or Alexa Fluor 488 conjugated goat anti­
rabbit antibody at 1:1000 dilution (Molecular Probes, Invitrogen, A11008) was 
incubated for 1 hr and two 3 min washes followed the secondary incubation 
step before adding 0.5 mg/mL DAPI (Sigma, D8417) for counterstaining the 
nuclei. After DAPI staining one more wash with PBS-T was performed and 
mounting was carried out by using two drops of Fluoromount-G water soluble 
mounting agent (SouthernBiotech, 0100-01) for each chamber which were 
covered by glass coverslips for visualisation by fluorescent microscopy on an 
Olympus BX60 microscope. To assess background fluorescence, primary 
antibody was omitted in a designated chamber and all other stages were the 
same as described above. Acquisition settings of Capture Pro6 software were 
on an Olympus BX60 microscope: gamma 1.23, gain 0.850, auto white balance 
red 0.9960, green 1, blue 0.9960, 680x480 FF, RTV power resolution, 
2560x1920 FF, Bin1 acquisition resolution, exposure power 1.800 except DAPI 
(exposure power 1.00) at 40x magnification. Pseudo-colours were extracted 
and recombined after acquisition to obtain merged images.
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2.3.7 Neurofilament immunostaining
Neurofilament mouse, monoclonal antibody was purchased from Abeam 
(Ab7255 DA2) and used at 1:500 dilution. For immunostaining of cells, the 
same protocol was performed but microscopic visualisation was undertaken 
using a x100 oil immersion objective.
2.4 ESI-IMS-MS experiments
2.4.1 Needle puller
10 cm, 1 mm diameter borosilicate thin wall glass capillaries (Harvard 
Apparatus, GC100T-10) were pulled to optimal shape by a Sutter Instrument 
Co. P-97 Needle Puller. Tips were visualised and trimmed to size with tweezers 
directly before acquisition on an Olympus, Zeiss light microscope. The adjusted 
settings of the needle puller for attaining a stable spray were as follows in Table
2.2.:
Parameter Round 1 Round 2 Round 3
Heat 246 224 250
Pull - - 250
Velocity 18 15 40
Time 100 75 90
Table 2.2. Parameters o f heat, pull, velocity and time used for needle pulling at 
various cycles.
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2.4.2 Sputter coater
Capillaries were filed in a glass petri dish and placed into the SC7620 Mini 
Sputter Coater (Emitech). The sputter coater was operated at pressurised 
atmosphere maintained by argon. The plasma sputtering time lasted 160 sec, 
following the manufacturer’s instructions.
2.4.3 Calibrations with known, globular protein standards
All spectra were collected using a Synapt G2 HDMS instrument (Waters, 
Manchester, UK) by use of gold coated home-made borosilicate nano­
capillaries in positive ion mode. Instrumental settings were extensively 
optimised by varying the backing pressure, bias, cone and capillary voltages of 
the standards predominantly under native conditions. Optimised instrumental 
settings for data acquisition were: capillary voltage of 1.70-1.90 kV, cone 
voltage of 30-70 V, source temperature of 60 °C, trap collision energy of 4.0 V, 
transfer collision energy of 10 V, trap bias 45, backing pressure of 3.0-3.1 mbar 
unless otherwise stated. IMS separations were performed at T-wave velocities 
of Trap: 311, IMS: 800 and Transfer: 200 m/s and T-wave amplitudes of 4-15 V 
using 3.6 mbar pressure of nitrogen gas maintained by a 90 mL/min gas flow. 
Native spectra were obtained by dissolving the protein in question to a 10-20 
pM final concentration in aqueous solution of 50 mM AA at pH 6.8 or pH 7.0. 
For attaining denatured spectra, all calibrants and mass standards were 
prepared before injection at 10-20 pM and a-syn at 10 and 40 pM and dissolved 
in 50 % acetonitrile, 10 % formic acid and 40 % ultrapure water (vol/vol/vol). 
Calibration curve for Os was obtained based on of multiple charge states of
cytochrome c from horse heart (Sigma, C7752), myoglobin from equine heart
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(Sigma, M1882) and ubiquitin from bovine erythrocyes (Sigma, U6253) as 
described previously (Smith et al. 2009). ESI-IMS-MS data of ADH from yeast 
(Sigma, A8656), a-lactalbumin from bovine milk (Sigma, L5385), bovine albumin 
(Sigma, A8531), (32 microglobulin from human urine (Sigma, M4890), carbonic 
anhydrase from bovine erythrocytes (C7025), lysozyme from chicken egg 
(Sigma, L6876), porcine elastase from porcine pancreas (Sigma, E7882) was 
also obtained in the same manner. Mass calibration was carried out by an 
infusion of Csl cluster ions, and arrival time distributions were determined by 
using the Mass Lynx v4.1 software (Waters, Manchester, UK).
2.4.4 ESI-IMS-MS analysis of unknown proteins
2.4.4.1 Mass spectrometry of metal ions
Stock solutions of monomeric a-syn, CuCI2, FeCI3 and ZnCI2 were prepared to a
final concentration of 50 pM working strength in 40 mM AA at pH 6.8. Similarly,
50 pM solutions of the metals were also prepared without Gly or in 6-fold
excess of Gly, pH 6.8 and used for the experimentation performed on the
Synapt G2 HDMS (Waters, Manchester, UK) in positive ion mode. The protein
to metal ratios were 1:0, 1:1 and 1:2 (v/v) using the 50 pM working strength
solutions directly prepared and mixed before analysis except for Cu(ll) for which
an extra 1: 0.5 (v/v) ratio was set up. The following instrument parameters were
used for data acquisition: capillary voltage 1.5 kV-2.0 kV, sample cone 50-60 V,
backing pressure 3.0 mbar, trap collision energy 4.0 V, transfer 20 V, IMS wave
velocity 800 m/s, IMS wave height 4 V, IMS gas flow 90 mL/min. The
instrument was calibrated using an aqueous Csl solution beforehand.
Calibration for Q measurements was performed as mentioned above.
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2A.4.2 ESI-IMS-MS of oligomers
The mass spectra were acquired by using the Synapt G2 HDMS instrument 
(Waters, Manchester, UK) fitted with an nESI source and optimised to allow 
transmission of ions and tuned to preserve non-covalent complexes. Acqusition 
parameters are specified in Chapter 4. Calibration and data processing was 
performed as discussed above.
In silico collision Qs were calculated utilising a projection approximation script 
developed by and verified by the Ashcroft group (Smith et al. 2010). In silico 
models were assuming the monomeric a-syn subunits were spherical with a 
radius of 19.9 A.
2.4A.3 Mass spectrometry of Tyr and DA binding studies
Equine cytochrome c, horse heart myoglobin, bovine ubiquitin, DA 
hydrochloride, glycine (Gly), a-Tyr and AA were purchased from Sigma-Aldrich 
(UK). Human, recombinant WT a-syn was expressed in E. coli BL21 (DE 3) and 
purified as described above. The concentration of pure monomeric a-syn was 
determined using the molar extinction constant 5960 cm'1 at A280 on a Jenway 
Spectrophotometer. Samples for ESI-IMS-MS experiments were prepared by 
dissolving a-syn to a 50 pM end concentration and by diluting DA or Tyr to a 
6.25 mM final concentration in aqueous solution of 40-50 mM AA, pH 6.8. The 
following proteins to ligand ratios of the working strength solutions were 
analysed: 1:125, 1:30 and 1:8 molar ratios, all prepared and mixed immediately 
prior to analysis. The experiments were conducted either in the presence or 
absence of 6-fold excess of Gly to avoid non-specific interactions. Samples 
were introduced to the Synapt G2 HDMS instrument (Manchester, Waters, UK)
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by using metal coated home-made borosilicate capillaries in positive mode. 
Typical instrumental settings for data acquisition were: capillary voltage of 1.70- 
1.90 kV, cone voltage of 50-60 V, source temperature of 60 °C, trap collision 
energy of 4.0 V, transfer collision energy of 10 V, trap bias 45, backing pressure 
of 3.1 mbar. IMS separations were performed at T-wave velocities T-wave 
velocities of Trap: 311, IMS: 800 and Transfer: 200 m/s and T-wave amplitudes 
of 4-15 V by using 3.6 mbar pressure of nitrogen gas maintained by a 90 
mL/min gas flow. Calibration for obtaining Cl was undertaken as discussed 
earlier.
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3 Chapter 3
Biochemical and biological characterisation of a range of in 
vitro a-syn oligomers
3.1 Introduction
3.1.1 a-syn oligomers are causative species in PD
PD is the second most common neurodegenerative disorder (de Lau et al. 
2006) in which toxic a-syn oligomers have a causative role (Demuro et al. 2005; 
Winner et al. 2011; Malchiodi-Albedi et al. 2011; Gurry et al. 2013). However, it 
is still poorly understood what triggers the natively unstructured monomeric 
protein to misfold in the cellular environment to produce toxic, oligomeric forms 
instigating disease. In addition, little is known about the stability, dynamics and 
morphological features of oligomeric subpopulations and how they exert their 
cytotoxic functions causing neuronal demise. A plethora of in vitro preparation 
protocols of a-syn oligomers have been developed recently (Danzer et al. 2007; 
van Rooijen et al. 2010; Wang et al. 2010b; Giehm et al. 2011; Nasstrom et al. 
2011; Cremades et al. 2012; Singh et al. 2013; Roostaee et al. 2013) with the 
aim of determining the potential modes of action in vivo. Different oligomeric 
procedures have shown disparate results regarding the size and biological 
effects of a-syn oligomers (detailed in Chapter 1), implying that different 
conditions alter the self-assembly pathway in their own manner. These 
oligomers can be both on pathway to amyloid self-assembly or represent an off 
pathway product (Lashuel et al. 2002; Ding et al. 2002; Cappai et al. 2005; 
Danzer et al. 2007; Kim et al. 2009; Angot et al. 2012; Gurry et al. 2013).
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3.1.2 Alternative toxic modes of action of a-syn oligomers
3.1.3 a-syn oligomers are capable of disrupting membranes
Several biological modes of action have been presented as hypotheses of how 
these oligomers elicit toxic effects. The first unifying notion that has gained 
importance is that these oligomers are potent disruptors of biological 
membranes (Davidson et al. 1998; van Rooijen et al. 2010; Ruiperez et al. 
2010; Stockl et al. 2013). When the monomeric protein converts to oligomers a 
structural transition takes place from natively unfolded state to a p-sheet rich 
conformation that is concomitant with amyloid fibril formation (Uversky et al. 
2009). It has been demonstrated that oligomeric species bind tighter to mainly 
phosphatidylglycerol (PG) containing synthetic membranes than monomeric or 
mature fibrillar forms (Voiles et al. 2001). In this study, disruption of fluorescent 
dye loaded vesicles by oligomeric a-syn was directly visualised by AFM and 
fluorescence increased in a concentration dependent manner. When oligomeric 
forms (~5 pM) bound to vesicles a p-sheet rich conformation was seen by CD 
spectroscopy, indicating that p-sheet conformation of these pre-fibrillar species 
was retained (Voiles et al. 2001) in contrast to the a-syn monomer which 
obtains an a-helical conformation upon membrane association (Davidson et al. 
1998). Oligomers binding to membranes may act on the ordering of the lipids 
within the membrane. It has been postulated that membrane disintegration may 
occur by decreasing the lipid order of the membrane or by formation of transient 
pores followed by rearrangement of the lipid bilayer or by insertion of ordered p- 
structure membrane spanning pores that then lead to death of neurons (Stockl 
et al. 2013; Stockl et al. 2012). It is plausible that the toxicity of a-syn oligomers
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is not solely due to the formation of membrane spanning channel like pores but 
may originate from disruption of lipid packaging through insertion of specific 
regions into the lipid bilayer (Stockl et al. 2013). a-syn oligomers have a net 
negative charge but contain positively charged residues within their core as 
determined by Lys residues at aa 6, 10, 12, 96, 97 and 102 may therefore 
interact favourably with negatively charged lipid head groups in the bilayer 
facilitating binding. Hydrophobic residues located near the N-terminal region are 
conceived to have higher affinities for negatively charged lipid head groups 
which then cause “phase separation” in membranes. An initial separation 
disturbing membrane packaging then may allow intrusion of further hydrophobic 
segments of a-syn into the inside of the membrane. This embedding of 
hydrophobic motifs could permit access to small hydrophilic molecules such as 
Ca(ll) (Stockl et al. 2013). a-syn oligomers also appear to facilitate “lipid flip- 
flop” as the resultant membrane rearrangements promote the movement of 
hydrophilic lipid head groups between two parts of the bilayer (Stockl et al. 
2012).
3.1.3.1 a-syn oligomers can induce Ca(II) influx
Biological consequences of membrane permeabilisation could be Ca(ll) influx 
into the cytosol, depolarisation of the mitochondrial membrane (Demuro et al. 
2005; Danzer et al. 2007; Kim et al. 2009; Giehm et al. 2011; Danzer et al. 
2012; Mattson 2012) or an increase of cytosolic dopamine in the cytoplasm 
(Lotharius et al. 2002b; Lundblad et al. 2012). Ca(ll) dysfunction leading to 
influx has been reported in relation to numerous other amyloidogenic peptides 
such as Api-40, amylin and serum amyloid suggesting a common mechanism 
(Quist et al. 2005). Oligomers of these amyloidogenic proteins and peptides
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share a common conformational epitope detected first in A(31-40 oligomers and 
this can be recognised by the anti-oligomeric antibody A11 (Kayed et al. 2007). 
This antibody reacts with numerous in vivo and in vitro oligomeric forms of 
different amyloidogenic proteins with p-sheet content. It has now been proved to 
be increasingly important in detecting shared generic oligomeric epitopes 
across protein aggregation diseases (Morten et al. 2007; Wang et al. 2009; 
Krishnan et al. 2012; Colla et al. 2012; Aidt et al. 2013).
Wang et al. hypothesised that elevated Ca(ll) levels in turn may activate CaN. 
This dephosphorylates a mitochondrial proapoptotic protein, BAD, which is 
member of the Bcl2 family, ultimately leading to cell death of neurons (Wang et 
al. 1999). Similarly, CaN dependent cell death upon oligomeric treatment has 
been reported by Martin et al. (Martin et al. 2012).
3.1.4 Extracellular a-syn oligomers cause seeding of a-syn
An alternative prevailing theory proposes that a set of a-syn oligomers act as 
seeds of aggregation and initiate the build-up of proteinaceous inclusions 
resembling Lewy bodies. Soluble a-syn oligomers have been detected in the 
extracellular space (Chai et al. 2013). Secretion of a-syn and its aggregates via 
exocytosis has been demonstrated in neuronal cells (Lee et al. 2005) as well as 
the internalisation of a-syn intermediates by endocytosis (Lee et al. 2008a). In 
vivo transmission of a-syn to neighbouring neurons and neuronal precursors, 
especially when lysosomal function was inhibited has been demonstrated in cell 
culture and in vivo transgenic mouse brains engrafted with stem cells. The 
inhibition of proteosomal system had little effect, inclusions were still observed 
but not at significant levels in the various cells, indicating that clearance occurs
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mainly in the lysosomes. The recipient cells containing abnormal protein 
inclusions displayed fragmented nuclei and signs of caspase-3 activation both 
in vivo and in vitro (Desplats et al. 2009). In another study, propagation of a-syn 
has been observed in co-culture model systems, where after endocytosis the 
extracellulary added a-syn associated with and seeded the aggregation of 
intracellular a-syn. a-syn injected into rats was internalised and its uptake 
abolished by supplementing endocytosis inhibitors such as dynasore and 
monodansylcadaverine. In addition, transmission of a-syn from host to grafted 
cells has been illustrated in transgenic mice overexpressing WT a-syn by 
confocal microscopy, flow cytometry and Western blotting (Hansen et al. 2011). 
In two isolated cases of PD patients who had received grafts of foetal 
mesencephalic dopaminergic neurons, Lewy bodies developed in the 
transplants after several years (Li et al. 2008).
Remarkably, prion diseases characterised by the misfolding of the cellular prion 
protein PrPc into infectious PrPSc particles can be readily transmitted by a self- 
propagating mechanism in the central nervous system (Prusiner 2012; Kraus et 
al. 2013). Therefore, a-syn and its oligomeric intermediates appear to replicate 
this pathology in many ways (Angot et al. 2010; Hilker et al. 2011; Angot et al.
2012).
3.1.5 The toxic oligomers of a-syn have heterogeneous morphologies 
and effects
In vitro preparation methods for a-syn oligomers lead to aggregates with a 
broad range of sizes and biological function. Cremades et al. have shown 
subpopulations of small size ~2-5-mers, medium size ~5-15-mers and larger
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assemblies ~15-150-mers by employing single molecule Fluorescence 
Resonance Energy Transfer (FRET). These oligomers were prepared by 
labelling a-syn at residue 90 with Alexa Fluor 488 and Alexa Fluor 647 beside 
unlabelled a-syn at protein concentration of 6 pM (Cremades et al. 2012). The 
heterogeneous mixture of oligomers was classed as type A small, A medium, B 
medium and B large oligomers. Type B oligomer appreared to be resistant to 
proteinase K digestion as opposed to type A oligomers and the natively 
unfolded monomer. Treatment with type B oligomers induced a rapid increase 
of ROS production in the cytosol. Type A oligomers had a less significant effect 
on cytoplasmic ROS exposure to monomers or fibrils had no effect. Fibril 
disaggregation samples contained a variety of species some of which were 
identical to the higher p-sheet containing type B oligomers at early incubation 
times. The energetics and assembly kinetics differed for the type A and B 
oligomers but interconversion was possible. All a-syn species were shown to be 
internalised rapidly within 6-8 min both in rat primary neurons and astrocytes 
and exposure to these oligomers did not affect cell viability over 24 hr 
(Cremades et al. 2012). Of note, oxidative stress can then enhance the rate of 
further oligomerisation (Maries et al. 2003) and ROS was found to trigger 
apoptotic cascades (Jenner 2007) driving a vicious circle. Oligomeric species 
may also damage mitochondrial DNA leading onto impairment of respiratory 
complex-l (Jenner 2003).
Two studies performed by Danzer et al. recapitulated some of the above
mentioned cytotoxic aspects of recombinant in vitro a-syn oligomers such as
different morphologies as judged by AFM, Ca(ll) influx and initiation of
intracellular aggregation post-oligomeric treatment in SH-SY5Y cells (Danzer et
al. 2007; Danzer et al. 2009). Type A preparations included freeze drying the
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soluble fraction during the lag phase of fibril growth and this yielded spherical 
structures under Fe(lll) free conditions, while addition of Fe(lll) resulted in more 
extended protofibrillar structures. These preparations spanned 40-45 nm in 
diameter as shown by AFM. This oligomer preparation had pore forming Ca(ll) 
channel-like activities that mediated Ca(ll) influx from the extracellular milieu. 
Exposure to these latter oligomers activated caspase-3 in a-syn overexpressing 
cell lines. Alternative type C oligomers produced in the presence or absence of 
Fe(lll) C1 and C2 respectively by spin concentrating the soluble fraction during 
the lag phase did not differ morphologically from each other and were observed 
to be a mixture of globular and protofibrillar species with spherical appearance. 
These oligomers were found to be nucleating species as they induced 
intracellular aggregation upon exposure in a-syn overexpressing cell lines 
(Danzer et al. 2007). With these findings in mind, it was clear that there was a 
gap in understanding how secondary and tertiary structure of these groups of in 
vitro oligomers correlated with their respective biological properties and 
cytotoxicity.
3.2 Aims and objectives 
Overall aims
To examine the hypothesis (Section 1.9), oligomer preparation protocols 
reported by Danzer et al. were adapted to MS compatible conditions and 
assayed by a number of methods to reveal biological key biochemical and 
functional differences between alternate oligomeric types.
The specific goals were:
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i. to produce type A and type C a-syn oligomers with the same biochemical 
and biological properties as published by Danzer et. al in the presence or 
absence of FeCI3.
ii. to modify exisiting protocols to produce oligomers suited to detailed 
structural characterisation by ESI-IMS-MS.
iii. to carry out spectroscopic measurements and epitope mapping as a 
novel aspect to understand more about oligomeric structure and folding 
entities.
iv. to evaluate and contrast the biological effects of alternate oligomeric 
subsets by an array of cell culture techniques in human SH-SY5Y cells.
3.3 Materials and methods
Protein expression and purification, oligomer preparation, ThT assay, dot 
blotting, Tyr and ANS fluorescence scans, MTT, Ca(ll) influx and ROS assay 
and immunocytochemistry were performed as described in Chapter 2.
3.4 Results and discussion
3.4.1 Protein expression, formation of a-syn oligomers and fibrils
a-syn is a natively disordered protein that has a high tendency to aggregate 
(Uversky 2008; Fink 2006). Oligomers are aggregation intermediates that 
precede fibril formation and have been shown to be key in the pathogenesis of 
PD (Jellinger 2011; Lashuel et al. 2013). Toxic in vitro oligomers prepared in 
various laboratories using alternate protocols have given vital clues as to how in
vivo oligomers evoke their toxic gain of function (Lashuel et al. 2002; Kim et al.
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2009; Angot et al. 2012; Cremades et al. 2012 Dettmer et al. 2013; Gurry et al.
2013). Limited evidence has been shown about how a particular oligomer type’s 
biochemical and biological functional properties correlate with its underlying 
structural properties (Bernstein et al. 2004; Rekas et al. 2010; Cremades et al. 
2012). A group of in vitro a-syn oligomers reported by Danzer et al. were shown 
to have diverse biophysical properties and essential functional properties 
contributing to neuronal damage (Danzer et al. 2007; Danzer et al. 2009). 
However, information about the composition of these heterogeneous oligomers 
regarding subunit size and shape was yet to be explored. To this end, 
preparation protocols were adapted and modified enabling structural 
characterisation of these oligomers by ESI-IMS-MS as discussed in detail in the 
following chapter.
One technical constraint of ESI-IMS-IMS is that data acquisition of oligomeric 
complexes near native states can only be undertaken in volatile buffers such as 
AA. The preparation protocol established above requires the use of 50 mM SP 
which would lead to extensive adduct formation and prevent ionisation. To 
overcome this limitation, buffer exchange was a conceivable approach; initial 
experimentation methods were hampered by the genuinely low yield of amyloid 
oligomers during preparation and resulted in loss of material during size SEC or 
in a loss through non-specific binding to the filter membrane during spin 
concentration. Therefore, it seemed a more plausible alternative to produce a- 
syn oligomers directly in AA buffer and address whether such modification of 
the protocol alters biochemical and biological properties when compared to 
well-defined oligomeric populations generated in SP buffer. First, it was 
necessary to demonstrate that features of type A and type C oligomers
produced in SP were consistent with published literature (Danzer et al. 2007;
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Danzer et al. 2009). In order to produce the required recombinant protein BL21 
(DE3) Escherichia coli competent cells were transformed with pET 23 a+ vector 
containing the human WT a-syn sequence. Expressed protein was first isolated 
by acid precipitation and purified by anion exchange and gel filtration to have a 
continuous supply for producing a-syn oligomers (Appendix Figure 8.1.). The 
mass of the protein was confirmed by mass spectrometry and by Western 
blotting using a polyclonal full length anti a-syn antibody (Appendix Figure
8.2.).
To confirm formation of low MW oligomers, SEC was performed that revealed 
that a small proportion of the monomeric protein converted to oligomeric forms 
consistently eluting near the void volume at ~6.5-8 mL on a Superdex 200 
10/300 GL column as shown in Appendix Figure 8.3..
Amyloid formation a-syn fibrillisation proceeds by a nucleation dependent 
fashion entailing a slow lag phase including the formation of a partially folded 
intermediate (Uversky et al. 2001a; Uversky et al. 2001), followed by the growth 
phase which then plateaus off (Lomakin et al. 1996; Fink 2006). Addition of 
preformed intermediate oligomeric species can accelerate the rate of fibril 
formation by shortening the lag phase and providing seeds for recruitment of 
monomers to assemble into large mature fibrils (Wood et al. 1999; Kim et al. 
2009). As it has been shown, metals including Fe(lll) and Cu(ll), lower pH, 
higher temperature have influence on the kinetics of this self-assembly (Uversky 
et al. 2001c; Uversky et al. 2002). Certain conditions disfavour fibril growth and 
do not facilitate recruitment of further monomers as in the case of DA (Leong et 
al. 2009a; Lee et al. 2011) or even disassemble fibrils (Li et al. 2004) and may 
divert the aggregation pathway or halt it. In order to confirm that the
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recombinant a-syn was able to form amyloid fibrils, aggregation of the 70 pM 
monomeric protein in both SP and AA was monitored over 7 days using ThT 
fluorescent dye (Naiki et al. 1989; Biancalana et al. 2010). The data showed a 
typical sigmoidal fibril growth profile consistent with previous observations 
(Uversky 2008). ThT incorporates into amyloid-like fibrils and its quantum yield 
significantly increases (Stsiapura et al. 2008) as shown for mature a-syn fibrils 
in Appendix Figure 8.4..
To investigate the seeding effect of the oligomers (type A1, A2, C1 and C2) 
prepared in SP buffer, the fibril formation of 70 pM a-syn was monitored in the 
presence of 10 % v/v of each oligomer types over 7 days. These oligomers 
were added at day 0 before incubation and are referred to as A1 SP, A2 SP, C1 
SP and C2 SP is illustrated in Figure 3.1. A. Oligomers were prepared in the 
same fashion but with the modification of the buffer, using 50 mM AA instead of 
SP to obtain oligomers suitable for ESI-IMS-MS measurements. This latter 
group of oligomers are referred to as A1 AA, A2 AA, C1 AA and C2 AA. Fibril 
formation of 70 pM a-syn in the presence of these oligomers was monitored 
over 7 days by ThT fluorescence with continuous shaking at 37 °C as shown in 
Figure 3.1. B. Fibril specific, conformation dependent antibodies have become 
available in recent years and here the LOC anti-amyloid fibrils antibody 
(Millipore) was used in parallel with ThT fluorescent measurements each day to 
verify the formation of amyloid material over non-specific aggregates. This 
antibody recognises generic epitopes common to many amyloid fibrils and 
fibrillar oligomers, but not monomers, prefibrillar oligomers or natively folded 
proteins according to Kayed etal. (Kayed etal. 2007) (Appendix Figure 8.5.).
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Figure 3.1. Fibril formation monitored over 7 days in the presence or absence 
of additional oligomers at 10 % v/v either in SP (A). Type A oligomers prepared 
in SP (open and closed blue triangles) seeded the aggregation o f a-syn (black 
cross) and abolished the lag phase o f assembly, whereas type C oligomers 
prepared in SP increased the quantum yield o f ThT. Oligomers prepared in AA 
(B) did not enhance the aggregation o f a-syn over 7 days. Relative fluorescent 
intensity plotted as a function of time and all readings are normalised to ThT 
only in matched buffer at 482 nm. Dot blotting was carried out in parallel with 
the ThT assays, using the LOC antibody that recognised mature fibrils only.All 
oligomers prepared in SP gave rise to LOC positive fibrils; day 7 is shown.
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As seen in Figure 3.1. A , type A oligomers prepared in SP had seeding 
abilities, reducing the length of the lag phase and enabling conversion of a-syn 
to fibrils after 24 hr. However, type C oligomers in SP buffer also promoted the 
formation of fibrils, the aggregation of species with cross-p structure became 
evident >96 hr. All fibrils were readily detected by the conformation specific 
LOC (Millipore) antibody at the day 7 time point, suggesting conversion to a 
more toxic p-sheet containing conformation. When these experiments were 
repeated for the alternate oligomers prepared in AA (Figure 3.1. B), it was 
observed that these oligomers did not promote fibril formation effectively and 
the rate of fibril formation was slowed in AA buffer. Dot blotting procedure with 
the LOC primary antibody showed a positive immunoreaction only with the 70 
pM a-syn sample on day 7, indicating that fibrils were not formed on this time 
scale.
3.4.2 Spectroscopic measurements
Further use of extrinsic fluorescent dyes or use of internal fluorescence based 
on naturally occurring fluorophores such as on Tyr or Trp residues are useful 
tools to study amyloidogenic structures at the molecular level (Vassar et al. 
1959; Lindgren et al. 2005; Munishkina et al. 2007). ThT and ANS are non- 
covalent extrinsic fluorophores commonly used in the investigation of 
protofibrillar oligomeric species and their self-assembly into mature fibrils. ANS 
has been widely used to reveal differences in hydrophobicity in a number of 
disease states related to a-syn, prion, transthyretin, serum amyloid A, amylin, p2 
microglobulin and Ap isoforms (Munishkina et al. 2007). ANS detects partially 
folded and molten states and associates with hydrophobic patches that is
reflected in a blue shift towards lower wavelengths (Munishkina et al. 2007;
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Roostaee et al. 2013). For this assay, ANS was dissolved in appropriately 
matched solvent. Amax of most oligomeric types was located -505 nm (black 
line), except type A1 and type A2 oligomers that displayed a blue shift with a 
Amax ~495 nm as shown by the dashed line with an arrow pointing to the Amax. 
Their quantum yield was also higher than any other oligomers’ or the 
monomer's as shown in Figure 3.2. A. Type A and C oligomers in AA had a 
similar emission spectra as the controls and type C oligomers or the monomer 
in SP, devoid of any apparent shifts towards lower wavelengths as indicated in 
B. ANS fluorescence screen of the alternate oligomeric types therefore 
indicated that type A1 and A2 oligomers fold such way that ANS could bind to 
the exposed hydrophobic residues and cause a Amax blue shift at 488 nm. In 
contrast, no Amax shift was observed for oligomers type C oligomers prepared in 
SP and type A and C prepared in AA.
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Figure 3.2. ANS fluorescence emissions scan of alternate oligomeric forms
between 420-550 nm. Emission spectra o f alternate oligomers alongside with 
the monomeric protein prepared in SP are shown in A or those prepared in AA 
illustrated in B. All measurements were performed in triplicates and mean 
values have been plotted. The dashed line indicates a -10  nm blue shift in the 
case of type A1 and A2 SP oligomers (A) in their Amax. as compared to the Amax 
of all other types of oligomers or monomeric protein or buffer control shown by 
vertical black lines.
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Internal Tyr fluorescence is a valuable indicator of the environment (Munishkina 
et al. 2007) of the four a-syn Tyr residues per monomer situated at aa Y39, 
Y125, Y133 and Y136. Upon performing a Tyr scan at 344 nm it was evident 
that quantum yields of type A1 and type A2 oligomers in SP was dramatically 
increased as opposed to all other oligomeric or monomeric form of a-syn as 
illustrated in Figure 3.3.. However, no shift in Amax occurred in either of these 
oligomeric types.
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Figure 3.3. Intrinsic Tyr fluorescence emission o f alternate oligomers and 
monomeric a-syn. All values represent three repeated measurements, mean 
values and ±SEM have been plotted. The relative fluorescence intensity o f type 
A1 and A2 SP oligomers exceeded the value o f all other types o f oligomers or 
the monomer.
3.4.3 Epitope mapping studies of a-syn oligom ers
To investigate the structural elements guiding the assembly of alternate 
oligomers, a range of specific monoclonal antibodies directed against different
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epitopes of the three main structural domains of a-syn were utilised for 
immunodetection. Dot blotting procedures have become a standard method to 
determine availability of antigenic epitopes on the surface of amyloid oligomers 
(Figure 3.4. A). In addition, an ever increasing number of conformational 
antibodies (Kayed et al. 2006) have identified common conformational epitopes 
towards oligomeric, protofibrillar or fibrillar species involved in AD, 
haemodialysis related amyloidosis and prion disease among others (Kayed et 
al. 2007; Morten etal. 2007; Yanamandra etal. 2011; Colla et al. 2012; Wall et 
al. 2012; Guilliams et al. 2013). Here, a-syn oligomers were subjected to dot 
blotting to probe their epitopes by a conformation dependent anti-oligomeric 
A11 antibody (Milipore) (a) and an in-house full length rabbit polyclonal antibody 
(b) at the 800 nm, green channel shown in Figure 3.4. B. A range of in-house 
monoclonal antibodies towards alternate regions of a-syn were also assayed 
and were a kind gift from Prof. R. Cappai, University of Melbourne. All 
oligomeric forms and positive and negative controls were subjected to dot 
blotting procedures using 35/10-7D2 antibody (developed against oxidised 
methionine containing epitope at the N-terminal, with a sequence of H- 
M[Ox]DVFM[Ox]KGLSKAKC-0H in mice) (a), 4H4-14-27-12 antibody (middle 
region, raised against KKDQLGK motif in mice) (b), a commercial antibody syn 
211 (aa 121-126) (c) and 45/08-5G7-1, (C-terminal, mice immunised with 
EAYEMP) (d) as demonstrated in Figure 3.4. C.
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Figure 3.4. Epitope mapping studies of different oligomeric populations 
performed by using a range o f antibodies in the presence of bovine serum 
albumin control. A: a picture o f oligomers with epitopes available for binding 
with a primary antibody detected by use of an appropriate secondary antibody; 
B: binding profile o f oligomers and controls with polyclonal, anti-a-syn antibody 
(a) or A11 antibody (b); C: a-syn is illustrated as a linear structure divided into 
three structural segments by two dotted vertical lines; 1 being the N-termini and 
140 being the C-termini. Alternate binding profile o f oligomers or controls is 
shown on each blot that were probed with a range o f mouse monoclonal 
antibodies developed against specific regions o f the monomeric protein (a-d 
with given aa sequences) and placed underneath the corresponding region of 
the monomeric protein.
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When a positive immunoreaction is observed a dot is detected on the 
nitrocellulose membrane due to by binding of a specific antibody (A) to its 
respective epitope that is visualised by an appropriate fluorescent secondary 
antibody marked with (A*). The absence or protection of the epitope by a 
particular structural rearrangement or folding renders the antibody unable to 
bind to the specific sequence and no dot is visible on the nitrocellulose 
membrane. All samples bound to rabbit polyclonal full length antibody except 
the control showing that all contained a-syn protein except the bovine serum 
albumin control (Figure 3.4. A). Two of these oligomers, A1 and A2 in SP gave 
a strong fluorescent signal when probed with the conformational antibody A11 
and weaker positivity was observed for type A1 and A2 oligomers prepared in 
AA with the same antibody (Figure 3.4. B). Figure 3.4. C illustrates the range 
of epitopes localised at various domains of the monomeric proteins that were 
detected by using mouse monoclonal antibodies. Dot blot a shows that 35/10- 
7D2 antibody (N-terminal, where mice were immunised with H- 
M[Ox]DVFM[Ox]KGLSKAKC-OH peptide containing oxidised Met at aa position 
1 and 5 in mice) recognised A1 and A2 oligomers prepared in SP and none of 
the other forms. Dot blot b illustrates that the middle region in these two types of 
oligomers is buried such that it was no longer available for binding of the 4H4- 
14-27-12 antibody (middle region, raised against KKDQLGK motif in mice) as 
opposed to other forms of monomeric, oligomeric or fibrillar a-syn. Dot blot c 
indicates that the epitope comprised of the 121-126 residues was exposed and 
detectable by the commercial syn 211 antibody. Dot blots d illustrate that C1 
and C2 SP oligomers gave a strong signal with the 45/08-5G7-1 antibody, (C- 
terminal, mice immunised with EAYEMP) and all other types appeared to be 
recognised to a lesser extent by this monoclonal antibody. The sequence of
45/08-5G7-1 overlaps the sequence of syn 211 and incorporates the last Tyr 
residue out of the four as marked by navy blue stars.
Importantly, dot blotting is unable to separate out subpopulations within the 
oligomeric mixture thus it gives a picture of gross immunoreactivity between a 
specific antibody and its respective epitope bound to it. Data of different a-syn 
oligomers indicated, that type A1 and A2 oligomers may have an exposed C 
terminal region, a buried middle region and probably have moieties that are 
partially exposed in the proximity of the C terminal. They also indicated that the 
N-terminal region has become oxidised. Of significance, these oligomers bound 
strongly to the A11 antibody indicative of the presence of a generic toxic 
conformational epitope shared between other amyloid disease states (Morten et 
al. 2007; Wang et al. 2009; Krishnan et al. 2012; Aidt et al. 2013). All other 
oligomers were unable to bind to the antibody raised against an oxidised N 
terminal epitope at aa 1-12, and displayed an exposed region at aa 96-102 and 
an accessibly exposed C-terminal epitope at aa 121-126. Another finding was 
that type C1 and C2 SP oligomers bound well to the antibody recognising the 
epitope encompassing aa 124-129, although none of the other oligomeric types 
were able to bind or bound less readily to this 45/08 5G7-1. These results gave 
a characteristic pattern for each type of oligomer produced in SP buffers and 
allowed to compare the oligomers produced in AA to those. Oligomers prepared 
in AA resembled to type C oligomers in SP associated with intracellular seeding 
properties.
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3.4.4 Migration of a-syn oligomers on native gels
To estimate the size of the oligomers, native gel electrophoresis followed by 
Silver staining were performed (Figure 3.5.). A variety of gel systems have 
been used here, however inconclusive indications were obtained about the 
sizes of alternate oligomers. Using a 12 % Tris-Glycine gel (Novex) native 
sample buffers and native Tris-Glycine running buffer, a smeared background 
was observed produced by oligomeric species as reported by others under 
different electrophoretic conditions (Cappai et al. 2005, Rekas et al. 2010; 
Nasstrom et al. 2011). A streaked background was visible for all of the alternate 
oligomers except A1 and A2 SP, however distinct bands of alternate 
subpopulations could not be resolved. A1 and A2 SP oligomers appeared to be 
>1048 kDa without a smeared background using the Tris-Glycine gel system. 
The monomeric protein migrated with an apparent molecular weight (MW) of 
146 kDa as noted by others in this native gel system (Fauvet et al. 2012), 
suggesting that determination of sizes would be inaccurate (A). NuPAGE®Tris- 
Acetate mini gels are recommended for the separation of large MW species by 
the manufacturer, however they have yielded limited information about the size 
and range of oligomers under native conditions as displayed below (B ).
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Figure 3.5. Silver stained 12 % Tris-Glycine gel with alternate oligomeric forms 
and monomeric a-syn (A). Silver stained NuPAGE® Tris-Acetate mini native gel 
is shown with different oligomers and a-syn (B).
Employing reducing conditions such as inclusion of SDS resulted in 
fragmentation or precipitation of a-syn oligomers, raising concerns once again 
about accurate sizing of the alternate groups (Appendix Figure 8.6.). More 
intense streaking in the background suggested formation of higher order 
oligomers, however they could not be individually resolved. The monomeric 
protein migrated as a -146 kDa species pointed out by the arrow in A. Type A1 
and A2 SP oligomers appeared to be larger than any other species and had no 
background. NuPAGE® Tris-Acetate mini gels were not able to resolve the
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different types of oligomers and samples did not fully enter the stacking gel as 
indicated by the presence of dark lines in the loading wells, suggesting poor 
solubility of oligomers in this system. Interestingly, A1 and A2 SP had clearer 
backgrounds and two populations, one with -720 kDa and another with >720 
kDa. The monomer did not display a distinct band perhaps due to a limitation of 
the gel’s resolving range (-30 kDa-400 kDa) as seen in B. These discrepancies 
demonstrated the technical limitations of using native gel systems and alternate 
buffer systems in which a-syn and its oligomers are still poorly characterised 
(Bartels et al. 2011; Fauvet et al. 2012).
3.4.5 MTT cell v iab ility  assay demonstrates that type A oligom ers are 
tox ic upon 48 hr incubation
Having undertaken spectroscopic studies and epitope mapping it remained to 
be seen whether the alternate oligomeric forms had relevant toxic gain of 
function in a cell culture model. To examine the functional features of a-syn 
oligomers, SH-SY5Y cell were cultured and treated with alternate oligomeric 
forms after which a number of selected bioassays were performed. This 
neuroblastoma cell line has been widely used to study PD due to its 
dopaminergic nature, its endogenous expression of a-syn and its suitability for 
mammalian overexpression of mutant a-syn (Forloni et al. 2000; Danzer et al. 
2007; Wright etal. 2009; Danzer et al. 2009; Camilleri etal. 2013)
Firstly, to address the influence of oligomeric forms on cell viability, MTT assays 
were performed at different time points of 4 hr (A), 24 hr (B ) and 48 hr (C) post 
exposure to 10 % v/v oligomeric treatment or matched vehicle controls as 
shown in Figure 3.6.. This technique is based on measuring the ability of
96
mitochondrial dehydrogenase (mtDH) to convert the yellow MTT to purple 
formazan crystals following oligomeric treatment for different periods of time. 
This assay is unable to differentiate between apoptosis or cell cycle arrest, 
therefore it cannot reflect cell proliferation accurately; its use is restricted to 
giving a snapshot of the metabolic state of treated cells based on the activity of 
mtDH.
97
treatment groups
^ W kW nW nW~ ------ - ~ - • • o <->
treatment groups, * p<0.05
E
100-
*P : w '*
treatment groups. *** p<0.0001
^  ^  ^  •$* ^  ^  -S4 -tf4 -J\*pb
*  ✓  s  j & p/
treatments groups, * p<0.05, *** p<0.0001
A^ A^ A^ A^ A^ A^ A^ A^ ^  *$\eb
- - - - - - - - - ,o 0>
jc4 ^  ^  ^  ^  ^  ^
» _s\p _oVj j \ o _«V> j \ 0  -cV> jjV* ^V=^pV
£#*£pN^
<5P * r *p
N< < o \< < < < d V V V V4 #  gJ-J-jS
®p *s° «r
✓
treatment groups. *** p<0.0001 tredment groups. *** p<0.0001
98
Figure 3.6. MTT cell viability assay of SH-SY5Y human neuroblastoma cells 
performed at 1.0x105 cells/well seeding density. A shows data obtained 
following a 4 hr treatment with 10 % v/v oligomers, their matched solvent 
controls and other controls. B represents values obtained post exposure of 24 
hr incubation with alternate oligomeric treatments in addition to controls at 10%  
v/v. C indicates MTT values in % obtained after 48 hr incubation with alternate 
oligomeric forms and respective controls at 10% v/v. All treatments were set up 
in triplicates and read at 570 nm and 690 nm. DMSO caused significant cell 
death over 24 hr treatment (p<0.0001). All readings were averaged, appropriate 
solvent controls were included and subsequently values have been normalised 
to untreated cells (100 %). Means are plotted with ±SEM, levels of significance 
and p values are indicated under each group.
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Following 4 hr treatment, only type A2 AA oligomer appeared to have a 
significant effect on cell viability and none of the other treatments reduced the 
viability of neuroblastoma cells at this time point. Essentially, type A oligomers 
seemed to be more toxic than any other type C oligomers following the 48 hr 
incubation period at statistically significant levels. These findings regarding type 
A1 and A2 SP oligomers are in agreement with Danzer et al., who showed that 
type A oligomers are more toxic in neuronal culture and act through activating 
caspase-3 leading to apoptotic pathways (Danzer et al. 2007). Experiments 
were repeated in the same way at 20 % v/v oligomeric treatment and controls 
and it was found that type A oligomers, in particular type A1 and A2 SP 
oligomers were capable of inducing cell death even at earlier type points to a 
statistically significant level (Appendix Figure 8.7.). These data demonstrated 
that type A oligomers in both AA and SP buffer had a propensity to reduce cell 
viability, whereas type C oligomers in both AA and SP buffer were not toxic to 
SH-SY5Y neuroblastoma cells.
3.4.6 Type A oligom ers prepared in SP evoke a Ca(ll) in flux in SH-SY5Y 
neuroblastoma cells
The dot blotting performed in section 3.4.3. would indicate that the type A
oligomers would have Ca(ll) channel like behaviour due to their ability to bind
A11. To confirm that the type A oligomers had Ca(ll) channel-like properties,
unlike type C oligomers (Danzer et al. 2007; Danzer et al. 2009), an assay was
performed utilising a new generation, high specificity fluorophore, FLIPR Fluo6
Assay Kit (Molecular Devices) developed for measurement of Ca(ll) influx. SH-
SY5Y cells were seeded in monolayer, allowed to adhere and next day loaded
with 50 pL, 2X FLIPR Fluo6 fluorophore diluted in modified Krebs buffer
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followed by incubation for 60 min at 37 °C, 5 % CO2 . Following the loading of 
cells with the FLIPR Fluo6 fluorophore, equal volumes of treatments were 
injected directly onto the fluorescent dye loaded cells. Fluorescence intensities 
were monitored immediately at multiple time points in triplicates. Only type A1 
and A2 oligomers had a propensity to increase intracellular Ca(ll) to statistically 
significant levels (Figure 3.7.), in good agreement with previously published 
results (Danzer et al. 2007; Danzer et al. 2009).
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Figure 3.7. Ca(ll) influx o f SH-SY5Y human neuroblastoma cells performed at 
1.0x105 cells/well seeding density. A1 and A2 SP evoked a significant increase 
(p<0.0001) in Ca(ll) levels as well as the positive control, ionomycin (p<0.001). 
Appropriate solvents were subtracted and means have been plotted with ±SEM, 
n-3, at the 60 min time point.
As reported previously, treatment with A1 and A2 SP oligomers caused a rise in
intracellular Ca(ll) levels comparable to ionomycin that is powerful bacterial
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ionophore (Abramov et al. 2003) produced by Streptomyces conglobatus. No 
other oligomer types or controls had the same effect on intracellular Ca(ll) 
levels, a-lactalbumin was included as a negative control with similar mass to 
monomeric a-syn. It is important to emphasise that none of the oligomers 
affected cell viability significantly <4 hr so the increase in Ca(ll) levels was not a 
secondary effect of cell death as shown by MTT assay.
Results obtained by using an older generation fluorophore, FLIPR Calcium 4 
Assay Kit (Molecular Devices) (data not shown) were in agreement with findings 
discussed here. In previous reports, it has been demonstrated through use of 
defined inhibitors of Ca(ll) homeostasis that this increase was attributed to influx 
of Ca(ll) from extracellular sources and not from mobilisation of intracellular 
stores e.g. endoplasmatic reticulum (ER) or co-activation of other cation 
selective ion channels. Conducting experiments in the presence of specific 
inhibitors i.e. thapsigarin that block ATPase Ca(ll) pumps of ER or cobalt (non­
specific inhibitor) (Demuro et al. 2005, Danzer et al. 2007) can further elucidate 
the mechanism of action and the involvement or exclusion of particular Ca(ll) 
channels evoking Ca(ll) imbalances (Zakharov et al. 2007; Martin et al. 2012; 
Reznichenko et al. 2012) and was not of primary interest here. The gold 
standard would be to carry out live cell imaging or electrophysiology 
measurements that are capable of monitoring conductivity changes at cellular 
levels, however this was not completed during the time of this thesis.
These data of the Ca(ll) influx assay in combination with the epitope mapping 
studies futher indicated that an A11 reactivity correlates with a Ca(ll) channel 
like activity as seen for type A1 and A2 SP a-syn oligomers. None of the other
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oligomers bound to the A11 antibody or bound to this conformational antibody 
weakly and were not capable of inducing Ca(ll) imbalances.
3.4.7 Reactive oxidative stress by CMF-DA
In addition to dysregulation of Ca(ll) homeostasis, a-syn oligomers have been 
shown to be involved in formation of reactive free radicals (Cremades et al.
2012) that can lead to lipid peroxidation and oxidation of vital proteins in 
neuronal networks (Jenner 2003). In contrast, there are theories that suggest a 
primary causative role for ROS and free radical formation rather than being a 
mere consequence, implying that they are key triggers of a complex sequence 
of events that initiate mitochondrial dysfunction, protein misfolding and 
neurotoxicity (Nasstrom et al. 2011; Ruiperez et al. 2010; Mattson 2011). To 
assess the formation of free radicals of protein oxidation resulting from cellular 
exposure to oligomers, a fluorescent cell tracker CMF-DA was utilised (Watabe 
et al. 2007; Idkowiak-Baldys et al. 2010). This marker diffuses freely across the 
membrane and once it is inside the cell intracellular esterases can cleave it and 
convert it to a fluorescent impermeable form that is able to react with thiols of 
proteins or peptides. To examine whether oligomers can cause detectable 
oxidative stress, neuroblastoma cell were exposed to oligomeric treatments for 
alternate lengths of time, where matched solvent controls and H2O2 were 
included as controls. Figure 3.8. A shows data collected after 4 hr incubation of 
SH-SY5Y cells with each alternate oligomers matched and vehicle controls. B 
represents fluorescent intensity measurements of SH-SY5Y cell overexpressing 
A53T mutant that were treated in the same manner. The neuronal phenotype of 
these cell lines was confirmed by staining for neurofilament as shown in
Appendix Figure 8.11.. A stable overexpression of the A53T mutant was kindly
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established by Mafalda Ramos, Erasmus Programme. Expression levels were 
confirmed by immunocytochemistry as illustrated in Appendix Figure 8.8.. 
These cells were maintained in DMEM with 250 pg/mL G418 selective 
antibiotics and used here to detect free radicals post-oligomeric treatment.
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Figure 3.8. ROS induction and protein oxidation after alternate treatments. SH- 
SY5Y cells (1x105 cells/ well) were treated with 10 % v/v oligomers, vehicle 
controls or other controls for 4 hr and measurements were taken in triplicates at 
485 nm and 530 nm (A). SH-SY5Y cells overexpressing A53T a-syn were 
exposed to the same treatments for 4 hr and readings were recorded and 
plotted as mean values ±SEM of three biological replicates (B).
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All other data collected after 8 hr treatment or overnight with alternate oligomers 
and the appropriate controls is shown in Appendix Figure 8.9.. None of the 
oligomeric treatments evoked statistically significant production of reactive 
oxidative species detectable by CMF-DA at 10 % v/v following 4 hr treatment in 
these cell lines, indicating that the oligomers do not exert their biological effect 
through the production of ROS. Another explanation may be that the assay was 
not sensitive enough to detect subtle changes in the production of ROS upon a- 
syn oligomeric treatment of neuroblastoma cells.
3.4.8 Functional assays in cell culture- Intracellular aggregation induced 
by extracellularly added oligomers
It has been documented that certain forms of a-syn from the extracellular
environment are internalised and induce a seeding mechanism (Danzer et al.
2007; Danzer et al. 2009; Luk et al. 2009; Angot et al. 2012) resulting in
intracellular a-syn being triggered to self-aggregate. The notion of intracellular
propagation of a-syn is in its infancy (Angot et al. 2010; Prusiner 2012; Kraus et
al. 2013) and much research has been performed to dissect this intracellular
cell-to-cell transfer mechanisms (Danzer et al. 2012) and follow the fate of a-syn
species through from intake, processing (Lee et al. 2005) to elimination of toxic
aggregates (Emmanouilidou et al. 2010a; Emmanouilidou et al. 2010b; Esteves
et al. 2011). Treatment with type C1 and C2 SP oligomers has been shown to
cause a marked reduction in otherwise homogeneous cytoplasmic staining of a-
syn and cause a striking increase of punctate, aggregate formation in the
cytosol and near the nucleus in neuronal cultures (Danzer et al. 2009). To test
the propensity of the previously described oligomers and other oligomers
compatible with mass spectrometry to induce intracellular aggregation of a-syn,
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SH-SY5Y cells overexpressing the a-syn A53T mutant were exposed to 
treatments. Effects of exposure of SH-SH5Y cells overexpressing A53T a-syn, 
to monomeric and solvent controls for 8 hr were also assessed. In brief, after 
exposure to and removal of excess extracellular a-syn treatments for 8 hr, 
fixation and washing steps were done followed by using monoclonal mouse, syn 
211 (Sigma) primary antibody that was detected by a fluorescent secondary 
Alexa Fluor 594 conjugated goat anti-mouse antibody for immunofluorescent 
microscopy imaging as described in more detail earlier. In a control experiment, 
primary antibody was omitted and confirmed that background fluorescence with 
the secondary antibody was not considerably high.
The findings shown here demonstrated that indeed type C1 and C2 SP 
oligomers prepared had a propensity to induce intracellular aggregation (Danzer 
et al. 2007; Danzer et al. 2009) (Figure 3.9.). In contrast, type A1 and A2 SP 
oligomer did not show an altered cytoplasmic staining in neuroblastoma cells 
overexpressing A53T a-syn mutation, indicating that these oligomers lacked the 
ability to induce intracellular aggregation (Figure 3.10.). Together, all types of 
oligomers produced in AA had an enhanced ability to induce intracellular 
aggregation. In line with this activity, their dot blotting profile matched type C1 
and C2 SP oligomers’ that have earlier been demonstrated to exclusively seed 
transmembrane aggregation of A53T a-syn overexpressed in neuronal cell 
types (Danzer et al. 2007; Danzer et al. 2009).
Experiments were repeated three times and results were uniform throughout, 
indicating that type C1 SP, C2 SP, C1 AA, C2 AA, A1 AA, A2 AA had a 
pronounced effect on seeding aggregation of intracellular a-syn when applied 
extracellularly. The same results were obtained in non-transfected SH-SY5Y
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cells (Appendix Figure 8.10.)- Punctate formation of these a-syn oligomers 
was evident in contrast to their respective vehicle controls or in contrast to type 
A1 and A2 SP. These data of the intracellular aggregation assay showed that all 
mass spectrometry compatible oligomer types and type C oligomers prepared in 
SP induced intracellular seeding when added extracellularly in human 
neuroblastoma cells.
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3.5 Conclusions
a-syn oligomers are believed to be toxic in PD and other neurodegenerative 
diseases (El-Agnaf et al. 2006; Jellinger 2011; Eller et al. 2011), however a 
comprehensive understanding of the role of these amyloid precursors is still 
lacking. Many oligomeric preparation protocols of a-syn have been developed in 
vitro in recent years with the aim to reveal the dynamics governing aggregation 
of the natively unfolded protein into these toxic forms and to elucidate how they 
exert their toxicity whilst interacting with biological membranes and cellular 
organelles such as mitochondria and lysosomes (Lashuel et al. 2002, Demuro 
et al. 2005; Kim et al. 2009; Danzer et al. 2007; Danzer et al. 2009; Giehm et al. 
2011; Winner et al. 2011; Cremades et al. 2012; Gurry et al. 2013). The 
presence of specific modulatory ligands during the oligomerisation process and 
their correlating biophysical and biochemical characteristics have also been 
addressed (Li et al. 2005; Wright et al. 2009; Leong et al. 2009b; Singh et al.
2013). It has been previously shown that alternate preprative methods lead to 
distinct classes of in vitro oligomeric forms of a-syn with alternate toxic gain of 
function. Type A oligomers were associated with Ca(ll) channel-like properties 
and were more toxic in neuronal cells (Danzer et al. 2007), whereas type C 
oligomers had a propensity to induce transmembrane seeding in a dose and 
time dependent fashion in both primary cortical neurons and neuronal cell lines 
(Danzer et al. 2009). AFM experiments suggested that type A oligomers had an 
annular morphology ~2-4 nm in height and type C oligomers were protofibrillar 
and globular structures with -4-10 nm in height (Danzer et al. 2007). No further 
information about the structural details of these oligomers has been uncovered 
to date. To reveal additional insights into the secondary and tertiary structures
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of these oligomers by mass spectrometry and to establish links between their 
structure and toxic gain of function, oligomer preparation protocols were 
adapted (Danzer et al. 2007) to aid further characterisation. The described 
biological properties of type A and type C oligomers both Fe(lll)-free (type A1 
and type C1 SP) and Fe(lll)-supplemented (type A2 and C2) prepared in SP 
were consistently reproducible in SH-SY5Y cells.
The main aim of this work was to determine the mass and geometry of 
prefibrillar aggregates by means of ESI-IMS-MS in a similar manner to other 
amyloidogenic proteins (Bernstein et al. 2009; Smith et al. 2010; Bleiholder et 
al. 2011; Grabenauer et al. 2010a; Woods et al. 2012). To achieve this, the 
previously established preparation protocols with using a relatively low 
concentration of the monomeric protein (7 pM a-syn) had to be altered by 
substituting SP buffer with AA buffer.
It was crucial to investigate whether these second set of oligomers had any 
similarity with those reported in the literature and are referred to as type A1 and 
A2 AA and type C1 and C2 AA. Since a-syn’s native conformation and 
assembly is largely influenced by its immediate environment is was necessary 
to perform comparisons of the mass spectrometry compatible oligomers with 
established variants produced in SP. Membrane binding properties and the 
aggregation kinetics of a-syn are also thought to be affected by alternative use 
of solvent, a-syn preferentially binds to small (20-25 nm) vesicles rather than 
larger vesicles with a composition of phosphatidic acid (PA), phosphatidylserine 
(PS) and phosphatidylglycerol (PG) and not to vesicles with a net neutral 
charge like phosphatidylcholine (PC) (Davidson et al. 1998; Munishkina et al. 
2007). It has been shown that an increase in NaCI concentration (0-500 mM)
i l l
resulted in a decrease of a-helix content and an increase in the random coil 
content, correlating with a decreased ability of a-syn to bind to synthetic 
vesicles as shown by biophysical structural tools (Davidson et al. 1998). 
Secondary structure analysis of a-syn using FTIR demonstrated that different 
types and percentages of alcohols as well as changes in pH cause alterations in 
the relative populations of partially folded state, (3-structure and a-helix 
(Munishkina et al. 2003).
Regarding fibril formation, addition of SP oligomers could seed fibrillisation to 
amyloid fibrils or at least the quantum yield of fluorescence was increased in SP 
when monitored by ThT assay. Type A oligomers produced in SP promoted the 
formation of mature fibrils with cross (3-sheet as indicated by both the ThT assay 
and the use of fibril specific anti-amyloid fibril LOC antibody, whereas type C led 
to an increased ThT signal. By contrast, fibrillisation of a-syn by agitation was 
slightly slowed in AA and the seeding effect of oligomers prepared in AA was 
negligible as measured by ThT assay. Oligomers with seeding ability diminish 
or shorten the otherwise slow lag phase of a-syn are considered as on pathway 
to fibril formation (Kim et al. 2009). This would infer that the cellular seeding 
oligomers are off pathway or that the concentration of oligomers produced in AA 
is below that required for an observable in vitro seeding effect.
The next step in addressing any differences between these alternate oligomers 
was to perform spectroscopic methods reliant on internal fluorescence of Tyr 
residues or externally added fluorescent ANS dye. Tyr fluorescence 
measurements showed that type A1 and A2 SP oligomers had enhanced 
quantum yields as compared to all other oligomeric types and again only these 
two oligomers displayed a blue shift upon addition of ANS that favours binding
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to hydrophobic patches. All other oligomer types had a lower fluorescence 
signal upon Tyr emission scanning and did not show Amax shift during ANS 
fluorescence emission scanning. These measurements indicated that the Ca(ll) 
channel-like oligomers are more hydrophobic and perhaps the mainly the C- 
terminally located Tyr residues reside on the surface and relatively unquenched 
in their assembly.
Epitope mapping studies by dot blotting have provided further support for this
concept and indicated that A1 and A2 SP oligomer types bound strongly with
the conformational antibody, A11 that has been indicated in pathogenic
conformations (Morten et al. 2007; Wang et al. 2009; Krishnan et al. 2012; Aidt
et al. 2013). Type A1 and A2 AA oligomers bound weakly to A11 antibody and
no binding was detected for type C oligomers in AA or SP. Kremer et al.
reported that aggregated Ap had a propensity to reduce membrane fluidity and
an enhanced aggregation rate and surface hydrophobicity correlated with lower
membrane fluidity (Kremer et al. 2000). In accordance with this, prefibrillar
aggregates of a variant of Ap 1-42 peptide showed a pronounced binding to
ANS and alterations in its ANS binding ability correlated with changes in toxicity
in SH-SY5Y cells (Bolognesi et al. 2010). An increment in ANS binding was
reflected in an increased effect on cell death in case of of WT Ap1-42, I59T
mutant of human lysozyme and an SH3 motif of PI3 kinase, indicating that the
exposure of hydrophobic motifs are central to cytotoxicity. The intensity of ThT
binding did not correspond to ANS binding or cytotoxicity when monitoring these
peptides or proteins in a time dependent manner (Bolognesi et al. 2010).
Furthermore, another recent finding showed that a region of yeast prion Sup35
(NM) could be arrested in its assembly pathway to produce either A11 positive
aggregates by use of a number of small molecules or cross-linking. The
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oligomers generated were either A11 reactive, more hydrophobic and toxic in 
neuroblastoma cells or produced OC positive, larger oligomeric states exhibiting 
less toxicity and hydrophobicity (Krishnan et al. 2012). These observations 
regarding an increased hydrophobicity and A11 reactivity hold true for type A1 
and A2 SP oligomers.
Probing the different oligomers with monoclonal in-house antibodies raised 
against distinct epitopes of a-syn dispersed on its 3 structural domains revealed 
further deviations in their epitope mapping profiles. Using the 4H4-14-27-12 
antibody raised against aa 96-102 did not bind to A1 and A2 SP oligomers. This 
could mean that these residues are folded in the core of A1 and A2 SP 
oligomers in a shielded position, prohibiting binding to this antibody. These 
observations may well be reflective of the toxic gain of function to disorder lipids 
and give an entry to extracellular Ca(ll) (Kremer et al. 2000; Stockl et al. 2012). 
It may be possible that such kind of folding affects packing of the lipid bilayer, 
where an initial membrane binding could be facilitated by the N-terminal domain 
that cause membrane perturbations that then permit penetration of further 
hydrophobic residues into the interior and access for small molecules i.e. Ca(ll). 
As shown by syn 211 antibody, the epitope located at aa 121-125 was exposed 
on each oligomers and binding was observed. This observation was similar to 
recent findings that suggested that the C-terminal region is not likely to be 
significantly involved in the formation of p-sheet structure of fibrils and it 
remains solvent accessible (Miake et al. 2002), enabling binding of nanobodies 
to C-terminal epitopes (Guilliams et al. 2013). Furthermore, the C terminal of a- 
syn contains numerous acidic residues and prolines described as structure 
breaking motifs (Zakharov et al. 2007) and tends not to acquire a structured 
fold.
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It was intriguing to examine whether the oligomers prepared in AA had 
biologically relevant characteristics that were comparable to those of SP ones. 
MTT cell viability assay demonstrated that type A oligomers, both AA and SP 
became significantly toxic after longer incubation times at 10 % v/v post 
exposure and toxicity was more pronounced at 20 % v/v. This gives support to 
the fact that weakly (A1 and A2 AA) or strongly positive (A1 and A2 SP) A11 
oligomers appear to be more toxic in neuronal cells. Type C oligomers did not 
cause statistically significant cell death when compared to matched solvents 
after the duration of 4 hr, 24 hr or 48 hr treatment.
Neither of these oligomers evoked significant protein oxidation when measuring 
cellular thiol content using CMF-DA probe following 4, 8 and 24 hr treatment 
with alternate oligomeric types. However, literature suggest that combined use 
of dihydroethydium measuring superoxyde anion levels (Yang et al. 2010; 
Cremades et al. 2012; You et al. 2013), C11-BODYPY581/591 (Chen et al.
2007) measuring lipid peroxidation and MitoSOX measuring mitochondrial 
species (Cremades et al. 2012) could have given more comprehensive 
information about ROS.
Ca(ll) measurements confirmed that type A1 and A2 SP oligomers evoked an 
increase in intracellular Ca(ll) levels consistently with Danzer et al. and none of 
the other subsets showed Ca(ll) channel-like properties (Danzer et al. 2007). It 
is interesting to note Campioni et al. inferred that high hydrophobicity of HypF-N 
oligomers correlated with an increased propensity to penetrate the cell 
membrane and caused intracellular influx of Ca(ll) (Campioni etal. 2010).
As the next step in functional characterisation, the transmembrane seeding of
oligomers was assessed it was found that all oligomers prepared in AA induced
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intracellular aggregation after treatment for 8 hr akin to C1 and C2 SP oligomers 
(Danzer et al. 2007; Danzer et al. 2009). Considering all spectroscopic data and 
the epitope mapping data alongside the intracellular (IC) seeding assay, it 
seems likely that type A1 AA, A2 AA, C1 AA, C2 AA, C1 SP and C2 SP 
oligomers have very similar biochemical and biological properties. The only 
features that set type A1 and A2 AA apart from type C oligomers in either SP or 
AA is that they reduced cell viability to a higher extent and they bound weakly to 
A11 antibody (Figure 3.11.)- The assembly of oligomers is a very dynamic 
process and the aggregation conditions such as concentration and buffer 
conditions will determine what types of oligomers are formed. It has been 
shown that type A pore forming oligomers could convert to type C oligomers 
inducing intracellular seeding poperties in neuroblastoma cells when the 
preformed type A oligomers underwent an additional “ultrafiltration step”. It is 
possible that type A1 and A2 AA had a subset of oligomers types that produced 
an A11 positive structure but these oligomers were not capable of introducing 
Ca(ll) influx at the conditions used here. Perhaps type A1 and A2 AA oligomers 
had subpopulations of type C like states and a minor subpopulation of 
oligomers resembling A1 and A2 SP oligomers that could be detected by the 
A11 antibody. This would employ a roll in buffer competition in tipping the 
aggregation between the two oligomer assembly pathways and will be 
investigated further in Chapter 4.
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Figure 3.11. The key findings of alternate a-syn oligomers formed from the 
monomer are shown regarding their biochemical and cytotoxic properties. 
Intriguingly, distinct oligomers of a-syn possess different degree of 
hydrophobicity and immunoreactivity with A11 antibody and elicit different 
responses in SH-SY5Y cells regarding cytotoxicity, transmembrane seeding or 
Ca(ll) imbalances. The oligomeric forms developed under mass spectrometry 
compatible conditions are highlighted by a blue line. The dotted line indicates 
that the pore forming type A oligomers can convert to the type C oligomers with 
seeding properties following ultrafiltration of preformed type A oligomers as 
reported earlier by Danzer et al. (Danzer et al. 2009).
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Finding clues as to why intracellular, transmembrane seeding was observed for 
all oligomers prepared in AA when seeding properties were moderate as judged 
by ThT will remain to be an endeavour.
Additional biochemical evidence mainly via spectrometric measurements and 
epitope mapping studies has been provided that in part helped to better explain 
some of the toxic functions of a set of in vitro oligomers. By revealing details 
about epitopes located at various regions and by shedding light on basic 
biochemical entities supporting biological behaviour of these oligomers it is 
conceivable that these new insights may inform the design of therapeutic 
agents targeting prefibrillar intermediates. It would be of particular interest to 
isolate oligomeric species from the CSF and sera of PD patients and examine 
whether there are any biophysical and biochemical similarities between in vivo 
and in vitro oligomeric populations of a-syn. In addition, a new group of altered 
oligomers with tangible biochemical and biological functions have been 
prepared reproducing previously described cytotoxic aspects of oligomers 
reported by Danzer et al. (Danzer et al. 2007). These oligomers have allowed 
the ascertainment of much needed structural information about subunit size and 
geometry and will be discussed in the next chapter.
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4 Chapter 4
Structural insights into oligomerisation of a-syn
4.1 Introduction
4.1.1 Applications of ESI-IMS-MS
The early pioneering work of Jarrold, Kemper, Bowers and their co-workers has 
laid down the foundations of investigating gas phase ion structures of atomic 
carbon clusters (Shvartsburg et al. 1998) cluster ion isomers (von Helden et al. 
1991; von Helden et al. 1993) and metal ions in the gas phase and built a 
framework for calculating and modelling mobilities of these molecules by 
projection approximation (PA) (Wyytenbach et al. 1997) or by exact hard sphere 
scattering (EHSS) (Shvartsburg et al. 2008; Shvartsburg et al. 1996; 
Shvartsburg et al. 2007). ESI-IMS-MS has subsequently become a favourable 
tool in analysing a broad array of inorganic and organic, biological systems 
(Heck et al. 2004; Koeniger et al. 2006). Due to its sensitivity, speed of analysis 
and ability to determine structural transitions, ESI-IMS-MS has been harnessed 
in investigating the structure and complex assembly of proteins (Ruotolo et al. 
2005; Frimpong et al. 2010), peptides (Michaelevski et al. 2010b; Harvey et al. 
2011), carbohydrates (El-Hawiet et al. 2012b) and nucleic acids (Rosu et al.
2008). ESI-IMS-MS has also found applications in analysing the structure and 
identity of small molecules, monitoring ligand binding interactions (Grabenauer 
et al. 2008; El-Hawiet et al. 2012a; Kitova et al. 2012; Deng et al. 2012; Soper 
et al. 2013), dissecting multisubunit amyloidogenic complexes (Bernstein et al. 
2009; Smith et al. 2010; Kloniecki et al. 2011), bacterial pili complexes (Leney
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et al. 2 0 1 1 ), bacteriophage (Shepherd et al. 2011) and complex multi-symmetric 
viral (Uetrecht et al. 2011) assemblies. This technique lends support when 
answering research questions regarding topology and dynamics of co­
populated complexes (Smith et al. 2010; Grabenauer et al. 2010a), dissociation 
of complexes or conformers (Ruotolo et al. 2007; Giganti et al. 2011; Kukrer et 
al. 2 0 1 2 ) and characteristics of small molecules that are pertinent in therapeutic 
applications (Woods et al. 2012; Marcoux et al. 2013b; Niu et al. 2013).
4.1.2 Instrumentational characteristics of ESI-IMS-MS
During an ion mobility experiment, the time taken for an ion to travel through a 
neutral gas under the influence of an electric field is measured. This time is 
dependent on the charge, mass and conformation of the ion; for a given ion of 
the same mass and charge an ion with a large Q would take longer to traverse 
through the buffer gas, while an ion of smaller Q would travel faster (Mason et 
al. 1988). The Q of an ion is therefore closely linked to its structural properties 
(von Helden et al. 1991; Wyytenbach et al. 1997; Jarrold 2000; Shvartsburg et 
al. 2008).
The introduction of biological molecules into the gas phase while preserving 
conformation and non-covalent interactions requires the use of so-called soft 
ionisation techniques. Electrospray ionisation is one such method that is 
strongly associated with the legacy of Fenn who was awarded a Nobel prize in 
Chemistry for his invention enabling “molecular elephants to fly” into the gas 
phase (“in vacuo") (Fenn et al. 1989). During this soft ionisation technique, 
samples are introduced in conductive gold coated borosilicate capillaries or by 
an automated sampling source (nanoMate) in the presence of a weak electric
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field and these parameters are critical in obtaining a stable electrospray for a 
good quality mass spectrum (Michaelevski et al. 2010b). The analyte of interest 
is subsequently extracted by the sample cone of the instrument. An 
electrospray source generates a "Taylor cone" from which a fine mist of 
molecules is produced. The use of volatile solvents result in highly charged 
droplets. Evaporation occurs when the Coulombic repulsion of the charges on 
the surface of the droplet overcomes the surface tension of the molecule 
resulting in fission. The point at which the fission occurs is termed as the 
Rayleigh limit (Rayleigh 1882, Konermann 2009). The progeny droplets 
undergo further evaporation and fission until only gas phase ions are present as 
illustrated in Figure 4.1. (University of Bristol, School of Chemistry). The 
number of charges on the ion is then dependent on the accessible surface area 
and the presence of ionisable groups. The size of the initial droplet also 
influences the ionisation process and such nanoESI (nESI) has been developed 
to facilitate a more efficient ionisation, using a fine tapered capillary with a filling 
volume of ~5-10 pL.
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Figure 4.1. Diagram o f the mechanism of electrospray ionisation, releasing 
dehydrated multiply charged analyte ions. Image taken from Univeristy of 
Bristol’s website (htpp://www. chm. bris. ac. uk/ms/images/esi-mechanism. gif)
(University of Bristol, School of Chemistry).
There are two models to describe the ionisation: i, the ion evaporation model 
that is associated with smaller ions (Thomson et al. 1979; Tang et al. 1993) and 
ii, the charge residue model that is associated with larger molecules e.g. 
proteins (Fernandez de la Mora, J. 2000; Kaltashov et al. 2005). According to 
the latter mechanism, the droplets evaporate completely and ions become 
desolvated. The protein is charged by the residual charges that located on the 
surface and provided that charge is conserved, during the ESI process the 
surface charges are transferred to the basic sites of proteins. The number of the 
basic residues on the surface will determine how many charges that protein 
obtains (de la Mora, J., F. 2000). The number of charges that the complex will 
obtain can be estimated based on the mass of the protein when sprayed from 
aqueous AA at neutral pH. The calculated charge can be estimated by the
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Rayleigh limit, with the size equivalent to the protein in question as follows 
(Heck et al. 2004):
i
z R =  8 n /e (y s 0R3y
Equation 2. Predicted charge calculation, where y is the surface tension of the 
water droplet, s0 is empirical permittivity o f vacuum, e is the elementary charge 
and R is the radius o f the droplet.
Making an assumption that the radius of the protein correlates to the mass of 
the protein and its density is similar to water a simplified equation can be 
created as shown below:
z R =  0.078 M I
Equation 3. Calculated charge of a protein (2?), in which M is the Mass in Da.
Hence, an 18.4 kDa folded globular protein for example would be expected to 
have 8  charges and a 36.9 kDa globular dimer would accommodate 12 charges 
and a 72.7 kDa heptamer would possess 18 charges (Heck et al. 2004).
During acquisition multiple charge states can be observed due to the inherent 
feature of basic amino acid side chains of proteins to pick up several charges 
when protonated. The range of these charges is referred to as the charge states 
distribution (CSD) or envelope. The highest observed charge state is dictated 
by the number of basic residues (Covey et al. 1988; Loo et al. 1988) and the 
electrostatic repulsions (Schnier et al. 1995) between protonated basic 
residues. Folded proteins are known to display a narrower CSD, with 2  to 4 
being observed due to the limited number of basic residues located on the
surface of the protein. Unfolded proteins display a wide CSD distribution due to
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all ionisation sites being available and the highest observed charge state is 
therefore shifted to the lower m/z ratios. This correlation between the surface 
area of proteins and the maximum CSD has been well researched and 
documented (Fernandez de la Mora, J. 2000; Heck et al. 2004; Kaltashov et al. 
2005).
Solvent accessibility adds another layer of complexity where folded protein 
conformations are likely to have residues that are inaccessible, buried and 
unable to carry as many charges as their unfolded counterparts. Another 
alternative theory hypothesizes that intramolecular interactions have a role to 
play and neutralisation of opposite charges may occur (Grandori 2003; 
Samalikova et al. 2003).
In experimental work, solvent compositions such as pH can practically alter 
basicity and CSD (Smith et al. 2007), high acid, base or alcohol can effectively 
unfold a closed conformation and shift CSDs to high charge states (Loo et al. 
1991; Samalikova et al. 2004; Grabenauer et al. 2008; Natalello et al. 2011; 
Santambrogio et al. 2011). Mutations with amino acid substitutions and the 
presence of binding partners i.e. metals, polycations may modulate the CSD 
(Loo et al. 1991; Grabenauer et al. 2008; Natalello et al. 2011; Grabenauer et 
al. 2010b; Hilton et al. 2010). Instrumental settings such as desolvating 
voltages, temperature (Loo et al. 1988; Benesch et al. 2003; Ruotolo et al. 
2005; Grabenauer et al. 2010b; Dupuis et al. 2009), sprayer tips and gas 
pressures (Michaelevski et al. 2010b; Sterling et al. 2012) are crucial to be 
controlled as they can cause artefacts and substantially alter CSDs. The use of 
supercharging additives e.g. m-nitrobenzyl alcohol, sulfolane and metals that 
change CSDs with potential technical benefits has been demonstrated as a new
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approach in ESI-IMS-MS analysis (Lomeli et al. 2009; Sterling et al. 2011; 
Sterling et al. 2012; Flick et al. 2012). Here a commercially available ESI-IMS- 
MS instrument, the Synapt G2 HDMS (illustrated in Figure 4.2.) has been 
utilised in the study of a-syn monomer and complex formation.
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Figure 4.2. A diagram o f the Synapt G2 instrument. Reproduced by permission 
of The Royal Society of Chemistry, (Zhong et al. 2011). The main 
compartments are: ionisation (nESI), ion selection (modified quadrulope mass 
analyser), ion mobility separation containing the triwave region and ion mass 
analysis (time-of-flight mass analyser). B is a detailed picture of the triwave 
region. Three major travelling waves operate to enable ion mobility separation. 
The light blue region is the trap region pressurised by Ar where pockets o f ions 
are collected, the green He pressurised gate region pulses the ions across into 
the middle darker blue regions where the ion mobility separation takes place in 
N2. The pink region is the transfer region filled with Ar allows furthering ions for 
mass detection.
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The ion mobility separation region consists of 168 x0.5 mm wide plates 1 mm 
apart in which the RF field operates to align ions axially, whilst travelling waves 
perform ion mobility separation by superimposing transient direct current (DC) 
to the electrodes in the stacked ion rings. Ions then enter the transfer region in 
which slower moving triwaves help to limit the diffusion of post- ion mobility ions 
in Ar gas. Subsequently, ions are separated and detected by their m/z values in 
the mass analyser (Giles et al. 2004; Harvey et al. 2011). Each region has a 
controlled gas flow that is critical in maintaining non-covalent interactions 
similarly to other parameters during the electrospray process such as 
desolvation voltages (cone and capillary).
The wave heights and wave velocities in the ion mobility separation region 
should also be tuned to enable adequate separation of ions and accurate 
experimental Q and informative of the molecular species under those particular 
conditions (Jurneczko etal. 2011; Zhong etal. 2011). Following a gated release 
of a pocket of ions 200 mass spectra are acquired and this process is repeated 
during which the next 200 spectra are added to the corresponding spectra until 
the next summation period commences. The cumulative mass spectrum is then 
produced by combining the total mobility data over a given acquisition time. 
Fragmentation of ions can be performed both pre- ion mobility enabling 
separation of product ions by ion mobility and post- ion mobility separations.
Protein confirmations are usually studied both in their denatured states 
dissolved in 50 % methanol 50 % water with 0.1% formic acid or in 10 % formic 
acid 50 % acetonitrile and 40 % deionised water and in their native states using 
AA as a solvent (Jurneczko et al. 2011). Ion mobility acquisitions presented in a 
mass spectrum that reports m/z values of ions (x axis) and on the y axis relative
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abundance of ions is seen. In addition, it provides mobilograms in the form of 
mobility plots, where drift time (in msec) is plotted as a function of m/z.
Due to the sensitivity of this technique isobaric species can be resolved as well 
as stereoisomers and conformational isomers. Isomers of Leu and lieu (131 Da) 
have been distinguished with Qs of 68.95 A2 and 70.51 A2, respectively 
(Knapman etal. 2010).
Ions resulting from proteins or complexes of the same conformation series 
cluster on a mobility plot due to the fact that ions with higher charge states 
traverse the drift cell more rapidly than larger molecular ions with greater m/z 
values and lower charge states. Conformational families can be distinguished 
from each other by comparison of these distributions (Kanu et al. 2008). As 
such, higher charge states of proteins and peptides tend to fall towards the 
bottom of mobility plots and decrease by 1 [H]+ between adjacent charge states 
in a diagonal fashion as it can be seen in case of cytochrome c on Figure 4.3.. 
Similarly to heat maps, the colour intensity of the Driftscope is reflective of the 
intensity of a respective molecular ion’s relative abundance and the peak 
maxima of its extracted drift time as illustrated for the commonly used globular 
protein standard cytochrome c. For example, the most abundant charge state 
ion of cytochrome c under native conditions is the +6 charge state ion being the 
darkest peak on the mobility plot (Figure 4.3. A) and the +15 charge state is the 
most dominant ion under denaturing conditions (Figure 4.3. B).
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Figure 4.3. Mobility plots of cytochrome c and corresponding mass spectra 
overlaid on the right. Under native-like conditions in 40 mM AA (pH 6.8) the 
protein maintained its globular structure and adopted fewer charges (A), 
showing a narrow CSD (+5 to +8). Under denaturing conditions (50 % 
acetonitrile, 10 % formic acid, 40 % ultrapure water) cytochrome c was fully 
unfolded and became easily protonated hence its CSD was much broader (+5 
to +18) (B). The nominal mass, calculated m/z values and corresponding 
charge states are indicated on the right for equine cytochrome c.
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By acquiring drift time measurements Os can be obtained for which protocols 
and workflow has been described in detail by and number of groups (Clemmer 
et al. 1997; Ruotolo eta l. 2007; Ruotolo et al. 2008; Smith et al. 2009). In brief, 
in conventional ion mobility measurements the mobility of a gas phase ion (K) is 
determined by its drift velocity (VD) and by the electric field (E), where the drift 
velocity (VD) is related to the drift time (tD) of an ion and the length (/_) of the drift 
cell (Revercomb et al. 1975) as shown here:
VD L K = -E - =E tDE
Equation 4. The mobility (K) o f an ion can be calculated from drift velocity (VD) 
and the electric field that relates to the length o f the drift tube (L) and and the 
drift time (tD) o f the ion o f interest.
The buffer gas density in which the ions are separated such as He or N2 
influence the mobility of ion and such reduced mobility (K0) is reported, where E 
is the electric field, L is the length of the drift cell, P is the buffer gas pressure 
and T is the temperature of the buffer gas and for simplicity the reduced mobility 
is normalised to the standard buffer gas pressure of 760 torr and temperature of
273.2 K (Clemmer et al. 1997):
273.2 P L 273.2 P K0 = K x — ^ X  —  = - x — ^ - XT 760 tDE T 760 
Equation 5. Calculation of reduced mobility (K0)
Then mobility of an ion (K) can be calculated from its drift time and then Q can 
be determined as indicated by the equation below. The number of charges on 
the ion is z, e is the charge on an electron (1.6022x 10' 19 C), kb is the Boltmann
constant, T is the temperature and N is the number density of the buffer gas
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(Lerme et al. 1999; Mosier et al. 2002). The reciprocal of the reduced mass
Equation 6 . Calculation o f the mobility of an ion by conventional linear ion 
mobility
Expressing K0 (Equation 5) by use of K (Equation 6) and rearranging to 
express Q, the following Equation 7 can be obtained. It describes the 
relationship between Q (A2) and drift time (tD) of an ion of interest with mass of 
rrij and charge of z, in which P is the buffer gas pressure (torr), T is the 
temperature (K) and L is the length of the drift cell (Revercomb et al. 1975; 
Valentine et al. 1999).
Equation 7. Calculation of O based on measurements o f drift times o f ions in 
the presence of a buffer gas
For triwave ion mobility separation, correction factors have been incorporated 
into conventional ion mobility equations developed for linear drift tubes 
(Revercomb et al. 1975; Mosier et al. 2002). This is required due to non-linear 
effects resulting from uneven electric fields, temperature and pressure in newer 
generation instruments.
Determination of the relationship between the drift time of an ion and its Q is 
more complex in triwave instrument than in a linear mobility cell. Hence,
between the ion’s and the buffer gas’s molecular mass is
i
i
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methods for experimental calibration of triwave instruments have been 
described and constants arising from the total effects of triwave parameters can 
be determined empirically once the acquisition parameters have been 
optimised. Compensation parameter A and B can be introduced into Equation 
7 to give Equation 8 . A is the correction factor for the electric field parameters 
(E and L in conventional ion mobility equations) and B is a compensatory factor 
for the non-linear effect of the triwave instrumentation.
In Equation 8 , kb is the Boltzmann constant, z is the charge of the ion, e is the 
charge of an electron (1.6022x1 O' 19 C), P is the pressure of the gas (in Torr), T 
is the gas temperature (in K), N is the gas number density (in rrf3), mN is the gas 
mass (mN (N2)=28 Da), mi is the ion mass and tD is the drift time of the ion (in 
msec).
Equation 8 . Q calculation for triwave instruments. A is a correction factor for 
electric field parameters and B is a correction factor for the non-linear effect of 
triwaves.
The Q can be defined as a charge and mass independent measure, termed as 
reduced Q (O’) by dividing Equation 8  by the absolute charge (ze) and reduced 
mass as shown in Equation 9.
, (18tt) 2 1 760 T 1 p
O ' =   _____   a  1-^16 -  P 273 2 N10 ( k b T ) 2  K z / *^z yv
Equation 9. Calculation of reduced Cl (Cl’) incorporating A and B calibration 
coefficients
i i
i
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These parameters can then be incorporated into one constant, A ’ as shown in 
Equation 10. A ’ is a correction factor for the temperature, pressure and the 
electric field and B is a correction factor for the non-linear effects of triwave 
device.
n ' =  A' tDB
Equation 10. Calculation o f O’ (in A2 C’1 Da'1) incorporating A ’ and B correction 
factors
Based on Equations 8 , 9 and 10 the O can be combined as shown in Equation 
11.
i i
/ I  1 V  , B / l  1 \ 2 ,n = ze I — : +  — -  A tD =  ze — 7 +  — — f l  \m i mN J \m i mN J
Equation 11. Q calculations incorporating constant A ’ that factors for 
temperature, electric field, pressure and other parameters.
It is also necessary to compensate for the mass dependent transit time of an ion 
outside of the mobility of region of the instrument and this is achieved by use of 
Equation 12 (Ruotolo et al. 2008).
t^ o = t D — (C yjm/z) / 1000 
Equation 12. Calculation o f correct calibrant drift times (at a single wave-height 
value) for mass dependent flight time, where t ’o is the corrected drift time 
(msec), tD measured drift time (msec), C is a constant.
C is found in the control software of IMS instrument as the enhanced duty cycle 
delay coefficient. C differs slightly from instrument to instrument and it is ~ 1.4- 
1.6. This correction factor results in a difference of -0.2 msec and does not 
modify the data overall.
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Given a known charge, mass and O, O' of an ion can be determined empirically. 
A ’ and B can be determined experimentally from drift times (to) obtained from a 
range of multicharged ions of known protein standards with known Os. Such 
standards are readily avalible from the work of Clemmer (Clemmer, D. E., 
Indiana University, Cross Section Database) and others (Bush, M.F., University 
of Washington, Cross Section Database). For example, the +15 charge state 
ion of cytochrome c (mi: 12355 Da) had a measured drift time 6.95 msec 
acquired in N2 (mN (N2 ): 28 Da) and its reported Cl from conventional IMS-MS 
experiments of 2579 A2. The O’ can be calculated (Equation 13) by substituting 
these values into Equation 10.
2579 A2 1 ,= r « ^ 0 0  1 o ^ a Da = 5.6726 xlO"21 A2 C-1 Da"115x 1.6022x 10-19C 0.1892
Equation 13. An example of calculating O’ of +15 charge state ion of 
cytochrome c
Q’s can be plotted against the measured drift times for which an example is 
shown below (Figure 4.4.). The calibration curve can be obtained by fitting 
these data directly to the equation y = AxB, giving values of A ’ and B (Smith et 
al. 2009).
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Figure 4.4. O’ (in A2 C 1 Da'1) calculated from Equation 10 versus measured 
drift times (msec) for the multiply charged ions arising from cytochrome c (blue 
diamonds), myoglobin (red squares) and ubiquitin (green triangles) under 
denaturing solution conditions. The line o f best fit is shown by a continuous 
black line.
Thereafter, experimentally determined A ’ and B values can be used to calculate 
the Q’s of unknown proteins then their respective Os. For example, the +7 
charge state ion of myoglobin (17562 Da) under native solvent conditions had 
an observed drift time of 11.356 msec, which from the O’ vs drift time calibration 
graph indicated a O’ of 7.24x 1021 A2 C' 1 Da‘1. Substituting this value for O’ in 
Equation 11, along with the charge state (+7), the charge on an electron 
(1.6022x 10'1 9 C) and the mass of the protein (mi: 17562 Da retaining its haem 
group) and the buffer gas (mN (N2): 28 Da), a O value of 1536 A2 was 
calculated. As proteins display multiple charge states, Os were calculated
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individually for each charge states and the mean Os were determined for each 
protein.
Once Os have been obtained the gross morphology of a protein or protein 
complex can be determined by comparison with model structures. Comparing 
experimental Os with coordinates of modelling allows the ascertainment of 
geometries and arrangements in 3 D. A freely available, often used modelling 
programme is MOBCAL (Jurneczko et al. 2011) that is based on the previously 
mentioned PA method (Wyytenbach et al. 1997), trajectory method (TM) 
(Shvartsburg etal. 1998) and EHSS (Shvartsburg et al. 1996; Shvartsburg etal. 
2007). Theoretical Os can alternatively be calculated from Protein Data Bank 
(PDB) format structures using an algorithm scripted in Leeds (Leeds Method) 
translated from MATLAB that allows modelling of a hard sphere interaction 
between the buffer gas and a protein (Smith et al. 2009; Knapman et al. 2010). 
Measured Os have been shown to be comparable to calculated Os using PDB 
coordinates from X-ray crystallography measurements and NMR coordinates, 
providing detailed structural data of biomolecular systems (Jurneczko et al. 
2011).
To date, a wealth of information has been unravelled about numerous 
amyloidogenic systems and this presents opportunities to define assembly 
pathways, to monitor the presence or absence of particular species in a rapid 
analysis. These aspects of assembly and dynamics could not be elucidated by 
using other high resolution biophysical techniques such as CD or NMR. This is 
partly due to the low abundance of subspecies and because these structural 
tools represent data of the total populations or bulk solutions (Ashcroft 2010). 
However, it is important to bear in mind that information obtained from ESI-IMS-
135
MS measurements are limited to the gas phase and molecules may well display 
altered shapes due to dehydration and charge repulsion when in solution. 
Therefore such data require careful interpretation and the use of combinatory 
methods e.g. molecular modelling to better correlate those with native solution 
conditions (Grabenauer et al. 201 Oa; Wyttenbach et al. 2011).
4.1.3 ESI-IMS-MS studies of a-syn and its oligomers
Despite the tremendous advances that have been made in characterising 
oligomeric states of Ap peptides (Murray et al. 2009a; Bernstein et al. 2009; 
Murray et al. 2009b), variants of prion proteins (Eghiaian et al. 2007; 
Grabenauer et al. 2010a; Grabenauer et al. 2010b; Hilton et al. 2010), human 
IAPP (Dupuis et al. 2009; Salamekh et al. 2011), p2 microglobulin (Smith et al. 
2010; Santambrogio et al. 2011; Woods et al. 2012;) and transthyretin (Zhou et 
al. 2012), the structural determination of a-syn oligomers and protofibrils by ESI- 
IMS-MS has been missing.
ESI-MS analysis of the monomeric protein has been undertaken by Frimpong et 
al. (Frimpong et al. 2010) and ESI-IMS-MS measurements of a-syn have been 
been carried out Natatello et al. (Natalello et al. 2011) and Grabenauer et al. 
(Grabenauer et al. 2008). Prior to these investigations, Electrospray lonisation- 
Electron Capture Dissociation- Fourier Transform Ion Cyclotron Resonance 
(ESI-ECD-FT-ICR) (Xie et al. 2006) measurements have uncovered effects of 
metals and alcohols or pH and the effect of spermine on the structure of a-syn, 
respectively.
The only ion mobility experimentation of type A oligomers established by
Danzer et al. (Danzer et al. 2007) has been demonstrated by the work of Vlad
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et al. (Vlad et al. 2012). Type A oligomers produced in SP were subjected to 
desalting on a column with a gradient after which monomeric, dimeric as well as 
a proteolytic, truncated peptide species of aa 40-140, aa 14-133 and aa 40-140 
of a-syn were observed. N-terminal Edman sequencing was also carried out 
alongside with gel electrophoresis to ascertain the identity of peptides, the intact 
protein and its dimeric oligomers. A follow up report by the same group has 
highlighted the emergence of key autoproteolytic fragments of a-syn in 
aggregation (Vlad et al. 2011). In this study, type A oligomers were incubated 
for varied lengths of time from 4 to ~21 day, deviating slightly from the 
preparation protocol to examine degradation of a-syn over time. The oligomers 
were subjected to gel electrophoresis, tryptic digest, MALDI-MS and high 
performance liquid chromatography- electrospray ionisation- mass spectrometry 
(HPLC-ESI-MS) and ESI-MS/MS analysis. MALDI-MS identified aa 40-140 and 
aa 72-140 truncated proteins and IMS-MS revealed intrinsic autoproteolytic 
fragments, aa 7-140 after a short incubation and aa 40-140 and aa 72-140 
truncated a-syn forms beside intact and dimeric forms at later time points. No 
higher order oligomers have been reported here.
4.1.4 Objectives 
Overall aims
The oligomer preparation protocols reported by Danzer et al. (Danzer et al. 
2007) were adapted and further characterised in Chapter 3 to produce both type 
A and type C oligomers suitable for ESI-IMS-MS experiments.
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Type A oligomers in SP deemed to be the most hydrophobic, cytotoxic and 
capable of binding to A11 antibody. The question remained as to how these 
oligomers differed in their structure from type C oligomers and how their 
molecular organisation might have dictated or influenced their effects observed 
in SH-SY5Y cells.
The specific aims were:
i. to tune instrumental parameters and resolve conformational families of 
monomeric a-syn by ESI-IMS-MS.
ii. to establish parameters enabling detailed structural characterisation of 
alternate oligomeric forms in the gas phase.
iii. to investigate the compactness of oligomeric subpopulations by 
measurements of Os and to compare those to Os of known proteins or 
other known oligomers.
iv. to understand how additional factors i.e. ionic strength, ethanol and metal 
ions might cause structural transitions and induce oligomerisation leading 
to aggregation.
4.2 Methods and Materials
For detailed protocols of expression and purification of the monomeric a-syn, 
formation of oligomers, pulling and sputter coating of capillaries, conducting 
calibration with known protein standards and ESI-IMS-MS analysis see Chapter
2.
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4.3 Results and discussion
4.3.1 Establishment of appropriate tuning parameters for calibration and 
calculation of Q of unknown protein
Selection of optimal settings is important in maintaining native like conditions. It 
is known that experimental parameters largely affect calculated Os (Ruotolo et 
al. 2008; Zhong et al. 2011; Bush et al. 2010). Wave heights, wave velocities 
can influence O meaurements (Grabenauer et al. 2008; Michaelevski et al. 
2 0 1 0 a) and adequate desolvating voltages have shown to be critical during ion 
mobility acquisition (Bernstein et al. 2004; Grabenauer et al. 2008). Thus, using 
a range of proteins of known structure experimental conditions were extensively 
optimised both in their denatured states and native-like states in AA to avoid 
fragmentations and obtain Os consistent with published values. The main 
considerations were given to backing pressure, bias and desolvating voltages. 
Having established acquisition settings, ESI-IMS-MS data for the monomeric 
protein was collected and mean O values were all incorporated into an 
accumulative data set serving validation of instrumental settings and shown in 
Table 4.1..
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Experimental values Theoretical values
Protein Mass
(Da)
Mean Q(A2) Standarddeviation Published values (A2) Leedsalgorithm(aS
PA (Az) EHSS(A2)
Bovine ubiqutitin 
native
8565 1199 65 1079 1059 1100 1313
Equine cytochrome c 
native
12355 1622 94 1444 1293 1130 1422
Bovine a-lactalbumin 
native
14178 1459 93 1360 1493 1207 1513
Hen egg lysozyme 
native
14305 1469 60 1496 1386 1568 1909
Horse heart 
myoglobin native
17562 1971 267 1639 1488 1628 1995
a-syn extended 14460 2482 159 2530 - - -
a-syn compact 14460 1851 276 1500 - - -
a-syn denatured 14460 2620 220 - - - -
Table 4.1. Compiled Os of a range of model proteins under native conditions 
expressed. The reported values are the mean O over all charge states of the 
proteins and standard deviations represent the spread in the recorded O across 
all charge states. Theoretical values were calculated by the Leeds algorithm 
based on their PDB coordinates from NMR and X-ray crystallography 
measurements. The MOBCAL calculations are also shown for the projection 
approximation (PA) and the exact hard sphere scattering (EHSS) model. 
Experimental published values were obtained from references (Smith et al. 
2009) and (Bernstein et al. 2004).
O values obtained and shown in Table 4.1. were consistent with values 
published in the literature (Smith et al. 2009; Bernstein et al. 2004), 
demonstrating that instrument settings did not cause significant artifacts. 
Comparison of obtained Os for globular proteins with a-syn revealed that indeed 
a-syn appeared to be more expanded than other globular protein standards with 
a similar mass. The fully denatured state of a-syn in 50 % acetonitrile, 10 % 
formic acid and 40 % water however yielded a larger O than that of the
extended conformation (Figure 4.5.), implying that the extended state has 
retained some structural arrangement. The Os of the denatured and extended 
state exceeded the average O of the compact conformation by -34-41 %.
3000-|
denatured a-syn
2500- , . .extended a-syn
r  i
a  1500-
compact a-syn
1 0 0 0 -
500
8000 10000 12000 14000 16000 18000 
Mass (Da)
Figure 4.5. Experimental Qs for bovine ubiquitin, equine cytochrome c, a- 
lactalbumin, hen egg lysozyme and horse heart myoglobin, native a-syn and 
denatured a-syn. Os are plotted as mean values across all charge states, error 
bars represent the spread in the recorded Q. White circles represent the 
experimental values acquired here, black circles represent previously published 
O values (Smith et al. 2009), black triangles represent the native extended and 
the compact conformational states o f a-syn alongside with the fully denatured 
protein. All spectra were acquired using a Synapt G2 HDMS instrument 
(Waters, Manchester, UK) by use of gold coated home-made borosilicate nano­
capillaries in positive mode.
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4.3.2 ESI-IMS-MS of a-syn monomer
It is widely accepted that compact states in solution when subjected to ESI 
acquire fewer charges and have a narrow charge state distribution, whereas 
unfolded states acquire a large number of charges and have a wide charge 
state distribution (Fenn et al. 1989; Kaltashov et al. 2005). The mass spectrum 
of a-syn clearly showed multiple charge state distributions centered at the +13 
and +7 charge state ions Figure 4.6. A. Both the +7 and + 8  charge state ions 
were more intense than would be expected for a completely unfolded protein. 
This charge state distribution is consistent with data for known globular proteins 
and given the mass of the protein (14.6 kDa), a narrow distribution can be 
expected based on Equation 3, centering around the +7 charge state ion (Heck 
et al. 2004) as observed here.
In order to further confirm that the compact conformation reflected populations 
present in solution and did not arise due to transfer to the gas phase, the mass 
spectrum of a-syn was acquired under fully denaturing conditions (50 % 
acetonitrile, 10 % formic acid and 40 % ultrapure water) as showed earlier in 
Chapter 4 (Figure 4.6. B). If the lower charge state ions of the protein 
underwent collapse during acquisition then one would expect this to be 
observed regardless of the solution conditions from which the protein was 
acquired. By contrast, charge state ions between +18 and + 8  were observed for 
fully denatured a-syn with no evidence of compact conformations at the lower 
charge state ions. The intensity of the charge state ions +9 to + 8  were markedly 
lower than that observed under native conditions indicating a single extended 
conformation. Hence, data of the control experiment supports the fact the
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com pact conform ational form s of a-syn are co-populated under native
conditions where residual structure of the protein is retained.
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dimers : /
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+17
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Figure 4.6. Mobility plots of a-syn and corresponding mass spectra overlaid on
the right hand side. Under native-like conditions in 40 mM AA (pH 6.8) the
protein consisted o f extended, compact populations and dimeric species.
Natively occurring conformational families were observed with a CSD of +6 to
+18, where the most dominant charge state ion was [M+13H]13+ (A). Under
denaturing conditions, a-syn was fully unfolded with CSD o f +8 to +19 with the
most dominant charge state of [M+15H]15+ (B). The nominal mass, calculated
m/z values and corresponding charge states are indicated on the right for a-syn.
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In comparison with other published data, Frimpong et al. ascertained 4 states of 
the protein in the pH range of 4-8: an expanded form (U) at high charge states 
( + 2 1  to +13 charge state ions), h representing helix-rich intermediates (+16 to 
+10 charge state ions), l2 entailing (3-rich intermediate state (+13 to +7 charge 
state ions) and a highly compact forms spanning low charge states (+9 to + 6  
charge state ions) (Frimpong et al. 2010). In negative ion mode study, two main 
conformational families for WT, A53T and A30P a-syn have been reported by 
the Bowers group, one dominating the lower charge states ( - 6  to -16 charge 
state ions) centered at - 1 1  with multiple features and one prevalent in high 
charge states ( - 6  to - 8  charge state ions) (Grabenauer et al. 2008). These 
conformational forms were in close agreement with data shown here, 
demonstrating multiple extended and compact features.
4.3.3 Conformational families of a-syn
Q was calculated for each charge state ion of a-syn and data was plotted 
against its respective charge state (Figure 4.7.) that enabled determination of 
the compactness of alternate molecular ions and resolution of alternatate 
conformational families. From the analysis of Os according to charge states, it 
was evident that at near native conditions a-syn had two main conformational 
families, an extended conformation with charge states + 6  to +18 and a more 
compact conformational family with charge states + 6  to +8 , having multiple 
series in both families in addition to less prevalent dimers.
Published theoretical values were superimposed on the collected experimental 
Os to help comparison of molecular arrangements.
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The compact state of a-syn has been modelled by a globular structure -1500 A2 
previously, whereas the extended state has been reported to have a O of 2530 
A2 (Bernstein et al. 2004) with a spread between -1800 A2 and 3000 A2 over all 
charge states (Grabenauer et al. 2008). Moreover, the extended state was 
shown to be more compact than a fully random coil conformation as predicted 
by small angle X-ray scattering and NMR (Uversky et al. 2001a). These models 
and reported O values have been taken from a previous publication (Bernstein 
et al. 2004) and plotted onto Figure 4.7. to aid comparison. Os of each of the 
charge states and conformational families observed here were in agreement 
with these previously reported values (Bernstein et al. 2004; Grabenauer et al. 
2008).
•  extended 
a compact
• all helical 
« native globular
Figure 4.7. Conformational series o f a-syn. Filled, black circles: experimental
Os o f extended conformational features, black triangles: experimental Os of
compact conformational forms. The dotted line represents theoretical Qs
calculated for structures having all helical conformation and the cross haired
line represents calculated values for native globular structures as reported by
Bernstein et al. (Bernstein et al. 2004). Experimentally measured values
represent means of three independent measurements with ±SD, taken on
alternate days using independent protein preparations.
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Despite the fact that a-syn is considered as a natively unfolded protein, it 
displays considerable conformational heterogeneity (Beveridge et al. 2013). It 
contains ordered regions as judged by the wide CSD and as shown previously 
by other biophysical methods including NMR and CD. The Bowers group has 
reported extended and more compact structures of a-syn observed by nESI 
analysis at various pH. It was demonstrated that WT, A30P and A53T mutants 
of a-syn populate compact and partially folded conformations whose Os have 
been determined in negative ESI-IMS-MS (Grabenauer et al. 2008). Moderate 
dimer formation was observed in each of the ion mobility experiments. The 
presence of the compact state was reported in this study which is thought to 
play a role in the misfolding of a-syn into toxic aggregates (Uversky et al. 
2001a; Uversky et al. 2009).
Here, O analysis of WT a-syn revealed a primarily extended population (charge 
state ions +8 to +18) and a subpopulation of a more compact conformational 
series (charge state ions +6 to +8) with multiple overlapping features in both 
series and less observable dimeric species under native conditions (Figure 
4.8.). Within the extended series three charge state ions +11, +12 and +13 
showed at least two major resolvable conformations. Since these charge states 
represented the most intense peaks within the mass spectrum it may be likely 
that the other charge state ions have also had multiple features but it was not 
possible to resolve them due their very low intensity. Alternatively, the larger 
H o f these three charge states could have been an artifact induced by 
coulombic repulsion due to the high charge on the molecule. Another alternative 
explanation is that there were indeed two major distinguishable conformational 
families present within the extended conformations, the first encompassing
146
charge states ions + 8  to +13 and the second encompassing charge states ions 
+ 1 1  to +18, these two major states would therefore have the + 1 1  to +13 charge 
state ions in common. This theory is consistent with the charge state distribution 
analysis of Frimpong et al. (Frimpong et al. 2010) mentioned earlier.
4.3.4 Addressing the effects of metal ions by ESI-IMS-MS
Since metal ions such as Fe(lll) have been added during the preparation of type 
A2 and C2 oligomers and Cu(ll) has been shown to alter the the aggregation 
kinetics (Uversky et al. 2001c) of a-syn, the interaction of these cations with a- 
syn and their effect on the conformations of the monomeric protein was 
examined.
Natatello et al. carried out a systematic study to determine structural transitions 
induced by a range of alcohols and Cu(ll) on a QTOF instrument (QStar Elite) 
equipped with an ESI source and demonstrated how these alternate 
conformational forms respond to co-factors and cause a shift in the CSDs of a- 
syn (Natalello et al. 2011). It was concluded that one high affinity Cu(ll) binding 
site could be detected by this experimental setup. CD, calorimetric titrations, 
NMR and EPR spectroscopy (Binolfi et al. 2008, Drew et al. 2008; Binolfi et al. 
2 0 1 0 ) demonstrated the presence of a collapsed species in the presence of 
Cu(ll).
While most metals predominantly interact with a-syn non-specifically or bind
with low-affinities, Cu(ll) has high binding affinity and is highly effective in
inducing fibrillation of a-syn via the increased population of this partially folded
conformation. The high affinity binding sites for Cu(ll) are located in at
1MDVFMKGLS9 and 48VAHGV52 and their respective binding affinity has been
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estimated as Kd ~0.1 pM. Notably, increased concentrations of Cu(ll), 
aluminium (Hirsch et al. 1991), zinc (Dexter et al. 1989) and sequestered iron 
deposits (Riederer et al. 1989; Castellani et al. 2000) have been found in the 
substantia nigra of the brain and elevated levels of copper in the CSF of PD 
patients have been reported (Pall etal. 1987).
It is clear that bi- and trivalent metal ions are involved in neuronal dysfunction 
and they have the propensity to shift the conformational equilibrium and trigger 
structural rearrangements of a-syn. Adding conformational information through 
Q calculations, it was therefore worthwhile to address binding of Cu(ll), Fe(lll) 
and a range of other bivalent and trivalent ions (Co(ll), Mn(ll), Zn(ll), Fe(ll), 
Al(lll)) to monomeric a-syn.
Representative charge state ions have been selected here for both the 
extended state and the co-populated compact conformational state to discuss 
metal binding events. The +13 charge state ion with a Q of 2635 A2 in its apo- 
form is a member of the extended conformational population with only a minor 
population of the more extended conformer. The second representative ion is 
the +7 charge state ion that belongs to the compact conformational family as 
shown in Figure 4.7., co-populating two compact states in its apo-form with Qs 
of 1845±65 A2 and 1628±80 A2 and having a very minor population assigned to 
the extended state with Q of 2080±82 A2.
Three different protein:metal ratios (1:0, 1:1 and 1:2 relative to a set
concentration of a-syn at 50 pM working strength) were analysed for each of
the metals. As displayed in Figure 4.8., it is noticeable that a maximum two
Cu(ll) copper ions could bind to all conformational ions of monomeric a-syn,
causing a mass shift of 1x or 2x 61.5 Da given that each Cu(ll) repels two
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protons from the protein to conserve charge. To investigate the specificity of 
binding, Gly was included in repeated reactions as a commonly used inhibitor of 
non-specific metal binding (Hong et al. 2009). Both in the absence and 
presence of Gly a-syn could facilitate the binding of 2 Cu(ll) ions. These results 
indicate that initial metal binding is determined at the primary structural level as 
the extended, disordered state is capable of binding two metal ions rather than 
a conformational change being required prior to metal binding. It is evident that 
molecular ions indicative of the more compact conformations become more 
dominant in the mass spectra post co-ordination of one or two molecules of 
Cu(ll) and the binding of the metal stabilised the compact conformations. This 
can be observed by the increased intensity of the lower charge state ions.
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With a closer focus on the chosen representative charge states +13 and +7, it 
was apparent that Cu(ll) could bind to both conformations with or without Gly as 
shown in Figure 4.9., containing peaks magnified in the region of interests.
+13
1:2
1:1
1:0.6
B +Gly
• • +131:2
S5itoco
• •
c
1:0.6
1:0
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Figure 4.9. The unbound forms o f a-syn are marked with open blue circles, 1 
Cu(ll)-bound forms of the protein are marked with single, filled, blue circles, the 
2 Cu(ll)-bound forms of a-syn are denoted with two blue filled circles. The x axis 
represents m/z and the y axis is relative abundance in %. Respective ratios are 
indicated on the right o f each spectrum. On the left hand side, spectra are 
shown without Gly (A) and on the right peaks are shown with Gly (B). Cu(ll) 
binding was observed to both representative charge states denoted as +13 and 
+7.
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Upon calculations of Os of the Cu(ll) adducts, it was found that at the lower +7 
charge state ion a structural rearrangement occurred that shifted the more 
extended populations toward the most compact conformation (Figure 4.10.)-
|~A~l -Gly B +Gly
+13
30002000 2200 2400
compact
1000 1500
2600 2800 
Q(A2)
extended
2000 2500
Q(A2)
2000 2200 2400
compact
2600 2800 3000Q(A2)
extended
3000 1000 1500 2000 2500Q(A2)
3000
+7
Figure 4.10. Experimental Qs (A2) o f +13 and +7 charge states o f wild type a- 
syn either in apo- or holo- forms without (A) or with Gly (B) displayed on an 
intensity scale. Blue traces represent the apo-form of a-syn, purple traces the 
one Cu(ll)-bound form and grey traces the two Cu(ll)-bound form o f the protein 
at the 1:1 ratio. Changes occurred most apparently at the +7 charge states, 
where the compact forms became more dominant at the expense o f more 
extended conformational structures after binding of Cu(ll), yielding a con former 
with a common Cl o f 1547.6 A2 as marked by the asterisks.
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Changes in the Os were not discernible between the apo- or holo- forms of the 
protein at the extended +13 charge state. In contrast, at the +7 charge state ion 
there was a shift upon Cu(ll) binding towards the most compact conformation 
when comparing to the unbound form of the protein. This transition was 
pronounced both in the absence and in the presence of Gly, resulting in a 
predominantly compact conformation with a O of 1547.6 A2. The Q of 2075.5 
m/z peak corresponded to the addition of one Cu(ll) molecule both without and 
with Gly. The Q of the 2084.3 peak m/z that is associated with the binding of 
two Cu(ll) ions populated only one dominant conformational population with the 
same experimental Cl as the apo-protein’s second more collapsed state (Figure 
4.11.)-
The respective mobility plots also reflected the formation of a-syn-1 Cu(ll) 
adducts and a-syn-2 Cu(ll) complexes at both ratios 1:1 and 1:2 both without or 
with Gly. The mobility plot representation of the data at the 1:1 protein to ligand 
ratio is shown in Appendix Figure 8.12.. The affinity of a-syn for Cu(ll) was so 
substantial that almost all of the protein was in its holo-form either incorporating 
one or two Cu(ll) ions.
Neither significant adduct formation, nor changes in the Cls could be observed 
after addition of other metals such as Zn(ll), Co(ll), Fe(ll) and Al(lll) to a-syn at 
the time scale and conditions of these experiments (<5 min) (data not shown).
The binding of Fe(lll) was of particular interest as the previously mentioned
oligomeric preparation protocols include the use of 10 pM FeC^to produce type
C2 and type A2 oligomers. Upon repeated attempts of ESI-IMS-MS analysis, no
binding was observed in the case of Fe(lll), or Fe(ll). Peng et al. have reported
observable adduct formation of Fe(ll) using Fe(NH4)2(SC>4 )2  and recombinant a-
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syn in methanol water solvent (1 :1  v/v) under which conditions the monomeric 
protein was fully unfolded (Peng et al. 2010). Complex formation between 
Fe(lll) as well as Fe(ll) and a-syn was shown by further cyclic voltammetry and 
fluorescence spectroscopy measurements. It is possible that alternate anion 
combinations could either promote or attenuate the binding of the cation to a- 
syn. For example FeCh did not result in an apparent binding to the protein, 
whereas literature reported complex formation of Fe(ll) with a-syn where Fe(ll) 
was present in Fe(NH4 )2(S0 4 )2 solution. Another concern is that oxidation of 
Fe(ll) to Fe(lll) could have also occurred in solution prior to mixing a-syn with 
the metal ion (Peng et al. 2010).
4.3.5 Investigation of the effects of ethanol prior to oligomerisation and 
other buffer conditions
Due to the inclusion of ethanol in the oligomeric preparation protocols it was
necessary to address its effect on changing the conformational populations of a-
syn. Previous evidence has indicated that alternate concentrations (%) and
types of alcohols, both fluorinated hexafluoropropanol, trifluoroethanol and
methanol modulated the conformational forms of a-syn and could selectively
enrich specific intermediates (Munishkina et al. 2003; Natalello et al. 2011). It is
important to note that the formation of partially folded conformer is a key event
in conversion to toxic conformations (Uversky et al. 2001a; Uversky et al. 2009).
To investigate the contribution of ethanol used in the particular oligomerisation
protocol of a-syn adapted here, a set of experiments were performed at
alternate alcohol percentages of 0, 10, 20 or 30 % added to 7 pM a-syn in 50
mM aequeous AA, pH 7.0. Previous evidence have suggested that ethanol and
other types of alcohols help promoting the formation of a partially folded
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intermediate of a-syn and subsequent formation of (3-sheet rich oligomeric 
forms as revealed by CD, FTIR and dynamic light scattering and ESI-IMS 
measurements (Munishkina et al. 2003; Natalello et al. 2011). In ESI-IMS-MS 
experiments performed here, no direct evidence was found for inducing 
structural conformations during the rapid time frame of the analysis (Figure 
4.11.).
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Figure 4.11. Comparison o f mass spectra after incremental ethanol 
concentrations added to 7 pM monomeric a-syn and analysed immediately by 
ESI-IMS-MS. The x axis represents m/z values, the y axis is relative abundance 
in (%). No apparent changes could be detected in the distributions o f extended 
or compact series. Instrument settings were: capillary 1.9 kV, cone 50 V, trap 4 
V, transfer 10V, helium gas flow 180.0 mUmin, IMS gas flow 90 mUmin, bias 
45, source wave velocity 200 m/s, trap wave velocity 311 m/s, IMS wave 
velocity 800 m/s, transfer wave velocity 200 m/s, backing 3.0 mbar.
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One environmental determinant of amyloid formation is ionic strength that 
influences the kinetics and thermodynamics of aggregation. Ions may 
concentrate non-specifically in the proximity of oppositely charged moieties. 
Grouping of ions therefore cause the dielectric charges of water to be elevated 
and cause the energy of electrostatic protein-protein interactions to fall off more 
readily with distance (Debye- Huckel screening). Repulsive interactions may 
become weakened giving way to intramolecular associations. Specific 
interactions with ions may affect the isoelectric point that is 4.7 for a-syn with 
possible changes in its solubility. In addition, specific types of salts dictate 
alternate effects (Klement et al. 2007).
To test the effect of the ionic strength of AA on the production rate of a-syn 
oligomers, incremental concentrations of AA were used during preparation 
protocols and each stage of the protocol was monitored. Oligomers were set up 
in increasing concentrations of AA at 50 mM, 100 mM, 250 mM and 450 mM 
and samples taken after a 4 hr incubation step are shown. It was clearly 
observable that the intensities of +6 to +8 ions belonging to the compact 
conformational forms (Figure 4.6. and Figure 4.7) were more dominant at 
higher AA concentrations than those at the lowest, 50 mM AA concentration 
(Figure 4.12.). Hence increased AA concentrations resulted in a higher 
population of the compact state.
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Figure 4.12. Comparison of the mass spectra o f type A2 AA oligomers 
dissolved in alternate AA concentrations during preparation from 7 pM a-syn at 
pH 7.0 that were analysed after the 4 hr shaking step by ESI-IMS-MS. The x 
axis represents m/z values, the y axis is relative abundance in (%). Apparent 
changes could be detected in the populations of the compact ion series (+6 to 
+9). Instrument settings were: capillary 1.7 kV, cone 50 V, trap 4 V, transfer 10 
V, helium gas flow 180.0 mUmin, IMS gas flow 90 mUmin, bias 45, source 
wave velocity 200 m/s, trap wave velocity 311 m/s, IMS wave velocity 800 m/s, 
transfer wave velocity 200 m/s, backing 3.0 mbar.
Beside an increase in the relative abundance of the compact conformers of
monomeric a-syn, the formation of oligomers were detectable early on at a 4 hr
incubation time point ranging from dimers to trimers as seen in the
corresponding mobility plots (Figure 4.13.). At 250 mM and 450 mM AA
concentration, a broader range of trimers were observed with charge states
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from +12 to +20 (T+12-T+20) and a set of tetramers (Q+17- Q+19) were present in 
the sample prepared in 250 mM AA (Figure 4.13.). These data suggest that 
increasing the AA concentrations led to a higher population of low order 
oligomers in the mass spectra. These oligomers and all other oligomers 
discussed later on in this chapter were assigned by creating a table of 
theoretical m/z values and charges (z) as shown in Appendix Table 8.1.. In 
addition to this, an in-house algorithm lent support to ascertaining the alternate 
subunit sizes by matching theoretical m/z values against measured m/z values 
and determining the associated series with the appropriate charge state 
distributions.
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4.3.6 Structural analysis of a group of in vitro a-syn oligomers- A1 and 
A2 AA oligomers
The oligomer prepation for A1 AA oligomer involved a number of successive 
steps over 7 days, including steps of freeze-drying and resuspension in buffer 
and incubation with or without agitation whilst the starting concentration of 7 pM 
monomer was retained throughout the process, serving as a pool for 
oligomerisation. To further probe structural properties of alternate oligomers 
resulted from the aggregation protocols adapted here, ESI-IMS-MS data was 
collected for each type of oligomers nearer to the final stages. The mass 
spectrum and mobility plot of type A1 AA oligomers revealed a range of 
oligomers from dimers to hexamers with a dominant population of both 
extended and compact populations of monomeric protein (Figure 4.14.). 
Calculation of corresponding Os was performed as outlined in section 4.3.8.
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Figure 4.14. Type A1 AA oligomer prepared in 50 mM AA, pH 7.0. The mobility 
plot is a log scale display with the corresponding mass spectrum on the right. 
The region >2900 m/z was enlarged by x82 to visualise the lower abundance, 
higher order oligomeric series. Oligomers fell into the populations o f dimers (D), 
trimers (T), tetramers (Q), pentamers (P) and hexamers (H). Their respective 
charge states are indicated as superscripts. Charge states of the monomeric 
protein denoted on the mass spectrum on the right. Instrument settings were: 
capillary 1.30 kV, source temperature 60 °C, cone 30 V, trap collision energy 4 
V, transfer collision energy 10 V, IMS gas flow 90 mL/min, helium gas flow 180 
mUmin, bias 45, source wave velocity 200 m/s, trap wave velocity 311 m/s, IMS 
wave velocity 800 m/s, transfer wave velocity 200 m/s, backing 3.20 mbar.
In this oligomeric preparation, dimers with a CSD of + 8  to +29 were observed, 
trimers spanned a CSD of +11 to +20, whereas the tetramers displayed a CSD 
of +16 to +18. The higher order pentamers had a CSD of +17 to +20 charge
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state ions and the largest hexameric oligomers comprised of +18 to +21 charge 
state ions.
Observation of each oligomeric series from dimer to hexamer suggests that 
oligomer growth progressed by in an isotropic manner, recruiting one monomer 
at a time in order to increase oligomer size. As seen in Figure 4.14. and as it 
appears in Appendix Table 8.1., some m/z values are shared between the 
alternate oligomeric series and have arisen from multiple populations with the 
same m/z value. Clustering and drift times of CSDs give clues to resolving 
these overlapping species, however in certain instances for example in case of 
the m/z 2066.7 and 2411.0 peaks populations could not categorically be 
assigned to only a monomeric, dimeric or trimeric series. During extraction of 
drift times of these particular peaks the individual peak maxima was taken and 
used to determine the associated Q.
Akin to type A1 AA oligomers, the mobility plot and mass spectrum of type A2 
AA oligomers consisted of the same range of oligomeric subpopulations (Figure 
4. 15).
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Figure 4.15. Type A2 AA oligomer prepared in 50 mM AA, pH 7.0. The mobility 
plot is a log scale display with the corresponding mass spectrum on the right. 
The region >2900 m/z was enlarged by x82 to visualise the lower abundance, 
higher order oligomeric series. Oligomers encompassed populations o f dimers 
(D), trimers (T), tetramers (Q), pentamers (P) and hexamers (H). Instrument 
settings were: capillary 1.60 kV, source temperature 60 °C, cone 30 V, trap 
collision energy 2 V, transfer collision energy 2 V, IMS gas flow 90 mUmin, 
helium gas flow 180 mUmin, bias 45, source wave velocity 200 m/s, trap wave 
velocity 311 m/s, IMS wave velocity 800 m/s, transfer wave velocity 200 m/s, 
backing 3.10 mbar.
Inclusion of Fe(lll) for the preparation of type A2 AA oligomer had a moderate 
effect on the aggregation of a-syn, however it is possible that larger aggregates 
were formed but the conditions employed and the time of sampling did not allow 
detection of those. Obtaining a stable spray from oligomeric solutions containing 
Fe(lll) proved to be somewhat challenging that may supports the notion the
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larger aggregates could have been present and remained inaccessible by ESI- 
IMS-MS analysis.
4.3.7 Structural analysis o f a group o f in v itro  a-syn oligom ers- C1 and 
C2 AA oligomers
Type C oligomers were prepared involving an overnight incubation step at 
continuous agitation followed by the use of 30, 000 Da MWCO VivaSpin500 
(Sartorius, Life Technologies) spin concentrators that retained the prefibrillar 
aggregates over this cut-off limit. The mass spectrum and ion mobility data 
indicated the presence of minimal monomeric peaks, peaks resultant of 
fragmentation and dimeric to hexameric oligomers that were interspersed with 
peaks that could not be assigned (Figure 4. 16.). The fragmentation observed 
in C1 AA oligomer type may have stemmed from the procedure itself e.g. from 
an interaction with the spin concentrator’s membrane or arose inherently for 
unknown reason.
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Figure 4.16. Mobility plot (log scale display) and mass spectrum o f C1 AA 
oligomer type prepared in 50 mM AA, pH 7.0. Instrument settings were: 
capillary 1.30 kV, source temperature 60 °C, cone 40 V, trap collision energy 4 
V, transfer collision energy 10 V, IMS gas flow 90 mL/min, helium gas flow 180 
mUmin, bias 45, source wave velocity 200 m/s, trap wave velocity 311 m/s, IMS 
wave velocity 800 m/s, transfer wave velocity 200 m/s, backing 3.20 mbar. 
Oligomeric populations of dimers (D), trimers (T), tetramers (Q), pentamers (P) 
and hexamers (H) were observed and CSDs indicated in superscripts. The 
monomeric protein’s CSDs are shown on the mass spectrum on the right.
An increase in the relative population of tetramers, pentamers and most 
dominant hexamers with charge state ions of +18 to +25 populating the mass 
spectrum of C1 AA oligomers was the main difference as compared to type A1 
or A2 AA oligomers. The dominance of higher order oligomers suggested that 
preparation protocols tipped the balance towards enrichment of higher order 
species.
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Addition of FeCh during the shorter preparation procedure resulted in lower 
order oligomers up to trimers, however this may be reflective of a technical 
impediment to attain an ideally stable spray for type C2 AA shown in Figure 
4.17.. Others have commented on amyloid proteins disfavouring ESI ionisation 
and clogging up tips in the time course of ion mobility separation (Bernstein et 
al. 2009; Murray et al. 2009a).
Figure 4.17. Mobility plot (log scale display) and mass spectrum o f type C2 AA 
oligomer prepared in 50 mM AA, pH 7.0. Settings were: capillary 1.40 kV, 
source temp 60 °C, cone 30 V, trap collision energy 4 V, transfer collision 
energy 10 V, IMS gas flow 90 mUmin, helium gas flow 180 mUmin, bias 45, 
source wave velocity 200 m/s, trap wave velocity 311 m/s, IMS wave velocity 
800 m/s, transfer wave velocity 200 m/s, backing 3.20 mbar. Monomeric 
populations, a set of dimers (D), and trimers (T) were detected.
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The lower order species observed could have represented residual oligomers 
left over after aggregation into larger protofibrils. It was an interesting
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observation that presumably more unfolded trimers with higher charge state 
ions of +14 to +21 were present in type C2 AA oligomers and no +12 and +13 
charge state ions were detected as opposed to type C1 AA oligomers. 
Furthermore, tetramers, pentamers and hexamers were not detected it the 
mass spectrum of type C2 AA oligomers, yet these oligomers were capable of 
inducing intracellular aggregation and appeared to be non-toxic to 
neuroblastoma cells. Obtaining a mass spectrum for type C2 AA oligomer was 
challenging from solution and it is possible that the aggregation of a-syn was 
accelerated in the presence of Fe(lll) such that species larger than trimers could 
not be detected at the final stage of the preparation protocol due to their 
assembly into higher MW protofibrils inaccessible to MS experimentation. 
Therefore, occurrence of this technical barrier does not allow conclusions to be 
drawn about the detected populations and observed functional properties.
4.3.8 Comparing CSDs and Qs of MS compatible oligomers with 
demonstrated biological functions to each other
For a detailed analysis of the ion mobility data of alternate oligomeric types, drift 
times were converted into Os as discussed in section 4.1.2. Oligomeric Os 
incrementally increased with subunit size but not in a linear fashion that pointed 
to structural rearrangements with a p-sheet formation during assembly into 
larger oligomers. Os values suggested a higher degree of compactness 
indicative of folding with increasing subunit size as shown by plotting O data as 
a function of oligomer order (Figure 4.18. A).
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Figure 4.18. Qs of oligomeric series according to oligomer size are shown for 
each mass spectrometry compatible oligomer types in panel A. The x axis 
shows subunit size and the y  axis shows obtained Qs in A2. Oligomeric 
conformational series are denoted in the legends, where blue diamonds 
represent dimers, red squares represent trimers, green triangles mark 
tetramers, purple cross hairs highlight pentamers and blue cross hairs indicate 
hexamers. Dimers are broad ranging in their Qs in type A1 (a) and A2 AA 
oligomers (b). Higher order oligomers (>dimers) the spread in Q became 
narrower reflective of compactness. Experimental Qs and oligomer size of Type 
C1 and C2 oligomers are shown in c and d, respectively. For type C1 AA 
oligomer, due to the low intensity of dimeric and trimeric peaks drift times could 
not be accurately extracted and calculation of Q was not carried out. The most 
prevalent oligomers were hexamers for for type C1 AA oligomer. In C2 AA 
oligomer, dimeric and trimeric families were present. In panel B, Qs (in A2) are 
plotted as a function of charge states for A1 AA oligomer (a), A2 AA oligomer 
(b), C1 AA oligomer (c) and C2 AA oligomer (d). Oligomeric series are listed in 
the legend.
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Experimental Os of dimers were ~ 2153 to 5584 A2 and trimers spanned Os of 
3365 to 4454 A2, whereas the O of tetramers was calculated to be 4279 to 4695 
A2, 4657 to 5015 A2 for pentamers and 5604 to 5671 A2 for hexamers in case of 
type A1 AA oligomers. These values were very similar in range for type A2 AA 
oligomers. In addition, dimers and trimers appeared to be less tightly packed, 
extended structures as compared to higher order oligomers, encompassing 
wide CSD ~ + 8  to +26 and ~+14 to ~+20 charge states in case of type A1 and 
A2 AA oligomers. The higher order oligomers were more compact and retained 
fewer charge states; for example tetramers had a CSD of ~+15 to +18, 
pentamers displayed charges of +17 to +18 and hexamers obtained +18 to + 2 0  
charges.
Type C1 AA oligomers encompassed tetramers with Qs of 3913 to 4158 A2, 
pentamers with 4490 to 4697 A2 and hexamers with 5138 to 5473 A2. Type C 1 
AA oligomers had dimers and trimers whose Q’s could not be calculated due to 
the low intensity of the signal, however the presence of tetramers, pentamers 
and more intense hexamers allowed to determination of experimental Qs. The 
calculated Qs for type C2 AA oligomers were between 2195-3118 A2 for dimeric 
series and 3558-4381 A2 for trimeric populations and no apparent higher order 
oligomers could be observed.
4.3.9 Comparing experimental Qs to standards and to model structures
Qs of a number of proteins with known Qs were acquired under native solution 
conditions. Appendix Table 8.2. shows all mean Q values with ±SD obtained 
over repeated measurements (n>3).
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Comparison of Os of the oligomers with Os of known protein structures in the 
mass range of 5734 to 159216 Da confirmed that higher order oligomers 
became more compact as their subunit size increased (Figure 4.19.)-
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Figure 4.19. Comparison of Qs of a-syn oligomers with that of known globular 
protein standards under native conditions. All measurements were carried out in 
triplicates, except two measurements, all represent mean values if it was 
possible to calculate; error bars show spread in Cl. Oligomeric series (filled, red 
circles) are means o f both Fe(lll)-free and Fe(lll)-supplemented preparations. D: 
dimeric Q, T: trimeric Q, Q: tetrameric Cl, P: pentameric Q, FI: hexameric Cl, 
open triangles: different Cls of alternate protein standards under native 
conditions are shown as a function o f mass in Da. Fully denatured, compact 
and extended populations o f a-syn is shown by filled, grey circles. The 
continuous black line represents expected Cls o f globular structures as decribed 
in detail earlier (Smith et al. 2010). For full details o f experimental Cl o f all 
proteins see Appendix Table 8.2..
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The O of a-syn dimer was greater than that of folded porcine elastase and 
folded carbonic anhydrase (Mass: 29090 Da). The O of a-syn trimer was larger 
than that of the folded ADH monomer (Mass: 39804 Da) and the pentamer’s O 
(Mass: 72300 Da) was slightly greater than the Cl of folded albumin monomer 
(Mass: 66463 Da).
Computational approaches complement ESI-IMS-MS data and provide 
additional value in determination of potential geometries of structural features of 
multisubunit systems (Ruotolo et al. 2008; Politis et al. 2010). Through 
calculation of theoretical Os it is possible to estimate whether a protein of 
unknown structure is likely to adopt a globular conformation by comparing its 
respective measured Os with predicted values. Thus a set of expected Os for 
globular proteins was adapted alongside with 3 D assemblies of compact 
subunits from Smith el al. (Smith et al. 2010) to gauge experimentally obtained 
O areas. The theoretical Os were calculated from spherical structures with an 
average density of 0.44 Da/A3 calculated from a range of proteins of known 
structure (Smith et al. 2009). The measured Os of a-syn oligomers were greater 
than that of the predicted globular proteins suggesting that they were not as 
compact as fully spherical structures. Measured Os of globular protein 
standards did however show a good agreement with the theoretically derived 
values. This correlation between simulated and experimental Os of globular 
proteins demonstrated that the experimentally obtained values being consistent 
with values documented by others (Smith et al. 2009) and that the acquisition 
did not dramatically alter the O of protein in question (Figure 4.19.).
To further ascertain the topology of type A1 AA oligomers, O values were 
compared to theoretically derived Os. Here, an in house algorithm was used to
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define theoretical Qs and guide in silico modelling. It was assumed in this 
modelling approach that the monomer is a fully folded sphere with a 19.9 A 
radius.This value was determined by assuming a mass of 14.6 kDa, with a 
density of 0.44 Da/A3 consistent with the most compact conformational form of 
the protein. A 4 A overlap between different subunits was allowed, giving a 
centre to centre distance of 36 A (Smith et al. 2009). This model is similar to 
that reported for the oligomers involved in Alzheimer’s disease Bleiholder et al. 
(Bleiholder et al. 2011), permitting some surface interaction between subunits. 
Both linear structures and partially packed trimers, more compact tetramers and 
ring-like pentameric and hexameric forms have been constructed to guide 
experimentally acquired Qs and plotted in addition to experimentally determided 
Os of type A1 AA oligomers or the monomeric protein as shown in Figure
4.20..
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Figure 4.20. Os of monomeric a-syn, oligomeric series o f type A1 AA are 
shown in addition to theoretical Qs of linear, ring and globular structures as a 
function of subunit size. The filled, grey dots represent mean values o f a-syn as 
shown in Appendix Table 8.2., lighter grey circles at subunit size 1 represent 
average Os of extended monomeric charge states of a-syn as shown in Figure 
Figure 4.7. and Os of oligomeric series (2 to 6 subunit size) o f type A1 AA 
denoted with open circles. Yellow, filled triangles: theoretical Os o f linear 
structures, orange, filled triangles: theoretical Os o f ring-like structures and red, 
filled triangles are theoretical Os of fully globular structures obtained by an 
algorithm described before (Smith et al. 2009). The blue coloured 3 D shapes 
above the graph depict possible molecular organisations based on the 
agreement or disagreement o f theoretical and experimental Os.
Experimental and modelling data indicated that although the monomeric protein 
is predominantly unfolded when it forms oligomers, in particular type A1 AA 
oligomers, a structural collapse takes place, resulting in a variety of multimers in
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size and compactness. Trimers appeared to be largely unstructured, open 
assemblies, the tetramers are not significantly packed, however they had fewer 
charges and they were less dispersed in Qs that indicated some degree of 
folding. Oligomers of the pentameric and hexameric series however deemed to 
be near ring-like or ring-like structures respectively as judged by molecular 
modelling and experimental data, having very narrow CSD and little spread in 
their Os. Similarly, Os of pentamers fitted to a near ring-like structure and 
hexamers of C1 AA oligomer fitted best to ring-like structures modelled in silico 
(data not shown).
4.3.10 Addressing the addition of Cu(ll) in oligomerisation
Owing to the high affinity binding of Cu(ll) to a-syn seen at the monomeric
protein level, a-syn oligomers were also prepared with the addition of 10 pM
Cu(ll), rather than FeCI3. The interactions between Cu(ll) and a-syn were
markedly preserved both after an overnight or over a 7 day incubation period.
High intensity adduct peaks of one Cu(ll) a-syn were detected beside the lower
intensity second Cu(ll)-bound peaks of the monomeric region of the mass
spectrum. A full mass shift in the presence of Cu(ll) by 61.5 Da could still be
observed after these extended incubation times and a variety of oligomers were
detected in the monomeric Cu(ll)-bound and oligomeric ensemble. Oligomeric
series were assigned as if they arose from the fully one Cu(ll)-bound, mass
shifted protein (14521.5 Da). In the presence of Cu(ll) oligomers were rapidly
formed. After a brief incubation and freeze-drying step at further 24 hr shaking
monomer-adducts, dimers to tetramers were identified Appendix Figure 8.13..
Pentamers were not observed and hexamers could not be assigned
unambiguously either. At the final stage of preparation protocol, type A oligomer
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prepared with C11CI2 in 50 mM AA (pH 7.0) was comprised of monomeric 
adducts with predominantly one Cu(ll) bound to a-syn and dimeric, trimeric and 
tetrameric oligomers. The maximum subunit size observed here was tetrameric, 
with no evidence for pentameric and hexameric forms as opposed to previously 
discussed oligomer types (Figure 4.21.)
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Figure 4.21. Mobility plot (log scale display) and corresponding mass spectrum 
of type A oligomer prepared with CuCfc in 50 mM AA, pH 7.0. Instrument 
settings were: capillary 1.30 kV, source temp 60 °C, cone 30V, trap collision 
energy 4 V, transfer collision energy 10 V, IMS gas flow 90 mUmin, helium gas 
flow 180 mUmin, bias 45, source wave velocity 200 m/s, trap wave velocity 311 
m/s, IMS wave velocity 800 m/s, transfer wave velocity 200 m/s, backing 3.10 
mbar. Monomeric populations, a set of dimers (D), and trimers (T) and a broad 
range of tetramers (Q) were detected. Charge states of the oligomers denoted 
as superscripts in each series on the mobility plot. Monomeric adduct series 
with one Cu(ll) or two Cu(ll) are shown in brackets alongside their charge 
states. The region >2900 m/z was enlarged x54 to visualise the low abundance 
oligomeric components.
The dominance of tetramers was obvious upon analysis of type C oligomer in 
AA that contained CuCb as an enhancer of aggregation instead of FeCk 
(Figure 4.22.).
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Figure 4.22. Mobility plot and mass spectrum of type C oligomer prepared with 
10 pM CuCI2 instead of FeCI3 in 50 mM AA, pH 7.0. Instrument settings were: 
capillary 1.30 kV, source temp 60 °C, cone 30V, trap collision energy 4 V, 
transfer collision energy 10 V, IMS gas flow 90 mUmin, helium gas flow 180 
mUmin, bias 45, source wave velocity 200 m/s, trap wave velocity 311 m/s, IMS 
wave velocity 800 m/s, transfer wave velocity 200 m/s, backing 3.10 mbar. 
Monomeric Cu(ll)-bound populations, a set of dimers (D), and trimers (T) and a 
broad range of tetramers (Q) were detected. Charge states of the oligomers 
appear as superscripts in each series on the mobility plot. Monomeric adduct 
series with one Cu(ll)-bound or another, second Cu(ll)-bound are shown in the 
mass spectrum with appropriate charge states. The region >2900 m/z was 
enlarged x54 to display the low abundance oligomeric components more visibly.
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The maximum subunit size was tetameric in case of these CuCI2 induced 
oligomers. Q areas of Cu(ll) induced type A oligomers appeared to be only ~1 
% greater than respective Qs of all other previously discussed oligomer types, 
making them directly comparable across all conditions tested as shown in 
Figure 4. 23..
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Figure 4.23. Qs of oligomeric series observed for type A oligomer prepared in 
the presence of 10 pM Cu(ll) are shown according to subunit size. The x axis 
indicates subunit size and the y axis shows obtained Qs in A2. Oligomeric 
conformational series are denoted in the legends, where the blue diamonds 
represent dimers, red squares represent trimers and the green triangles mark 
tetramers (A). Measured Qs plotted as a function of charge states for modified 
type A2 AA oligomer prepared with CuCI2 in 50 mM AA, pH 7.0. X  axis shows 
subunit size and y axis shows obtained Qs in A2 (B). The blue diamonds 
represent dimers, red squares represent trimers and the green triangles denote 
tetramers.
It would be very interesting to investigate the behaviour and biochemical 
propensities of these oligomers prepared in the presence of Cu(ll) as it was 
carried out for type A1, A2, C1 and C2 oligomers both in AA and SP (Chapter
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3). The presence of low order oligomers up to tetramers might be relevant in 
understanding the behaviour of low order species observed in type A 1 and A2 
AA oligomers including an increased toxicity.
4.4 Conclusions
In order to obtain a better understanding of structure and function relationships 
of a group of in vitro a-syn oligomers, it was necessary to characterise their 
structure and topology by ESI-IMS-MS in detail. NMR and CD and other 
complementary structural biology methods are vital in precisely elucidating 
amyloid assemblies, although limitations originating from large molecular 
weights, low concentrations and transient formation of oligomers may pose 
technical obstacles. Since ESI-IMS-MS has been shown to have unique 
advantages in probing multi-subunit complexes and determining in-depth 
structural characteristics (Ashcroft 2010; Woods et al. 2012; Marcoux et al. 
2013a), this technique was the method of choice to uncover structural 
information about in vitro a-syn oligomers.
The conformational heterogeneity of a-syn has now become widely documented 
(Uversky et al. 2009; Ullman et al. 2011; Beveridge et al. 2013) and data 
presented here confirmed that under equilibrium monomeric a-syn consists of 
more extended and several more compact conformational forms that are co­
populated at near native conditions, at neutral pH (Frimpong et al. 2010). The 
Os measured here are in agreement with previously published values 
(Bernstein et al. 2004; Grabenauer et al. 2008; Smith et al. 2009). Ion mobility 
instrumentation allows observing ligand binding at low concentrations and
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monitoring resultant complex formation by detection of mass shifts (Kaltashov et 
al. 2006).
Upon investigation of co-ordination of bi- and trivalent ions to a-syn over 
different protein to metal ratios, Cu(ll) bound most strongly to the monomeric 
protein detectable on the rapid time scale of ESI-IMS-MS analysis, which was 
retained over increased lengths of time. One and two Cu(ll)-bound metal- 
protein adducts were observed at each conformational states of the protein, 
however evidence for a structural transition towards a more collapsed 
conformation was observed only for the compact conformational form of the 
protein. This may be important in understanding why this metal drives amyloid 
fibril formation in vitro (Uversky et al. 2001c; Uversky et al. 2009) and why in the 
ageing brain increased level of metals including copper could trigger 
undesirable effects on the structure of a-syn (Pall et al. 1987; Hirsch et al. 
1991).
A number of reports have highlighted the influence of various salts altering the 
aggregation specifics of amyloid proteins. For example, the effect of ionic 
strength on the amyloid formation of amylin (Marek et al. 2012) or human or rat 
variant of AP(1-42) (Kriz et al. 2013), the particulars of different salt ions 
affecting the propensity and aggregation of A(3(1-40) (Klement et al. 2007). 
Using ESI-IMS-MS, it was apparent that increased ionic strength was capable 
of altering the conformational states of the a-syn analysed at 4 hr into 
oligomerisation. Higher AA concentrations enriched the compact conformations 
of the monomeric a-syn. Data suggested an increased aggregation rate in the 
presence of higher AA concentrations with an increase in oligomeric distribution 
of trimers.
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Structural characterisation of type A oligomers prepared in AA have shown that 
dimers to hexamers were co-populated in addition monomeric conformations. 
Type C1 AA oligomer consisted of mainly tetrameric, pentameric assemblies 
and were enriched in hexameric oligomer series. Although addition of FeCb is 
thought to increase yield of oligomeric species, it may have altered or diverted 
the aggregation pathway of these oligomers, however conclusive evidence 
could not be obtained either for immediate binding of this metal or for its 
influence on the oligomerisation of a-syn. Type A2 AA oligomers prepared with 
Fe(lll) were similar to type A1 AA oligomers in the series of oligomeric species 
observed. Nevertheless, type C2 AA oligomers seemed to be lower order 
oligomers ranging from dimers to trimers that could have reflected the assembly 
at the point of sampling but could have been an artefact arising from an uneven 
electrospray due to clogging of capillaries.
To determine structural organisation of alternate oligomers, Os were calculated 
that revealed that in proportion to subunit increase, the compactness of 
oligomers increased. Charge state distribution of oligomers became narrower 
as the subunit size grew which indicated folding into more ordered self- 
assemblies. The experimental Os were greater for larger oligomers, yet they did 
not increase in a linear fashion supporting the notion of a structural collapse 
upon oligomerisation. The (3-sheet content of oligomers presumably increased 
as a result of a structural collapse. A similar collapse was described from 
trimers to tetramers in case of p2 microglobulin, however the Os of these series 
was larger than would be expected for globular proteins of a similar mass and 
corresponded to elongated assemblies (Smith etal. 2010).
182
Molecular modelling (Smith et al. 2009) and experimental data suggested that 
dimers and trimers were primarily extended structures; however increasing 
oligomer size resulted in more compact features, whereby pentamers 
resembled a near ring-like structure and hexamers were reminiscent of a closed 
ring-like structure with considerable compactness. The assembly of oligomers 
proceeded up to the hexameric stage. This hexameric ring-like structure would 
have needed to reopen to recruit a further monomer that may have presented 
an energy barrier halting the aggregation process.
The low yield of oligomeric species and broad peak areas could not rule in or 
rule out the presence of oxidised Met residues.
It is important to consider that these A1, A2, C1 and C2 AA oligomers have 
been demonstrated to have biological propensities promoting aggregation of 
intracellular a-syn.
Structural properties of type A2 and type C1 oligomers incorporating Cu(ll)were 
shown here with a maximum tetrameric order. Obtaining data from functional 
assays could aid further characterisation of the Cu(ll) induced assemblies 
performed in a similar fashion as for Fe(lll)-free or Fe(lll) containing oligomers.
One shared observation among these alternate oligomers was that oligomeric 
assembly proceeded through by addition of one monomer at a time with even 
and odd number oligomers co-populated in each of these (Jang et al. 2010) 
assemblies. In case of A(342 oligomers dimers, tetramers, hexamers and 
dodecamers were observed, whereas in case of WT Ap isoform only dimers 
and tetramers were observed and no odd number oligomers (Bernstein et al. 
2009; Clemmer et al. 2009). P2 microglobulin self-aggregation was shown to
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proceed by monomeric addition (Smith et al. 2006) at pH 2.5. However, the p2 
microglobulin oligomers in that system gave rise to monomers to tetramers, and 
these oligomers were more expanded than assumed with Os consistent with 
elongated structures (Smith etal. 2010).
Taken together, the ESI-IMS-MS experiments described here showed 
parameters of mass, size and shape of in vitro a-syn oligomers with functional 
propensities for the first time. Molecular modelling of type A1 AA oligomers 
implied that theoretical Os of dimers and trimers and tetramers resembled most 
closely to unstructured features. In contrast, theoretical O of a nearly closed 
ring-like structure showed an excellent agreement with observed Os of 
pentamers and a theoretical O of a fully closed ring organisation agreed with the 
measured O of hexamers. ESI-IMS-MS data in conjunction with functional 
characterisation suggest that hexamers and pentamers show a correlation with 
intracellular seeding and that the lower order oligomers may be responsible for 
cytotoxicity in SH-SY5Y neuroblastoma cells.
Evidence has also been shown that alternate preparation protocols can tip the 
balance between the formation and enrichment of certain subpopulations and 
oligomeric series, demonstrating the dynamics and complexity of a-syn self- 
assembly. In-depth details of kinetics and stability would be of additional value 
in future investigations for these a-syn oligomers.
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5 Chapter 5
Binding of dopamine to a-syn assessed by ESI-IMS-MS
5.1 Introduction
Oxidative stress has been shown to be one of the key mechanisms involved in 
neurotoxicity giving a possible explanation as to why dopaminergic neurons are 
highly vulnerable to cell death. In the cytoplasm, dopamine (DA) can undergo 
oxidation due to its labile quinone ring in the presence of molecular oxygen 
producing ROS such as hydrogen peroxide, superoxide and dopamine- 
quinones e.g. dopamine-o-quinone (Graham 1978). ROS can then account for 
the damage in the cellular components, for example in the mitochondria 
association of a-syn with oxidised lipids alters viable membrane properties 
(Ruiperez et al. 2010). Alternatively, DA can also be a target of enzymatic 
degradation by monoamine oxidase (MAO), yielding free radicals and 
potentially reactive DA-metabolites such as 3,4-dihydroxyphenylacetaldehyde 
(DOPAL) (Jinsmaa et al. 2011). However, following its synthesis DA is taken up 
into synaptic vesicles by the vesicular monoamine transporter 2 (MAT2) where 
the low pH prevents its degradation and the subsequent re-uptake of DA to the 
pre-synapses is undertaken by the dopamine-transporter (DAT) (Lotharius et al. 
2 0 0 2 b).
a-syn is thought to play an essential role in the modulation of synaptic vesicle 
recycling, DA storage and release at the nerve terminals (Chadchankar et al. 
2011). Mutations in the protein in the familiar form of the disease or changes in 
its expression or aberrant folding in the sporadic forms can consequently result
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in impairment of neurotransmitter storage or release contributing to PD. In case 
of a breakdown in vesicle handling, an increased level of cytoplasmic DA may 
trigger the production of free radicals and the formation of toxic intermediates 
with a-syn (Lotharius et al. 2002a; Lundblad et al. 2012). Importantly, 
administration of levodopa and its derivatives alleviate the symptoms of PD in 
many cases (Muller 2012).
Recent research has focused on revealing the biochemical and molecular 
interactions of a-syn and DA with implications on the rate of secretion of DA-a- 
syn oligomers to the extracellular space, mitochondrial respiration and 
autophagy (Lee et al. 2011; Outeiro et al. 2009; Munoz et al. 2012). In vitro, DA- 
a-syn oligomers are devoid of a defined secondary structure, exhibit various 
non-ordered aggregate morphologies with alternate size and shape under 
electron microscopy (EM) and are SDS resistant (Cappai et al. 2005). However, 
it is still debated whether the DA-a-syn oligomers are primarily covalent or non- 
covalent by nature, therefore the type of interaction between a-syn and DA 
remains elusive. Some early evidence has indicated that oxidated ligation of DA 
stabilised a-syn, yielding accumulation of DA-a-syn protofibrils (Conway et al. 
2001). Since this report, inhibitory effects of DA and several other analogues on 
fibrillation of a-syn have also been demonstrated and the cytotoxicity of 
predominantly large oligomeric intermediates of cross-linked DA-a-syn to 
neuronal cells was underpinned (Li et al. 2005). The covalently cross-linked a- 
syn DA oligomeric intermediate forms have demonstrated an altered ability for 
self-assembly and propensity to disrupt biomembranes in a yeast model and 
may also be critical in sustaining neurodegeneration in PD (Rochet et al. 2004).
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Met oxidation seems to be relevant in the formation of a-syn-DA polymers in 
addition to hydrophobic and long-range interactions (Zhou et al. 2010b; Zhu et 
al. 2013). Leong et al. defined Met oxidation as a primary mechanism for 
generating soluble, SDS-resistant a-syn-DA oligomers (Leong et al. 2009b) 
rather than the necessity of the C-terminal sequence 125YEMPS129 partaking in 
a non-specific hydrophobic interaction leading to DA-a-syn complexes which 
inhibit fibrillisation as concluded by others (Herrera et al. 2008; Norris et al. 
2005). Small angle X-ray scattering (SAXS) and CD data indicated that Met 
oxidised monomers are extended worm-like features akin to a-syn monomers, 
while DA-a-syn dimers and trimers had some degree of secondary structure 
(Rekas et al. 2010). By contrast, an ESI-MS study in conjunction with other 
biophysical methods demonstrated that one intact, unoxidised a-syn was 
capable of binding three DA molecules that in turn led to oligomerisation to a 
range of higher order protofibril species (Shimotakahara et al. 2012).
5.2 Materials and Methods
The relevant methods have been described in section. 2.4.4.3.
5.3 Objectives
Here, the aim was to examine how binding of DA affects the alternate 
conformational populations of human, recombinant WT a-syn and their 
respective Os at the initial phase of assembly. In order to investigate this, the 
potential of ESI-IMS-MS has been harnessed to provide in-depth structural 
information in the gas phase.
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5.4 Results and Discussion
5.4.1 Addressing binding of Tyr and DA to a-syn by ESI-IMS-MS
Numerous in vitro studies have shown that DA and some of its metabolites act 
as modulators of a-syn oligomerisation and inhibit its fibrillisation (Conway et al. 
2001; Cappai et al. 2005; Norris et al. 2005; Jinsmaa et al. 2011). ESI-MS in 
conjunction with other biophysical methods has demonstrated that one intact, 
unoxidised a-syn is capable of binding three DA molecules that in turn led to 
oligomerisation to a range of higher order protofibril species (Shimotakahara et 
al. 2 0 1 2 ).
Here, the effect of DA binding on the population of conformational states of a- 
syn (Figure 5.1. A) was examined in conjunction with changes in the 
corresponding Os. a-syn-DA complexes observed by ESI-IMS-MS are shown in 
Figure 5.1. C DA ligands are highlighted with black dots on the mass spectrum 
in Figure 5.1. C and are only observed on the +17 to +10 charge states. If the 
expanded state was the sole conformation present or DA binding was non­
specific, then it might be expected that DA adducts would be present on all 
charge state ions (+17 to +6 ) in the gas phase. However, binding of three DA 
can only be observed to the +17 to + 1 0  charge state ions in the same envelope 
that contains the most expanded forms of the protein. The +10 charge state ion 
bound only a single DA ligand. The lower charge state ions +9 to + 6  did not 
show any DA binding and these ions in the absence of DA still retained the 
structural features of the most compact conformation Figure 5.1. C. It is 
possible that ligand binding stabilises the extended state preventing structural 
collapse, however the conformational states that the ligand binds to appeared to
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be present in the absence of the ligand. This data can therefore be interpreted 
as DA binding to only the most extended conformations in solution.
Tyr serves as an early precursor in the synthesis of DA (Felger et al. 2012) and 
differs only by a carboxyl group in its chemical composition. The assess the co­
ordination of DA and Tyr experiments were performed upon the addition of 
these ligands compared to a-syn only and a-syn-DA complex with excess of Gly 
as shown in Figure 5.1..
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Figure 5.1. B details the resultant a-syn-Tyr spectra obtained from a 1:125 ratio 
of a-syn:Tyr. A maximum of two molecules of Tyr were involved in complex 
formation with a-syn indicated by one or two stars above the respective peaks, 
these ions however had a markedly lower intensity as compared to apo- and DA 
bound forms of a-syn. Again, ligand binding was only observed to the +17 to 
+10 charge state ions for DA, and no binding was observed to the more 
compact conformational populations of a-syn. Inclusion of Gly is useful when 
preventing non-specific or low affinity binding and here it completely negated 
the ability of DA to bind to a-syn as shown on Figure 5.1. D, suggesting the 
interactions were low affinity and electrostatic in nature. Together these results 
demonstrated that the extended conformations populating the +17 to +10 
charge state ions of a-syn bound up to one to three DA molecules and that this 
binding could be overcome by the presence of Gly. In addition to the mobility 
plots, the ESI-IMS-MS spectra of apo a-syn (A), a-syn-DA (B ), a-syn-Tyr (C) 
and a-syn-DA-Gly (D) are included (Figure 5.2.).
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Figure 5.2. a-syn only and a-syn and DA or Tyr complexes observed by ESI- 
IMS-MS are shown. ESI-MS spectra extracted from the mobility plots o f Figure 
5.1. were obtained from 50 mM A A solution of 50 pM a-syn, at pH 6.8 with or 
without further addition o f either DA or Tyr at 6.25 mM. Charge states and the 
presence or absence o f the appropriate ligands are indicated on the plots. A: 
WT a-syn, B: a-syn in the presence o f Tyr, C: a-syn in the presence of DA and 
D: a-syn in the presence o f DA and Gly.
DA ligands are highlighted with black dots on the mass spectrum in B and were 
only observed on the +17 to +10. A maximum of two molecules of Tyr were 
involved in complex formation with a-syn indicated by one or two stars above 
the respective peaks, these ions however had a markedly lower intensity as 
compared to apo- and DA-bound forms of a-syn.
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As revealed by the mobility plots, the main observations were that a maximum 
of three DA molecules were co-ordinated to the extended charge state ions of a- 
syn and up to two Tyr molecules could bind to the extended conformational 
series of monomeric a-syn. Adduct formation was not observed at charge state 
ions of the compact conformational form of the protein.
5.4.2 E lucidating conform ational transitions upon ligand binding
To further elucidate the conformational transitions taking place upon DA co­
ordination, selected populations of the extended and compact conformational 
families of a-syn have been chosen (Figure 5.3.).
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Figure 5.3. Qs determined from alternate DA and Tyr adducts at 1:125 protein
to metal ratio or from the apo-form of a-syn without any ligand binding at the
+ 13 charge state ion (a member o f the extended conformation) and at the +7
charge state ion (a member o f the compact conformation). The alternate colours
highlighted in the legends denote the number o f ligand bound or a-syn only.
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The +13 charge state ion was assigned as being representative of the extended 
conformational family. The arrival time distribution for the +13 charge state ion 
acquired in the absence of any DA is shown in Figure 5.3. A: black line and 
indicates two clearly resolvable peaks at -2590 A2 and -2720 A2 along with 
another feature at -2500 A2. In the presence of DA the most extended forms of 
the protein bound to the ligand with a shift toward the more extended states. 
The stepwise binding of one, two or three DA ligands initiated a shift in the 
conformation towards the more expanded conformations (Figure 5.3. A) as 
evidenced by an increasing drift time and increase in the Qs. Upon binding of 
three DA ligands, the -2500 A2 and -2590 A2 states were absent and the highly 
extended state, -2720 A2 was uniquely observed. The remaining apo-form of 
the protein acquired in the presence of DA predominantly showed the 
populations of the -2500 A2 conformations and significant depletion of the 
-2590 A2 and -2720 A2 conformations. The +7 charge state ion was taken as 
being representative of the compact states of a-syn and co-populated compact 
conformations along with a minor population of the extended state. DA binding 
was not observed to +7 charge state ion, nor a shift in its Q was observed.
One or two Tyr ligands were also observed to bind to the extended states of a- 
syn charge state ions of +10 to +17. Analogously to DA, the binding was to the 
most extended forms of the protein. However, as Figure 5.3. B demonstrates 
this binding yielded lower intensity adducts as compared to DA at the same 
protein to ligand ratios. Therefore Tyr was able to bind to a-syn in a similar 
manner to DA but a maximum of two Tyr molecules were co-ordinated to the 
protein, and structural changes caused by this binding were minimal as
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compared to DA. These results demonstrated that DA binds to a-syn in a 
conformational dependent manner, binding exclusively to the most extended 
states of the protein.
To assess that adduct formation and subsequent conformational rearrangement 
following DA ligation occured across repeated measurements and at alternate 
protein to ligand dilutions, replicate experiments have been conducted at 1:125, 
1:30 and 1:8 ratios (a-syn:DA). Up to three DA molecules were co-ordinated in 
each case, however the intensity of the adduct peaks were lower as the ligand 
concentration decreased (Figure 5.4.).
+ 13
1:125
•  1 DA bound 
• •  2 DA bound 
•••3  DA bound
*  1 Tyr bound 
* *  2 Tyr bound
1:30
Figure 5.4. Binding of DA or Tyr to a-syn at alternate protein to metal ratios as
shown on the left hand side. DA adducts denoted with black circles, Tyr-bound
forms of the protein indicated by asterisks and finally apo-form o f the protein
remained unmarked at the +13 charge state ion.
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The corresponding theoretical and measured m/z ratios are given in Table 5.1. 
both at the +13 and at the +7 charge state ions depending on the number of DA 
or Tyr molecules bound to a-syn.
DA__________________________Tyr
Charge state 
ion
Number of 
ligand bound
Theoretical
m/z
Measured
m/z
Theoretical
m/z
Measured
m/z
+13 0 ligand bound 1113.3 1113.0 1113.3 1113.0
1 ligand bound 1125.1 1125.0 1127.2 1127.0
2 ligand bound 1136.9 1136.8 1141.2 1141.0
3 ligand bound 1148.7 1148.6 n/a n/a
+7 0 ligand bound 2066.7 2066.4 2066.7 2066.4
Table 5.1. The theoretical and measured m/z ratios are shown both in case of 
DA and Tyr at the +13 and +7 charge state ions according to the number of 
ligands bound to a-syn.
The measured m/z values were in close agreement with the expected m/z 
values, indicating 1 Da of mass error. Calculated Qs of the one DA bound forms 
of a-syn were consistent at 1:8 and 1:30 and 1:125 protein to ligand ratios, 
similarly to those of the two DA bound forms. Os of the three DA bound adducts 
were the same at the 1:30 and 1:125 protein to ligand ratios. One Tyr adducts 
also gave the same Os at all three protein to ligand ratios and the two Tyr 
bound adducts had the same Os both at the 1:30 and 1:125 protein to ligand 
ratio. Binding was observed to the extended form of the protein only such as the 
+7 charge state ion remained ligand-free whose Os are shown below in Figure
5.5..
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Figure 5.5. Qs determined upon repeated measurements of alternate DA and 
Tyr adducts at 1:8, 1: 30 and 1:125 protein to ligand ratio or of the apo-from of 
the protein without the binding of any ligand at the +13 charge state ion (a 
member of the extended conformation) and at the +7 charge state ion (a 
member of the compact conformation). The x axis is the Q (A2), the y axis is 
intensity (%).
As indicated by Figure 5.5., the alternate a-syn:DA ratios did not dramatically
affect the absolute Qs recorded for the extended state conformations, with two
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and three DA bound at low ratios inducing the same Q as two and three DA 
bound at high ratios. These results indicate that it is the specific binding of the 
ligand that causes the conformational change rather than a change in the 
solution environment.
5.4.3 Met oxidised residues
a-syn contains four Met residues; two Met residues are located at aa positions 
1 and 5 on the N terminal and further two Met residues reside at aa positions of 
116 and 127 on the C terminal. Met oxidation has been shown to affect both 
electrostatic and hydrophobic interactions of a-syn. Furthermore, oxidation of 
Met is thought to play a role in inhibiting fibrillisation of the protein in vitro, 
yielding non toxic oligomers of a-syn (Zhou et al. 2010a). Previous evidence 
have suggested that Met oxidation of a-syn occurs upon interaction with DA 
(Leong et al. 2009b). Consistently with this, Rekas et al. also reported Met 
oxidised monomeric and lower order oligomeric species of a-syn. This study 
speculated that Met oxidation in the presence of DA stabilises oligomers and is 
a key event in inhibiting the end-to-end association of a-syn molecules, 
preventing the formation of large fibrils with a cross-(3 structure (Rekas et al. 
2010).
Utilising short time frames during these experiments performed here, no direct 
evidence was found for pronounced Met oxidation upon addition of DA as 
judged by ESI-IMS-MS analysis (Figure 5.6.).
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Figure 5.6. Met oxidised peaks are shown at alternate a-syn to DA ratios 
(1:125, 1: 30 and 1:8) or at the apo-form of the protein as indicated by black 
crosses on each mass spectrum. The x axis represents m/z values and the y  
axis indicates relative intensities in %. The relative intensity of Met oxidised 
peaks was negligible as compared to the intensity of DA bound adduct peaks 
(black circles) and apo-forms of a-syn.
As it is seen in Figure 5.6., low intensity peaks indicative of Met oxidation of the 
monomeric protein were observed prior to the addition of DA and remained 
negligible even after binding of DA. Similarly, the intensity of Met oxidised 
adduct peaks of a-syn-DA were very low as compared to that of un-oxidised DA 
bound peaks. Hence Met oxidation is not required for DA binding.
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5.5 Conclusions
Crucial insights have been gained into how DA might be involved in aggregation 
and the fibrillisation of a-syn from in vitro studies (Conway et al. 2001; Cappai et 
al. 2005; Li et al. 2005; Jinsmaa et al. 2011) and evidence now emerges that 
polymers of a-syn-DA or other reactive intermediates are linked to neuronal cell 
death in PD (Outeiro et al. 2009). Although the co-ordination of DA to a-syn has 
been observed before (Shimotakahara et al. 2012), here it has been shown that 
co-ordination of three DA molecules to WT a-syn induced a highly extended 
conformation specifically binding to the extended states and caused an increase 
in O. No binding of DA was observed under the employed conditions to the 
compact states. This concept of expansion is not dissimilar from that which 
Rekas et al. have reported, however, the experimental conditions, buffer 
conditions and protein concentration used by Rekas et al. (Rekas et al. 2010) 
were different. In that study, a-syn was incubated for 5 to 7 days in the presence 
of DA after which the protein was observed to be oxidised. The resulting Met 
oxidised a-syn monomer and a-syn-DA trimer had elongated shapes versus 
untreated monomers based on SAXS and CD results which could be brought 
about by the association of the DA bound extended states observed here prior 
to incubation. Met oxidation has been observed to be required for DA induced 
oligomerisation (Leong et al. 2009a; Leong et al. 2009b). Utilising short time 
frames, only low intensity Met oxidised DA bound peaks of a-syn have been 
observed which were seen beside the more pronounced, un-oxidised higher 
intensity DA-bound peaks and ligand-free peaks. Minor Met oxidation was 
present without any prior addition of ligand and hence it did not result from DA
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exposure. By contrast, longer incubations of a-syn in the presence of DA (12 
hr) have been previously shown to result in a pronounced oxidation of the 
monomeric protein (Appendix Figure 8.14.) similarly to other studies (Chan et 
al. 2012). Regardless of this observation, during the time frame of the 
experiments discussed here the un-oxidised a-syn-DA complex was 
considerably more dominant, demonstrating oxidation is not required for initial 
binding and further oxidation is a result of longer term exposure to DA.
Alternate ligands have been reported to bind to a-syn, each affecting the
conformational state of the monomer in its own way. Electrospray lonisation-
Electron Capture Dissociation- Mass Spectrometry/ Mass Spectrometry (ESI-
ECD-MS/MS) has been used in probing non-covalent protein-ligand binding
interactions in relation to a-syn. Spermine is a polyamine compound widely
found in many tissues and has a role in increasing the aggregation rate of a-syn
(Antony et al. 2003). The spermine binding site has been localised to the C-
terminal 106-138 residues of the WT a-syn, as demonstrated by Xie et al. (Xie
et al. 2006) using ESI-ECD-MS/MS consistent with previous NMR data
(Fernandez et al. 2004). Changes in the charge state distribution were however
not observed in this study. The DA binding site of a-syn is also located on the
highly negatively charged C-terminal region of the protein, at 125YEMPS129 that
has been implicated in DA interactions and in modulation of DA induced
aggregation (Norris et al. 2005). This region however has been reported to be
necessary only for oxidation but not complete binding (Leong et al. 2009b).
Interestingly and similarly to the DA binding results here, data presented in the
Supplementary Information of the paper by Xie et al. showed the 1:2 protein-
ligand complex binding only to the high charge state ions (+18 to +11 charge
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state ions) (Xie et al. 2006). ESI-IMS-MS has also been used to gain 
conformational information for the familial point mutation of a-syn A53T upon 
spermine binding. Evidence from NMR data suggested that although spermine 
binds specifically to the C-terminal of the a-syn, it induces changes in the N- 
terminal in the proximity of Gly and Tyr residues in the region of amino acids 22- 
93 and it leads to the adoption of a (3-sheet conformation typical of fibrillar a-syn 
(Fernandez et al. 2004). Spectra acquired in negative ion mode by Grabenauer 
et al. reported a significantly greater percentage of the population of the 
spermine:protein complex in the compact form as compared to the unbound 
protein. Either the presence of the A30P point mutation may be involved in the 
binding on spermine through long range interactions and or its inclusion 
facilitates aggregation through preferential population of the compact state.
Here, the shift in the population towards a more extended state on DA binding 
may well be the point at which the aggregation pathway is switched from the 
amyloid forming pathway linked to the collapsed state (Uversky et al. 2001; 
Uversky et al. 2001b; Natalello et al. 2011) to the pathway resulting in soluble 
DA induced oligomers. DA first binds to extended conformations of the protein, 
followed by oxidation of Met residues (Leong et al. 2009a, Leong et al. 2009b) 
resulting in oligomer formation. Previous SAXS data has demonstrated that DA 
induced a-syn oligomers on extended incubation have highly expanded 
conformations (Rekas et al. 2010) and these structures may well result from the 
stabilisation of a highly extended monomeric state. DA is therefore a potent 
modulator of a-syn assembly and exerts its effect at the very early stages of 
aggregation by influencing the conformational dynamics of the monomeric 
protein.
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6 Chapter 6
Main conclusions
6.1 Background to the investigations
a-syn instigates both sporadic and idiopathic PD by various modes of action 
(Lashuel et al. 2013). It is the major component of intracellular LBs and Lewy 
neurites in the brain (Forno 1996) that are characteristic features of PD. Both in 
vivo and in vitro a-syn forms soluble toxic oligomers and larger fibrils with typical 
amyloid properties (Conway et al. 2000; Kim et al. 2009).
Growing evidence suggests that soluble oligomeric forms of a-syn are causative 
triggers of neurodegeneration with dopaminergic cell loss (Kalia et al. 2013). A 
number of recent reports have described the appearance and detection of the 
monomeric and soluble oligomeric forms of a-syn in the CSF and sera of PD 
patients (El-Agnaf et al. 2006; Tokuda et al. 2010; Foulds et al. 2012; Toledo et 
al. 2013). Data obtained from numerous in vitro a-syn oligomer studies have 
implicated relevant toxic gain of function in the disease state via two main 
pathways: i, causing Ca(ll) imbalances and ii, inducing transmembrane seeding 
(Lashuel et al. 2013). a-syn pathology has been shown to spread from cell to 
cell in both cell culture models and in vivo models of PD (Prusiner 2012). As 
such, concentrated efforts have been made to elucidate the seeding properties 
of exogenously applied a-syn and its alternate forms in primary and secondary 
cell culture models (Luk et al. 2009; Angot et al. 2012; Cremades et al. 2012; 
Danzer et al. 2012). The morphology and associated toxicity displayed by these
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alternate types of in vitro oligomers are largely dependent on the environmental 
conditions under which they have been prepared from the natively unstructured 
monomeric protein (Danzer et al. 2007; Giehm et al. 2011; Wang et al. 2010b; 
Nasstrom et al. 2011; van Rooijen et al. 2010; Cremades et al. 2012; Singh et 
al. 2013; Roostaee et al. 2013). Structural characterisation of these assemblies 
by the use of high resolution biophysical methods i.e. NMR spectroscopy and 
CD remains however challenging due to their low concentrations and transient 
nature in solution.
ESI-IMS-MS addresses these issues by providing information about the mass, 
the shape of oligomeric assemblies in a rapid time frame using submolar 
concentrations (Ashcroft 2010). Ion mobility meaurements accompanied by 
molecular modelling permit assignment of possible geometries for unknown 
protein complexes giving insights into the topology of self-assemblies (Ruotolo 
etal. 2008; Politis etal. 2010).
In this thesis, a previously reported group of in vitro, toxic, transient, oligomeric 
forms of a-syn have been adapted and their different biochemical 
characteristics have been further examined (Danzer et al. 2007; Danzer et al. 
2009). The main aim of this project was to determine the structure and subunit 
size of this selected group of a-syn oligomers, and correlate those with their 
toxic gain of function, in order to obtain a fuller understanding of structure and 
function relationships.
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6.2 Advancements in understanding oligomeric structure and function
6.2.1 a-syn shows two main conformational familes under equilibrium
In preparation of elucidating the subunit size and topology of oligomers, it was 
of critical importance to establish optimised acquisition settings for both 
detection and sensitivity by ESI-IMS-MS. Qs consistent with values published 
in the literature (Smith et al. 2009) were obtained through a wide mass range 
using common protein standards both under denaturing and native conditions. 
Conformational families of a-syn from pure and non-degraded recombinant 
protein were resolved consistent with other studies (Bernstein et al. 2004; 
Grabenauer et al. 2008) upon successive ESI-IMS-MS measurements, a-syn 
co-populated both a family of extended structures and a family of compact 
structures under equilibrium at neutral pH, showing a good agreement with 
previous negative mode ESI-MS or ESI-IMS-MS measurements (Bernstein et 
al. 2004; Grabenauer et al. 2008; Frimpong etal. 2010).
6.2.2 DA selectively binds to the extended populations of monomeric a- 
syn and causes a conformational shift towards an expanded 
conformational state
In the presence of DA a-syn yields a diverse range of SDS resistant, non­
amyloid oligomers (Conway et al. 2001; Cappai et al. 2005; Li et al. 2005; Lee 
et al. 2011), however the precursor state conformation has not been 
established. Previously, three DA molecules have been observed to bind per a- 
syn monomer using ESI-MS (Shimotakahara et al. 2012). In accord with this, a
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alternate types of in vitro oligomers are largely dependent on the environmental 
conditions under which they have been prepared from the natively unstructured 
monomeric protein (Danzer et al. 2007; Giehm et al. 2011; Wang et al. 2010b; 
Nasstrom et al. 2011; van Rooijen et al. 2010; Cremades et al. 2012; Singh et 
al. 2013; Roostaee et al. 2013). Structural characterisation of these assemblies 
by the use of high resolution biophysical methods i.e. NMR spectroscopy and 
CD remains however challenging due to their low concentrations and transient 
nature in solution.
ESI-IMS-MS addresses these issues by providing information about the mass, 
the shape of oligomeric assemblies in a rapid time frame using submolar 
concentrations (Ashcroft 2010). Ion mobility meaurements accompanied by 
molecular modelling permit assignment of possible geometries for unknown 
protein complexes giving insights into the topology of self-assemblies (Ruotolo 
et al. 2008; Politis et al. 2010).
In this thesis, a previously reported group of in vitro, toxic, transient, oligomeric 
forms of a-syn have been adapted and their different biochemical 
characteristics have been further examined (Danzer et al. 2007; Danzer et al. 
2009). The main aim of this project was to determine the structure and subunit 
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maximum of three DA molecules formed adducts with a-syn but the additional 
dimension of ion mobility separation has allowed demonstration of DA 
molecules bound exclusively to the extended conformation of a-syn only. 
Binding was not observed to the compact state of the protein such as the +7 
charge state ion. Measurements of O areas showed that the incremental uptake 
of the DA pushed the protein towards a highly extended population, becoming 
fully populated upon the binding of three DA ligands that was illustrated at the 
+13 charge state here. The primary binding site for DA has been assigned to 
residues 125YEMPS129 (Norris et al. 2005) on the C-terminal of the protein. It 
would be intriguing to ascertain exactly to which motif of a-syn each of the three 
DA molecules can bind to through repeating similar experiments with truncation 
mutants of the protein.
Tyr as a closely related structural analogue differing only by a carboxyl group in 
its chemical structure exhibited limited binding to the protein as compared to 
DA, with a maximum of two ligands being observed to co-ordinate to a-syn. An 
expansion upon DA or Tyr binding to a-syn has shown another example of how 
a-syn is capable of undergoing different types of structural transitions under 
alternate conditions. The conformational rearrangement conferred by DA or Tyr 
occurred in the opposite way to that described as a structural collapse during 
ligation of Cu(ll) to a-syn discussed in the next section. Calculation of Qs 
suggested that DA was able to modulate a-syn self-assembly by inducing the 
population of a highly extended state, consistently across various protein to 
ligand ratios.
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6.2.3 Cu(ll) binds to monomeric a-syn and causes a conformational 
collapse towards a more compact state
The conformational equilibrium of a-syn between the compact and extended 
states can be modulated by altering the protein environment, for example by the 
addition of bi- and trivalent metal cations. To determine the effects of metals on 
the conformations of a-syn, especially Fe(lll) due to its inclusion in the 
oligomerisation protocol, ESI-IMS-MS experiments were carried out at three 
alternate protein to metal molar ratios in AA at neutral pH. Experiments were 
also conducted in the presence or absence of Cu(ll), Zn(ll), Mn(ll), Co(ll), Fe(ll), 
and Al(lll). No immediate binding was observed for any of these metal ions, 
except Cu(ll). Despite of the fact that no direct binding was detectable with 
these metals apart from Cu(ll), they are thought to have a role in altering the 
fibrillisation of a-syn in vitro and their binding sites have been mapped out 
(Bisaglia et al. 2009). Binding of one or two Cu(ll) was observed to a-syn at all 
charge states of the monomeric protein. These adducts remained preserved 
even upon addition of Gly that acts as a metal chelator preventing non-specific 
binding. This high affinity binding correlated with a conformational transition 
towards a more compact conformational form and may indicate an increased 
aggregation in the presence of Cu(ll). These data may help to understand how 
a-syn reacts with Cu(ll) in the aging brain and is promoted to misfold into a 
more compact conformational form that can assemble into soluble oligomers 
and fibrillar forms. Evidence into the toxic aspects of Cu(ll) derived a-syn has 
been emerging from a number of in vitro studies (Brown 2007; Paik et al. 1999; 
Gaggelli et al. 2006; Drew et al. 2008; Dudzik et al. 2011; Lucas et al. 2011).
208
Elucidation of the the dynamics of Cu(ll) co-ordination to a-syn will continue to 
be invaluable in understanding how an increase of metal load (Pall et al. 1987) 
upon environmental exposure or age related changes may lead to predisposing 
this protein in an altered milieu to self-assemble into toxic species (Paik et al. 
1999). In addition, oxidative stress is an important element of redox-metal 
induced neurotoxicity associated with amyloidogenic proteins and peptides. As 
such, Ap and a-syn can directly bind metal ions such as Cu(ll) and the resultant 
complexes have been shown to give rise to H20 2 by reacting with ascorbic acid 
and 0 2 in a cellular environment. H20 2 is a powerful ROS and is a precursor of 
other free radicals. Uncomplexed, free redox metal ions can also produce
hydroxyl radicals (OH*) by reacting with H20 2 wathe Harber-Weiss and Fenton
reactions. Thus, a-syn-Cu(ll) complexes are thought to be responsible for 
oxidative damage, contributing to the loss of dopaminergic cells in PD (Wang et 
al. 2010a).
6.2.4 In vitro  a-syn oligomers suitable for ion mobility mass spectrometry 
analysis have functional properties
To produce a-syn oligomers suitable for ESI-IMS-MS analysis, previously 
described oligomer preparation protocols have been adapted such that SP was 
substituted by AA buffer. Evidence has shown that alterations both in buffer 
conditions and ionic strength affect the way in which natively unstructured 
proteins such as a-syn fold (Kriz et al. 2013; Buell et al. 2013). In order to 
examine the changes caused by altering the buffer conditions from 50 mM SP 
to 50 mM AA, a range of in vitro functional assays have been performed such
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as fibril formation experiments, spectroscopic measurements, dot blotting, MTT, 
Ca(ll) influx, ROS assay and transmembrane seeding. Findings from these 
assays were compared to the original subset of oligomers as discussed in detail 
in Chapter 3 and summerised in 6.2.7-10.
6.2.5 Di- and trivalent metal ions influence the assembly of a-syn 
oligomers
Insights into the assembly of a-syn have been gained from alteration of 
conditions during the preparation protocols such as inclusion of FeCI3. Addition 
of Fe(lll) may have accelerated the self-assembly and at the time of sampling 
the mass range of oligomers was not accessible by the Synapt G2 HDMS and 
only a subpopulation of monomers, dimers, trimers could be seen in type C2 AA 
oligomers. By contast, ion mobility data collected from type A2 AA oligomers 
prepared in the presence of Fe(lll) did not deviate from that of Fe(lll)-free type 
A1 AA oligomers. These discrepancies could be resolved by monitoring of 
assembly over frequent time intervals during the overnight incubation to better 
discern the role of Fe(lll) in oligomerisation.
When Fe(lll) was replaced by Cu(ll), monomers to tetramers were detected that 
could have assembled from Cu(ll)-bound a-syn, which unambiguously retained 
its Cu(ll) adducts throughout the entire incubation protocols (either overnight or 
>7 days). It would be interesting to uncover how these oligomers stalled at a 
tetrameric subunit size could compare in their functional properties to those 
discussed in section 6.2.7-9.
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6.2.6 Alteration in buffer conditions affect the kinetics of oligomerisation
When the ionic strength of AA was incresead, to examine the effect on 
oligomerisation, it was observed that the more compact conformational ion 
series of the monomeric protein became more predominant early on at 4 hr into 
oligomerisation. In addition, a broader range of trimers and tetramers were early 
present at 250 mM and 450 mM AA concentrations as opposed to 50 mM AA 
concentration. These data suggest that higher ionic strength promotes the 
formation of lower order oligomeric species and increases the relative 
population of the compact conformational forms of the monomeric protein. The 
importance of salt ions and ionic strength with regards to other amyloidogenic 
systems has gained attention (Klement et al. 2007; Marek et al. 2012; Kriz et al. 
2013; Buell et al. 2013). For example, molecular dynamics simulations of rat 
and human p-amyloids in three alternate salt environments have been carried 
out and implied that ionic strength affected the stability of internal hydrogen 
bonds. Increment in ionic strength raised atomic fluctuations in the hydrophobic 
core of the human variant and decreased it in the non-fibrillar rat variant. 
Changes in flexibilities subsequently may promote formation of helices or p- 
sheet elements (Kriz et al. 2013).
6.2.7 Mass spectrometry compatible oligomers have distinguishable 
epitope mapping profiles and transmembrane seeding properties
Mass spectrometry compatible in vitro a-syn oligomers appeared to have 
unique, distinguishable properties as demonstrated by epitope mapping and
recapitulated toxic aspects of previously reported transmembrane seeding in
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human neuroblastoma cells (Danzer et al. 2007; Danzer et al. 2009). Ca(ll) 
imbalances induced by the mass spectrometry compatible type A1, A2, C1, C2 
AA oligomers were not detectable in contrast to the results seen with type A1 
and A2 SP oligomers.
6.2.8 Mass spectrometry compatible type A oligomers are toxic; lower 
order oligomers may be associated with cytotoxicity in SH-SY5Y 
neuroblastoma cells
Ion mobility mass spectrometry experiments indicated a range of oligomeric 
species, consisting of dimers to hexamers for type A1 and A2 AA oligomers with 
increasing compactness proportional to subunit size. These data in conjunction 
with findings of the MTT assay suggested that neuronal toxicity correlated with 
the presence of smaller order oligomers within the ensemble. In agreement with 
this, dimers of a-syn produced in a different manner have been shown to be 
toxic and critical in the early phase of aggregation and could be worthwhile 
targets of therapeutic agents (Roostaee et al. 2013).
In an alternate oligomeric system, Cremades et al. described a population of 
cross-linked, lower molecular weight yeast Sup35 (NM) oligomers ranging from 
dimers to trimers that displayed a blue shift upon addition of Nile Red dye, 
reacted with A11 and were very toxic in neuroblastoma cells (Cremades et al. 
2012). In addition, Ono et al. reported that dimers were -3  times more toxic 
than the monomeric A(3 protein and tetramers -13 times more toxic than the 
monomer itself. It is proposed in this study that it would be logical to design
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therapeutic interventions targeting dimers or develop agents that could stabilise 
the monomeric disordered state to prevent its assembly (Ono et al. 2009).
6.2.9 Non-toxic type C oligomers are predominantly pentameric and 
hexameric and cause intracellular aggregation in SH-SY5Y 
neuroblastoma cells
Type C1 AA oligomers displayed pentamers and hexamers and less tightly 
packed tetramers with Os comparable to type A1 and A2 AA oligomers. These 
oligomers were however not toxic to human neuroblastoma cells. The lack of 
toxicity was perphaps due to the scarcity of monomeric, dimeric and trimeric 
series as compared to type A1 and A2 AA oligomers in which the lower order 
oligomers were more intense. The observed differences in enrichment of 
particular subsets were most likely due to alternate preparation protocols tipping 
the balance between lower order and higher order species. Type C2 AA 
oligomers displayed only lower order oligomers up to largely unstructured 
trimers, however this data may not reflect solution conditions as data acquisition 
was limited by an exacerbated aggregation in the sample perturbing the 
electrospray process. All mass spectrometry compatible oligomers induced 
intracellular aggregation in SH-SY5Y cells post-exposure to oligomeric 
treatment. The ability to induce intracellular aggregation may be attributable to 
the higher order e.g. tetrameric, pentameric and hexameric populations.
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6.2.10 Assembly of in vitro a-syn oligomers progresses in an isotropic 
fashion up to a ring-like hexameric structure
Oligomers assigned here followed an isotropic growth where each series 
differed by one subunit size from the next up to hexameric stage being the most 
compact molecular organisation. Experimentally determined Os alongside with 
molecular modelling (Smith et al. 2009) suggested that the smaller oligomeric 
species (dimer, trimer and tetramer) were unordered structures that became 
gradually more akin to fully compact, globular shapes as they increased in 
subunit size. Pentameric assemblies are consistent with an open ring-like 
topology and the most compact hexamers represent the end point of assembly 
with a closed ring-like morphology. The energetics and complexity governing of 
aggregation at the early stages of oligomerisation have been illustrated by 
recent molecular modelling experiments, showing that each aggregated form of 
dimers, trimers and tetramers could have a number of different morphologies 
(Gurry et al. 2013) akin to the dispersed Os observed here. These closed ring 
conformations are similar to those observed by the Bowers group for the Ap 
peptide and may represent a common oligomeric architecture (Bernstein et al. 
2009). It would be highly desirable to obtain more comprehensive information 
about a-syn oligomers that have been successfully detected in the CSF and 
sera of PD patients (El-Agnaf et al. 2006; Foulds et al. 2011; Foulds et al. 
2012). The challenge will remain to isolate oligomers from clinical specimens of 
PD patients or other living systems under near native conditions (Bartels et al. 
2011; Fauvet et al. 2012) and elucidate how the oligomers produced in vitro 
would compare to those. Further structural and functional characterisation of in
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vitro a-syn oligomers however may inform finding points of interaction against 
self-assembly into toxic a-syn oligomers that occur in the disease state.
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8 APPENDIX
8.1 Protein expression in E. coli and purification
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Figure 8.1. A shows the Q- Sepharose anion exchange profile of the crude WT 
a-syn including a linear salt gradient marked with a green line and 
corresponding conductivity increase (red line) across the blue trace (OD214 nm) 
eluted on the AKTA purifier. The pooled fractions (L2-L5) were resolved on an 
SDS PAGE and stained with Coomassie dye and destained subsequently to 
reveal the monomeric protein with <16 kDa mass. B is a High Load 26/90 
Superdex TM 75 Prep Grade gelfiltration trace and the resultant pooled 
fractions analysed by SDS-PAGE and Coomassie staining protocolyielding  
pure monomeric a-syn. The protein then underwent dialysis and freeze drying 
before storage at -20 °C for <3 months.
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Figure 8.2. ESI-IMS-MS spectrum o f monomeric a-syn with the corresponding 
charge states, where charge states of less prevalent dimers is shown in italics 
(A). B is a Western blot o f a-syn probed with rabbit polyclonal full length 
antibody developed in the Licor fluorescent system using a CW conjugated 
polyclonal anti-rabbit IgG (H+L) at 800 nm.
8.2 Size exclusion chromatography
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Figure 8.3. SEC chromatography traces o f A1 and A2 SP oligomers (A) and 
SEC traces of type C1 and C2 oligomers (B) on a Superdex 200 100/300 GL 
column (GE Healthcare) in 50 mM SP buffer, pH 7.2. C shows the elution profile 
of the monomeric protein (MW: 14.6 kDa) marked with continuous black line in 
relation to other globular standards in 25 mM Tris buffer with 10 mM NaCI, pH  
8.0.
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Two oligomeric populations were observed in type A oligomers prepared in SP, 
one eluting at -6.5 ml and another eluting -7.5 mL in addition to a population 
eluting >12.5-15 mL which represented the remnants of the monomer. For type 
C oligomers, an oligomeric population eluted at -8  mL and another dominant 
population eluted -10 mL that could be a lower order, higher yield oligomeric 
population i.e. dimers and trimers and noticeably the monomeric protein peak 
was no longer observable, probably due to the use of 30,000 Da spin 
concentrator that allows retention of only higher MW species above the cut off 
limit.
SEC of MW standards was performed Superdex 200 100/300 GL column (GE 
Healthcare). Discontinuous green line represents beta amylase from sweet 
potato (MW: 200 kDa), dotted pink line represents albumin from bovine serum 
(MW: 66 kDa), purple discontinuous purple line represents carbonyl anhydrase 
from bovine erythrocyte (MW: 29 kDa), discontinuous brown line depicts 
cytochrome c from horse heart (MW: 12.5 kDa). It is evident that the natively 
unfolded monomeric protein elutes later than that would be expected for its MW 
close to the carbonyl anhydrase with a globular structure and mass of 39.5 kDa. 
This aberrant elution profile with apparently larger hydrodynamic radii has been 
widely documented and consistent with those observations by Conway et al. 
(Conway et al. 2000). Additionally, the monomer perhaps underwent some 
structural rearrangements or oxidisation during the different types of oligomer 
preparation protocols that may have caused a structural collapse with shorter 
elution volumes in case of type A, however the elution buffers were also 
different not allowing to draw conclusions.
256
8.3 ThT emission spectra and dot blotting of a-syn fibrils
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Figure 8.4. Fluorescence emission spectra o f monomeric protein and fibrils 
(after 7 day agitation at 37 °C) after ThT buffer subtraction at 470-600 nm in 
triplicates. All samples were dissolved in 20 mM Tris buffer at pH 7.2. A 
quantum yield increase (~250-fold) is seen in case o f mature fibrils (dotted 
lines) when compared with 7 pM monomeric a-syn (asterisks).
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Figure 8.5. Dot blotting of 7 pM monomeric a-syn, 70 pM quiescent fibrils in 
the presence o f bovine serum albumin (BSA) negative control probed with anti­
amyloid fibrils LOC antibody (Millipore) primary antibody and syn 211 antibody. 
The mature fibrils showed a positive immunoreaction, whereas the natively 
unfolded monomer did not react with LOC as described by Kayed et al. (Kayed 
et al. 2007). Both the monomeric protein and fibrils were detectable by the 
mouse monoclonal anti-a antibody, syn 211 (Sigma).
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8.4 a-syn oligomers on native gels under denaturing conditions
A
10% Bis-Tris gel under denaturing
Lane 1: Unstained NativeMark
Lane 2: C1 AA
Lane 3: C2 AA
Lane 4: A1 AA
Lane 5: A2 AA
Lane 6: a-syn monomer
conditions
Lane 1: Unstained NativeMark
Lane 2: C1 SP
Lane 3: C2 SP
Lane4:A1 SP
Lane 5: A2 SP
B kDa
220“ — 
H I -
55 -
4 1 “
Tris acetate gel under denaturing conditions (LDS 4x sample) 
Lane 1: SeeBlue Plus2
Lane 2: C1 AA 
Lane 3: C2 AA 
Lane 4: A1 AA 
Lane 5: A2 AA 
Lane 6: C1 SP 
Lane 7: C2 SP 
Lane 8: A1 SP 
Lane 9: A2 SP 
Lane 10: monomeric a-syn
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Figure 8.6. Migration of oligomeric forms and a-syn under denaturing 
conditions. 10 % Bis-Tris gel showed an array of oligomeric subsets in each 
sample that could have resulted from the solvent conditions used. The 
monomeric protein also displayed multiple bands in lane 6. A1 and A2 SP 
deemed to be more sensitive to reducing conditions, producing an array of 
bands detectable by Silver staining (A). Tris acetate gel, 4X LDS sample buffer 
and Tris-Acetate running buffer system indicated one set of low MW  
intermediate in all oligomer types prepared in AA and C1 and C2 SP, whereas 
an array of oligomers were displayed in type A 1 and A 2 SP samples. This might 
be indicative of an increased sensitivity of these latter two oligomers to 
denaturing conditions, inducing further aggregation of fragmentation. The size 
of the low MW bands could not be estimated by using this type o f ladder on this 
system (<41 KDa) (B).
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8.5 MTT cell viability after 20 % v/v treatment of a-syn oligomers
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treatment groups treatment groups, ** p<0.001
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82
Figure 8.7. MTT cell viability assay ofSH-SY5Y human neuroblastoma cells 
performed at 1.0x105 cells/well seeding density. A shows the data obtained 
following a 4 hr treatment with 20 % v/v oligomers, their matched vehicle 
controls and other controls. B represents values obtained after 24 hr exposure 
of oligomeric treatment in addition to controls at 20 % v/v. C indicates MTT 
values in % obtained after 48 hr incubation times with alternate oligomeric forms 
and respective controls at 20 % v/v. All treatments were set up in triplicates 
three times (n=9) and read at 570 and 690 nm. All readings were averaged, 
appropriate solvent controls were included and subsequently values have been 
normalised to untreated cells (100 %). Means are plotted with ±SEM, levels of 
significance and p values are indicated under each group.
262
8.6 Immunocytochemistry, DAB staining of A53T a-syn
SH-SY5Y overexpressing SH-SY5Y, W T 1°Ab omitted, SH-SY5Y
A53T a-syn endogeneous a-syn
Figure 8.8. Immunocytochemistry o f a-syn performed with DAB staining 
(Vecstatin kit) visualised by light microscopy, a-syn is mainly expressed in the 
cytosol and it is also localised closed to the nuclei. In the cell line transfected 
with A53T a-syn mutant and expressing the protein stably on the right hand 
side, the arrow heads point to the increased levels A53T a-syn in the cytoplasm 
and near the nuclei. In the middle, the endogeneously expressed WT a-syn is 
shown. On the right, no primary antibody (Sigma, syn 211 antibody) was added 
and no significant background was seen with secondary antibody only. Staining 
of nuclei was performed using DAPI as displayed by blue colour in the merged 
images (40X magnification).
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8.2 Assessing seeding properties of a-syn oligomers in SH-SY5Y cells
C1AA C2AA C1 SP C2 SP
B■■■
A1AA A2AA A1 SP A2 SP
RRHR
j E M
+o H lb H  I —e H1 c I M
C<DE03Q)
wSmKm «  "L J r n  IRSIRfE Wmm SMB" H  ~^R11 -1 H 1
Oz ^ R F  ^ l |  cR p H R ^ jp R  zj ■
Figure 8.10. Seeding effect of type C and A oligomers after 8 hr exposure of
SH-SY5Y cells. Immunostaining of syn 211 antibody (red colour) after treatment
with 10 % v/v a-syn oligomers or matched solvent controls as detected by Alexa
495 goat anti mouse antibody. DAPI is shown by blue counterstain, 40x.The
arrows point at cytoplasmic a-syn aggregates formed post-oligomeric treatment.
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Figure 8.10. illustrates that cytosolic a-syn was decreased and an increased 
punctate formation (white arrows) was observed after treatment with all 
oligomers except A1 and A2 SP.
8.3 Neurofilament staining of SH-SY5Y cells
SH-SY5Y SH-SY5Y overexp. A53T
Figure 8.11. Neurofilament staining of SH-SY5Y cells and SH-SY5Y cells 
overexpressing A53T a-syn at x 100 magnification. Anti-neurofilament antibody 
(Abeam) was dected by Alexa Fluor 594 conjugated anti-mouse antibody IgG 
(red colour) and nuclei were counterstained with DAP! (blue colour) in both cells 
line primary antibody was omitted for control staining.
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8.4 Binding of Cu(ll) to a-syn
A - Gly
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Figure 8.12. Mobility plots of a-syn either in their apo-form (1:0 protein to metal 
ratio) or holo-form with up to 2 Cu(ll) bound (1:1 protein to metal ratio) at the 
+ 13 and +7 charge state ions. Binding studied in the absence (A) or the 
presence of Ox excess of Gly (B). Instrumental settings were: capillary 1.50 kV, 
sampling cone 50 V, trap collision energy 4.0 V, Transfer collision energy 10.0 
V. source wave velocity 200 m/s, trap wave velocity 311 m/s, IMS wave velocity 
800 m/s, transfer wave velocity 200 m/s, backing 3.0 mbar.
The appearance of new adduct series was evident upon Cu(ll) binding as 
judged by a mass shift, resulting in incresead m/z values. The corresponding 
drift times of these Cu(ll)-bound adducts were shortened in case of the +7 
charge state ions when compared to the unbound form of the protein, indicating 
a structural rearrangement. The unbound, extended population of a-syn is 
indicated by a square with dotted blue line, which almost completely 
disappeared after co-ordination of Cu(ll).
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8.6 Calculated Qs of a broad range of proteins
Protein Mass (Da) Q (A 2) SD
folded horse heart myoglobin 17562 1971 267
folded hen egg lysozyme 14305 1469 60
folded bovine ubiquitin 8565 1199 65
folded equine cytochrome c 12355 1622 94
folded ADH monomer 39804 3010.6 74.2
folded ADH tetramer 159216 8497 227.7
folded albumin monomer 66463 4183.7 299.7
folded albumin dimer 132926 7059.3
folded carbonic anhydrase 29090 2011.6 185.7
folded p2 microglobulin 11860 1990.6
folded bovine insulin 5734 760 47.5
folded bovine a-lactalbumin 14178 1533.3 81
folded porcine elastase 25907 2133.5 101.5
extended a-syn monomer 14460 2482 159
compact a-syn monomer 14460 1851 276
denatured a-syn monomer 14460 2620 220
a-syn dimer 28920 3375.2 750.6
a-syn trimer 43380 3906.6 231.6
a-syn tetramer 57840 4228.6 225.3
a-syn pentamer 72300 4803 167.2
a-syn hexamer 86760 5553.1 212.4
Table 8.2. Qs o f a range of protein standards over a wide mass range were 
acquired under native conditions at repeated measurements (except albumin 
dimer and native /32 microglobulin). Qs are expressed as mean and standard 
deviation is given.
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8.7 ESMMS-MS of Cu(ll) induced type A oligomers
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Figure 8.13. Mobility plot and corresponding mass spectrum o f modified type 
A2 AA oligomer where 10 pM FeCI3 was replaced with CuCI2 in 50 mM AA, pH  
7.0 after re-suspension o f a freeze-drying step at 24 hr shaking. Instrument 
settings were: capillary 1.30 kV, source temp 60 °C, cone 30V, trap collision 
energy 4 V, transfer collision energy 10 V, IMS gas flow 90 mUmin, helium gas 
flow 180 mUmin, bias 45, source wave velocity 200 m/s, trap wave velocity 311 
m/s, IMS wave velocity 800 m/s, transfer wave velocity 200 m/s, backing 3.10 
mbar. Monomeric, dimeric (D), and trimeric (T) and a broad range o f tetrameric 
populations (Q) co-existed. Charge states o f the oligomers denoted as 
superscripts in each series on the mobility plot. Monomeric adduct series with 
one high intensity Cu(ll) or another, second Cu(ll) with lower intensity are 
shown in the mass spectrum in a bracket alongside their charge states. The 
region >2900 was enlarged x54 to view the low abundance oligomeric 
components.
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8.8 Oxidisation of Met residues following 12 hr incubation with DA
A
+7 + DA+13 + DA100 - 100-,
100-1 +7+13
—i 1-----1-----1 r <nrz
1120 1122 11241116 20852065 2070 2075 2080
m /z m /z
Figure 8.14. Oxidation o f methionine can be observed on long term exposure of 
a-syn to DA as reported by Leong et al. (Leong et al. 2009b). Samples ofa-syn- 
DA at a 1:8 ratio were allowed to incubate at room temperature without agitation 
for 12 hr. The +13 (A) and +7 (B) charge state ions are shown, arrows indicate a 
+16 Da increase in mass consistent with the oxidation o f the four Met residues. 
Data was acquired by Dr David P. Smith.
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